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Abstract 
 
Aims:  The overarching hypothesis is that circulating levels of pro-inflammatory cytokines 
and other inflammatory markers are genetically associated with depression in adolescents.  
Specifically, it is hypothesised that there will be a correlation between variation in genetic 
risk of depression and genetic variation of circulating pro-inflammatory cytokines and 
inflammatory markers.   
Methods:  A systematic review of the literature was conducted to establish the current 
understanding of the relationship between inflammatory markers and depression in 
adolescents and to inform study design.  Multiple approaches (including different types of 
genetic analyses and multiple data sets) were used to address the overarching hypothesis.  
A pilot study measuring cytokines, inflammatory markers, and other biomarkers involved in 
immune regulation (including Vitamin D, antibodies to infectious agents, and gliadin 
antibodies (found in coeliac disease)) was conducted in 107 monozygotic (MZ) and 160 
dizygotic (DZ) twin pairs (mean age 16.2 years, standard deviation (SD) 0.25 years) from 
the Brisbane Adolescent Twin Study.  A clinical study was undertaken to collect biological 
samples and clinical data from an in-patient adolescent mental health unit.  
Investigation of the relationship between iron measures (altered in inflammatory states) 
and measures of depression was undertaken in community cohorts of twins and their 
parents (3,416 adolescents from 1,688 families, and 9,035 adults from 4,533 families). In 
the adolescent cohort, depressive measures were assessed through the Somatic and 
Psychological Health Report (SPHERE) (mean age 15.1 years (SD 3.2 years)). In the 
adult cohort, a quantitative score of depression was measured by the Delusions 
Symptoms State Inventory (DSSI) (mean age 23.2 years (SD 2.2 years)).  Heritabilities of, 
and phenotypic and genetic correlations between, traits were estimated.  Association 
analyses, genetic profile risk score analyses, and LD score analyses were also used to 
investigate the genetic relationship between the iron and depression measures. 
The phenotypic and genetic relationship between the inflammatory marker C-reactive 
protein (CRP) and depression and anxiety was investigated in a community sample from 
the Australian Twin Registry.  Mean age at CRP measurement was 45.3 years (SD 10.1 
years), with 14,750 individuals with CRP measures; 8,234 individuals with DSM-IV MDD 
data; 8,679 individuals with DSM-IV anxiety disorders data; 8,847 individuals with genome-
wide SNP data.  Analyses were stratified based on experience of childhood trauma. 
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Genetic profile risk score analyses were used to explore the genetic relationship between 
these variables. 
Results: In the pilot study, cytokines that were successfully measured in plasma were 
found to be moderately heritable (transforming growth factor- β1 (TGFβ1), 0.57 (95% CI 
0.26 – 0.80) and tumour necrosis factor-receptor type 1 (TNFR1), 0.50 (95% CI 0.11- 
0.63)).  A negative correlation between Vitamin D and the cytokine IL-18 (-0.14) was not 
statistically significant (p=0.054).  However, major difficulties were encountered in 
measuring cytokines, in particular due to the low levels of circulating cytokines in healthy 
adolescents.  Challenges were also encountered in the cytokines study of the clinical 
sample of adolescents, which were able to be broadly divided into patient factors, blood 
collection factors, and other data collection factors.   
Iron measures were found to be highly heritable in both adolescents and adults: 
Adolescents: iron 0.46 (95% CI 0.15-0.66), transferrin 0.64 (95% CI 0.42-0.81), transferrin 
saturation 0.61 (95% CI 0.39-0.70), and log10 ferritin 0.56 (95% CI 0.28-0.72); Adults: iron 
0.35 (95% CI 0.25-0.41), transferrin 0.52 (95% CI 0.38-0.56), transferrin saturation 0.50 
(95% CI 0.44-0.55), and log10 ferritin 0.42 (95% CI 0.27-0.49).  Heritabilities calculated for 
depressive measures were 0.46 (95% CI 0.29-0.52) and 0.30 (95% CI 0.11-0.40) for 
adolescents and adults respectively. In adolescents, depression measures were 
significantly higher in those in the middle 10th percentile versus top 10th percentile of 
transferrin saturation measures (p=0.002).  No evidence was found for a genetic 
contribution to the relationship between measures of iron and depression in adolescents or 
adults.   
The relationship between CRP and Major Depressive Disorder (MDD) appears to be 
moderated by age, sex, and body mass index (BMI).  No evidence was found that this 
relationship reflected genetic differences between individuals in CRP.  Rather, BMI is likely 
to be the key factor mediating the relationship between circulating CRP, MDD and anxiety 
disorders. 
Conclusion:  
 Cytokines measured in plasma were found to be moderately heritable implying that 
there is a genetic contribution to variation between individuals in circulating levels of 
these inflammatory markers.   
 Collection of blood inflammatory markers in an in-patient adolescent mental health 
unit is challenging.  
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 We found no evidence for a genetic relationship between blood inflammatory 
markers and measures of depression in community samples.  
 Recommendations for future research are: 
o Longitudinal study designs are likely to improve the understanding of the role of 
cytokines / inflammatory markers in adolescent mental illness in relation to 
genetics, stress, early childhood adversity, and neurodevelopment.    
o A less invasive way is needed to accurately measure cytokines in low 
concentrations 
o Additional treatment options of adolescent mental illness are needed, 
particularly for those individuals who have associated raised pro-inflammatory 
markers. 
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CHAPTER 1:  
 
Background 
 
Cytokines are small proteins with immune modulating activity (1, 2).  They can be pro-
inflammatory or anti-inflammatory (3, 4), or have a combination of pro-inflammatory and 
anti-inflammatory effects (5).  At the commencement of this thesis, there was emerging 
evidence that pro-inflammatory cytokines (specifically tumour necrosis factor-alpha (TNF-
α) and interleukin-6 (IL-6)) were associated with Major Depressive Disorder (MDD) in 
adults (6), however there were few studies in adolescents.  The small number of studies in 
adolescents suggested there would be evidence of immune system dysregulation, 
however the role of cytokines in adolescent MDD could possibly be influenced by factors 
such as neurodevelopment and hormonal changes.  
During the course of the thesis, further literature emerged on cytokines and other 
inflammatory markers, including the potential for these to act as biomarkers of illness in 
MDD.  In addition to cytokines, and the inflammatory marker C-reactive protein (CRP) (7), 
other potential blood biomarkers of depression include biochemical measures altered in 
inflammatory states.  These include iron measures (8, 9), antibodies to infectious agents 
(10), and antibodies present in coeliac disease (11).   
Vitamin D has also been found to have a role in the immune system, through modulation 
of cytokines (12) and has also been identified as a potential biomarker in MDD (13).  This 
role in the immune system, combined with changes in plasma levels observed in MDD, 
suggested Vitamin D may be a useful biomarker of illness in MDD, particularly in 
adolescents.  This thesis has aimed to examine the role of these biomarkers involved in 
immune regulation (or altered in inflammatory states) in adolescent MDD. 
Biomarkers can potentially be used as markers for illness or diagnosis, or as markers of 
response to treatment (14).  Throughout this thesis, biomarkers are examined in the 
context of biological markers of illness. However, changes in inflammatory markers can be 
seen in other mental illnesses besides MDD, including in anxiety disorders and psychosis 
(15, 16). This non-specificity produces challenges, especially as non-specific symptoms 
(such as irritability) can also be seen across mental illnesses (17).   
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Figure 1-1 provides an overview of the biomarkers examined in this thesis. Inflammatory 
markers can include pro-inflammatory cytokines, CRP, and biochemical measures altered 
in inflammatory states.   
Figure 1-1:  Overview of biomarkers involved in immune regulation, or altered in inflammatory 
states 
 
 
 
 
 
 
 
 
 
 
When commencing this thesis, there was very little literature on how identification of 
biomarkers in MDD might translate into clinical practice (18, 19).  Recently studies have 
emerged examining  particular sub-types of MDD and associated biomarkers (18), 
although this line of research is in its infancy. This is addressed further in Chapter 6, which 
includes an investigation of the association of CRP and MDD in those with co-morbid 
anxiety disorders. 
Overall thesis aims  
 
This thesis focuses on cytokines and other inflammatory markers in depression in 
adolescents. The starting hypothesis of the thesis was that pro-inflammatory cytokines, 
other inflammatory markers, and biomarkers altered in inflammatory states would be 
phenotypically and genetically associated with measures of depression.  To examine this, 
some exploration of cytokines and inflammatory markers in depression in adults was 
required as few studies had previously been conducted in adolescents.  This provided 
guidance for study design, and also allowed comparison of cytokines and inflammatory 
markers in adolescent versus adult depression.   
    Inflammation  
    Pro-inflammatory             
Cytokines 
   C- reactive protein Changes in iron measures, 
antibodies to infectious agents, 
antibodies in coeliac disease 
    Vitamin D 
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The aims of this thesis are: 
1) To review systematically the literature so as to identify differences in the role of 
cytokines in depression in adolescents compared to adults.  This review would also 
assist in informing study design.  
2) To investigate the genetic variance of cytokines, inflammatory markers, and 
biomarkers altered in inflammatory states in healthy adolescents.   
3) To investigate the phenotypic and genetic relationship between other biomarkers 
altered in inflammatory states (specifically iron measures) and depression, using 
several different strategies.  
4) To investigate the phenotypic and genetic relationship between the inflammatory 
marker CRP, MDD, and anxiety disorders. 
 
Chapter overview  
 
Chapter 2 is a systematic review critically analysing all studies available at the time 
examining the role of cytokines in adolescent major depressive disorder.  This review 
identified potential barriers to testing the overarching hypothesis that pro-inflammatory 
cytokines and other inflammatory markers would be phenotypically and genetically 
associated with measures of depression.  Importantly, the review showed there were some 
emerging differences in cytokines in depression in adolescents compared to adults (20).  
This had not been clearly identified previously and informed the need to consider the 
similarities and differences in the roles of cytokines and other inflammatory markers 
between adolescents and adults with MDD. 
The literature review also demonstrated the paucity of studies examining the role of 
cytokines and inflammatory markers in adolescents. Important areas of research were 
identified including the role of cytokines in relation to stress, early childhood adversity, and 
genetics (20).  In addition to identifying gaps in the research that needed addressing, this 
systematic review identified other issues pertaining to the project, such as technical 
difficulties associated with validity of the measurement of cytokines. This literature review 
was published in 2013 and has 34 citations (Google Scholar 26/04/16) at the time of 
submission. 
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Chapter 3 
This chapter reports on the measurement and analysis of cytokines, inflammatory 
markers, and other biomarkers altered in inflammatory states in healthy adolescent twins.  
This study highlighted that measuring cytokines presents significant challenges.  Some 
cytokines are present in low levels in physically healthy adolescents and young adults 
(15), so assays need to be sufficiently sensitive to detect cytokines.  Cytokines are fragile 
and measurement of circulating levels is complicated by inter-laboratory variation and 
timing of blood collection (21, 22). Unfortunately the plasma cytokines included in the 
multiplex assays (rather than measured individually) did not generate useable results.  In 
view of these difficulties, the cytokines were also measured in dried blood spots (DBS).  
This posed other challenges, so this chapter also reports on some of the difficulties in 
measuring cytokines and inflammatory markers. 
In spite of these challenges, there was evidence that the association between antibodies 
(gliadin antibodies and antibodies to infectious agents) and mental illness was in the 
context of the immune response / inflammatory response (including raised levels of pro-
inflammatory cytokines) (23, 24).  There have been very few studies examining this, 
particularly in adolescents.  Therefore, this chapter also reports analyses of antibodies to 
infectious agents and gliadin antibodies measured in DBS in the same study participants in 
whom cytokines were measured.   
The role for Vitamin D in the immune system through modulation of cytokines (12) had not 
been examined in adolescents.  To address this gap in the literature, this chapter also 
explored a potential association between Vitamin D and inflammation by measuring 
Vitamin D in DBS (same study participants in whom cytokines and antibodies were 
measured).  Part one of this chapter was published in February 2015 (25).   
Chapter 4 
Following on from the study of cytokines in healthy twins, I set out to study cytokines in a 
clinical setting. Undertaking a clinical study involved all aspects of study design, from 
ethics approval to recruiting of study participants, data collection, and meticulous data 
entry. The challenges in measuring cytokines, and the need for an improved 
understanding of cytokines in adolescents in the context of early childhood adversity, also 
needed to be considered in this study, which aimed to study cytokines and inflammatory 
markers in a clinical group.    
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Challenges of implementing a protocol enabling the collection, processing and storage of 
blood in an acute clinical setting as well as collecting clinical data are discussed in this 
chapter.  These challenges are broadly divided into patient factors (such as degree of 
morbidity), blood collection factors (including co-ordinating blood collection and the low 
acceptability of venepuncture by adolescents), and other data collection factors (such as 
timing the obtaining of consent from parents).    
Chapter 5 
Difficulties in measuring cytokines in plasma and DBS as outlined in Chapters 3 and 4 
presented potential barriers to testing the overarching hypothesis that I had set out to 
investigate.  However, questions relevant to the hypothesis could be addressed using data 
collected on large community samples of twins. The review of the literature had shown 
other biochemical measures associated with depression in adults, including iron 
measures.  Specifically, decreases in serum transferrin and increases in serum ferritin are 
seen in inflammatory states (8).  These changes of decreased serum transferrin and 
increased serum ferritin have also been found in adults with MDD (9).  There were few 
studies examining the relationship between iron measures and MDD in adults.  To the best 
of this candidate’s knowledge, there were no studies that had examined the relationship 
between iron and MDD in adolescents.  To address this gap in the literature, Chapter 5 
investigates the phenotypic and genetic relationship between measures of iron and 
depression in adolescents and adults.  In the chapter, several different strategies are used 
to investigate the genetic relationship between these measures.  
Chapter 6 
As work on the thesis progressed, literature on the interaction between stress and 
depression was emerging and expanding.  There were a number of studies investigating 
cytokines in those with a history of childhood maltreatment, both in healthy adults (26) and 
in adults with MDD (27).  There were also more studies investigating the role of the 
inflammatory marker C-reactive protein (CRP) in adults with MDD and a history of early 
childhood adversity (28, 29).  A small number of studies had investigated cytokines and 
inflammatory markers (specifically interleukin-6 (IL-6) and CRP) in adolescents with 
depression and a history of childhood adversity (30, 31).   
Studies investigating the relationship between CRP and MDD had shown evidence  of a 
complex interplay between body mass index (BMI), CRP, and MDD (32).  This association 
between BMI and CRP extended to anxiety disorders, with a longitudinal study showing 
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that the relationship between CRP and Generalised Anxiety Disorder (GAD) appeared to 
be mediated by BMI (33).  Investigating the relationship between BMI, CRP, anxiety 
disorders and a history of early childhood adversity had not been previously undertaken.  
There were also very few studies examining the genetic relationship between CRP, BMI, 
MDD, and anxiety. 
Chapter 6 addressed these important gaps in the literature. The clinical study (Chapter 4) 
demonstrated the high frequency of early childhood adversity in this sample, and the 
systematic review (Chapter 2) highlighted the need to better understand the relationship 
between CRP, BMI, and MDD / anxiety disorders. This chapter addressed these gaps by 
investigating the phenotypic and genetic relationship between CRP, MDD and anxiety and 
included analyses that stratified based on experience of childhood trauma.   
Chapter 7 
In this discussion chapter I assess how the findings reported in this thesis add to the 
existing literature, consider limitations of the studies undertaken, discuss implications for 
clinical practice (with the aim of improving treatment for MDD in adolescents), and 
recommend areas for future research.  Recently, a number of groups have discussed 
examining the association between these potential biomarkers and stage of mental illness 
(34, 35), and how this may translate into clinical practice.  These recent discussions on 
biomarkers and stage of illness have focussed on adults.  However, review of the adult 
literature provided guidance for study design in the previous chapters, and suggested 
areas for future research in adolescents.   
A small number of recently published studies investigated the relationship between 
cytokines or inflammatory markers in anxiety disorders in adolescents.  Therefore, this 
chapter includes some discussion of directions for future research in adolescents with 
mental illnesses other than MDD. 
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CHAPTER 2: THE ROLE OF CYTOKINES IN DEPRESSION IN 
ADOLESCENTS: A SYSTEMATIC REVIEW 
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Abstract 
 
Background: Cytokines have been implicated in the pathophysiology of depression in 
adults, however the potential role in younger age groups such as adolescents is less clear. 
We review the literature (i) exploring the relationship between cytokines and depression in 
adolescents and (ii) examining how cytokines may be related to adolescent depression in 
the context of other neurobiological theories of depression. 
Method: A systematic review of the scientific literature on the subject was conducted in 
February 2013, searching the Web of Knowledge, PubMed (Medline), PsycInfo, and 
Cochrane electronic databases. 
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Results: Eighteen studies were identified measuring both depression or depressive 
symptoms and cytokines or immune markers in adolescents. Adolescents with depression 
show age specific characteristics of the immune and inflammatory system, specifically in 
NK cell activity and in pro-inflammatory cytokines (such as IL-1β and TNF-α). In addition, 
the role of cytokines in adolescent depression is influenced by neurodevelopment, 
hormonal changes, stress, and trauma.  
Conclusions: There may be differences in the neurobiology of adolescent MDD 
compared to adult MDD. Increased understanding of the role of cytokines in adolescent 
MDD may lead to improved outcomes in the treatment of adolescent depression. 
 
Key Words:  Cytokines, inflammation, immune system, adolescents, depression, 
cognition, stress 
 
Abbreviations: MDD=Major Depressive Disorder; CD=Conduct Disorder; 
HPA=Hypothalamic-Pituitary-Adrenal; IL=interleukin; TNF-α=tumor necrosis factor-α; IFN-
γ=interferon-γ; NK cells =natural killer cells; TRP=tryptophan; KYN=kynurenine; 3-HAA=3-
hydroxyanthranilic acid; QUIN=quinolinic acid; tCho=total choline; PUFAs=polyunsaturated 
fatty acids; CRH= corticotrophin-releasing hormone; CRP=C-reactive protein; 
LPS=lipopolysaccharide; SSRI=selective serotonin re-uptake inhibitor 
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Introduction 
Major depression is a leading cause of disability worldwide (36), with lifetime prevalence in 
most countries ranging between 8 to 12% (37). It is responsible for the greatest proportion 
of disease burden attributable to non-fatal health outcomes, accounting for almost 12% of 
total years lived with disability worldwide (38). Major Depressive Disorder (MDD) in young 
people is estimated to be experienced by approximately 2% of children and 4% to 8% of 
adolescents (39) and  carries its own burden of disadvantage often persisting or 
reemerging in adulthood (40, 41). The Diagnostic and Statistical Manual of Mental 
Disorders 4th edition (DSM IV) considers major depression in adolescents and adults to be 
similar, although adolescents may show irritability rather than report depressed mood (42).  
The 5th edition of the DSM (DSM 5) maintains these criteria (43).  Similarities in the clinical 
presentation of MDD in children, adolescents and adults are supported by additional 
evidence (e.g. (44, 45)), yet there is also support for differences in risk factors, clinical 
outcome, and biological correlates between adults and adolescents (44, 46-49). Apparent 
differences in underlying aetiologies between adolescent- and adult- onset depression (44) 
may be attributable to developmental differences, or biologic changes that are sub-
syndromal and too subtle for studies designed to detect the effect sizes reported in adult 
studies. Alternatively, it could be speculated that biologic changes observed in depressed 
adults but not in adolescents or children might be attributable to medication intake since 
adults with depression often have a prolonged medication history as compared to 
adolescents and children with depression. 
Although there are differences in risk factors for depression in adolescent- and adult- onset 
depression, family history and stressful life events including childhood maltreatment are 
significant risk factors for both (49, 50). A family history of depression does not 
automatically indicate a genetic contribution to the disorder, as it reflects both shared 
genetic and common (family) environmental effects. However, twin studies designed to 
tease out the heritability (proportion of variance that can be attributed to genetic factors), 
consistently indicate a substantial genetic component, particularly in clinical samples (e.g. 
(51)). Yet, identification of gene variants that robustly associated with depression have 
remained elusive, with environmental factors that interact with genetic predisposition being 
of potential relevance. A particularly important environmental mediator in depression is 
stressful life events, particularly childhood maltreatment (52). Such experience may result 
in dysregulation of the adaptive stress response system (53). To investigate the interaction 
of genetic and environmental risk factors requires large data sets in which participants 
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have provided DNA and have been consistently measured, preferably longitudinally, for 
environmental risk factors. Unfortunately, such data sets are rare. The on-going debate 
about the interaction between stressful life events and the serotonin transporter length 
polymorphism illustrates how differences in the measurement of environmental risk factors 
might, in part, be responsible for inconsistent findings between studies (54-58).   
In adults, accumulating evidence suggests that MDD may be associated with immune 
system dysregulation (1), at times occurring in the absence of specific immune challenges 
such as infections. Cytokines are signaling molecules that mediate key steps in cellular 
and humoral immunity, and a biological relationship with MDD is supported by a large 
number of mechanistic studies in vivo and in vitro (59).  Cytokine genes, such as variants 
of the IL-1β and TNF-α genes, have been implicated in impaired emotion processing in 
major depression and in hippocampus formation in recent functional magnetic resonance 
imaging (fMRI) studies (60, 61). Furthermore, a recent review suggested that genetic 
variants of cytokines are possibly involved in the pathophysiology of depression (62). Of 
particular relevance, cytokines have also been implicated in the stress response, important 
in depression (63). In both adults and adolescents, childhood maltreatment has been 
associated with an elevation in CRP levels, indicating a dysregulation of the immune 
system, further compounded by concurrent depressive symptoms (28, 53). In addition, 
cytokines are implicated in neurodevelopment and with stress regulation since pro-
inflammatory cytokines may exert direct effects on the hypothalamic-pituitary-adrenal 
(HPA) axis (64, 65). Prolonged periods of excess corticosteroids following chronic stress 
are particularly important during adolescence, as brain structures such as the 
hippocampus are susceptible to adverse stress-associated effects (66). Also, biological 
susceptibility to stress related brain damage may be heightened during adolescence when 
myelination processes within the central corticolimbic circuitry of the brain occur (67).  
The primary purpose of this review is to assess literature on the role of cytokines in 
adolescent depression by identifying studies that measured both cytokines and symptoms 
of depression in adolescents. By doing this, we aim to clarify if cytokines have a differential 
role in depression in adolescents compared to adults.  The secondary purpose of this 
review is to examine how cytokines may be related to adolescent depression in the context 
of other neurobiological theories of depression.  
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Method 
 
The literature search included published articles until February 2013 according to the 
PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines 
as they apply to systematic reviews (68). The primary purpose was to identify all studies 
that provide empirical data on the measurement of cytokines and symptoms of depression 
in adolescents. In order to compare findings in adolescents to other age groups, the 
search was expanded to all age groups.  In addition, as some studies in older patients with 
MDD found a relationship between cytokines and cognition and cognitive dysfunction 
which may present as a symptom in depression, we also searched for studies that 
measured cytokines and cognitive performance in adolescents.  As a family history of 
depression is also considered a risk for MDD, ‘genes’ was included as a search term. To 
help identify publications considering a differential role for cytokines and immune markers 
in adolescent MDD, we conducted a further literature search applying the following 
combination of search terms – Cytokines, Immun*, and Depression and Stress. The final 
search strategy is illustrated in Figure 2-1. 
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Figure 2-1: Study inclusion flowchart  
        
 
    
Legend:  
Inclusion criteria: Search was carried out applying the following combinations of terms – 1. 
Cytokines AND adolescents AND depression, 2. Cytokines AND adolescents AND 
cognition, 3.Cytokines AND depression AND genes, 4. Cytokines AND cognition AND 
genes, 5.Cytokines AND depression AND cognition, 6.Cytokines AND immun* AND 
depression AND stress.   
Exclusion criteria: articles written in languages other than English                          
 
Results 
 
Several detailed reviews have reported on the cytokine theory of depression (2, 6, 59, 64, 
69-74), with a primary focus on adults, or older age groups. Our review comprises three 
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main sections: (i) the cytokine theory of depression as reported in adults, (ii) evidence 
specifically relevant to adolescent-onset depression, and (iii) clinical implications.  
 
I. The Cytokine Theory of Depression  
 
Biological Properties of Cytokines 
Cytokines are small pleiotropic proteins (4). The term cytokine includes a large and diverse 
family of signaling molecules that primarily have immune modulating activity, and are 
produced widely throughout the body by cells of diverse embryological origin (75, 76). 
Cytokines can be viewed as either ‘pro-inflammatory’ or ‘anti-inflammatory’, depending on 
their primary effects on target cells (4).  Pro-inflammatory cytokines include interleukin-1α 
and β (IL-1α and IL-1β), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6).  These 
molecules are believed to co-ordinate the local and systemic inflammatory response to 
microbial pathogens (59).  Others, such as interleukin 10 (IL-10), are considered ‘anti-
inflammatory’(77), however this distinction of pro and anti-inflammatory cytokines has 
been regarded as an over-simplification in the context of depression (64).  In the brain, as 
in systemic organs, the natural balance between pro- and anti-inflammatory cytokines 
regulates the intensity and duration of the response to immune stimuli (59).    
Heritability of cytokine levels (IL-1β, IL-1ra, IL-6, IL-10, and TNF-α) have been estimated to 
exceed 50% (78). However, in this study cytokine levels were measured with an ex-vivo 
whole blood assay in response to lipopolysaccharide (LPS) stimulation, so heritability 
estimates may more accurately reflect “immune-response” and not necessarily naturally 
circulating levels of cytokines in the blood. Nonetheless, other studies based on circulating 
levels of cytokines implicate an important role for genetic factors (e.g.(79-81)). Dysfunction 
in genes controlling key proteins in cytokine production have been identified as 
vulnerability factors for cytokine-induced depression (71), and recent studies have 
reported that variation in IL-1 and TNF-α  genes, and elevated levels of TNF-α, are 
associated with reduced responsiveness to antidepressant treatment (82-84). Overall, the 
molecular genetic basis of cytokine production in humans in the context of depression is 
currently not well understood.  
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Cytokines and Depression 
Increasing evidence suggests that pro-inflammatory cytokines play a major role in the 
pathophysiology of depression. A role of cytokines in depression was first proposed by 
Smith in the form of the ‘macrophage theory of depression’ stating that excessive secretion 
of macrophage monokines cause depression (85).  Although no consistent association 
between cytokines and MDD has been reported (86, 87), a recent meta-analysis that 
included 24 studies reported an association between elevated levels of two pro-
inflammatory cytokines, IL-6 and TNF-α, and major depression (6).  
Additional research in humans is required to clarify whether cytokines are causally 
involved in clinical depression since the majority of studies have been cross-sectional (73), 
with only a few prospective studies in humans allowing for causal inferences. For example, 
findings from a 12 year study of a large British occupational cohort in adults concluded that 
inflammation predicted cognitive symptoms of depression (88). Moreover, in support of a 
role of inflammation in the etiology of depression, Baune et al. showed in older adults that 
the pro-inflammatory cytokine IL-8 predicted first onset of mild to moderate depressive 
symptoms over a 2 year period, indicating IL-8 could be a marker of first onset of 
depressive symptoms in the elderly (89). Such studies are sparse in adolescents with 
clinical depression, and would require a longitudinal study design.   
Both biological and environmental factors can precipitate an episode of depression, 
possibly through an increase in circulating plasma cytokines. For example, external factors 
such as psychosocial stressors and medical conditions such as organic inflammatory 
disorders or physiological conditions (i.e. the postpartum period), may trigger clinical 
depression via inflammatory processes (74). Clinical depression may also be induced by a 
therapeutic administration of interferon in hepatitis C (90). Experimentally, peripheral 
administration of lipopolysaccharide (LPS), or of recombinant cytokines, such as IL-1β or 
TNF-α, induces nonspecific symptoms of sickness, including fever, activation of the HPA 
axis, reduction of food intake, and withdrawal from the physical and social environment, 
termed as sickness behaviour (71).  
Further mechanistic studies demonstrate that LPS not only causes a peripheral 
inflammatory response, but also induces a neuroinflammatory reaction with increased 
production of pro-inflammatory cytokines such as TNF-α in the brain (91, 92). Pre-
treatment with antidepressant drugs have also been found to abrogate LPS- or IL-1β- 
behaviour related to reduced consumption or rewards of sweetened solutions or sucrose in 
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rats (93, 94). Brain circuits involved in depression-like behavior have also been identified 
using LPS induction of cytokines in animal models (e.g., in the amygdala, hippocampus, 
and hypothalamus) (95).  However, a functional dissociation between those brain 
structures that underlie cytokine-induced sickness behavior and cytokine-induced 
depressive-like behavior has been reported, indicating the need for further research on the 
temporal relationship between cytokine elevation, structural and behavioural changes (95). 
Figure 2-2 shows the cellular and humoral immune factors implicated to have a role in 
depression.  Specifically, cellular neuroimmune mechanisms implicated in the 
pathophysiology of depression include dysfunction of T helper (Th 17) cells and 
CD4+CD25+ T regulatory (Treg) cells (70, 96).  Findings on the possible involvement of 
natural killer (NK) cells in adult and adolescent MDD are discussed later.    
Figure 2-2: Immunological Factors involved with Depression 
 
Key: IL= interleukin; IFN= interferon; NK= natural killer cells; TNF= tumor necrosis factor; Th = T helper cell; 
T reg = regulatory T cells 
 
Cytokines in the brain 
Cytokines can exert direct and indirect effects on brain function through their influence on 
neurotransmitters, neurogenesis, and the HPA axis influencing neuroplastic changes 
relevant to depression (97). While cytokines do not readily pass through the blood-brain 
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barrier (69), five potential pathways for cytokine signals to reach the brain have been 
described:  1) passive transport of cytokines into the brain at circumventricular sites 
lacking a blood-brain barrier (98-100); 2) activation of the cerebral vascular endothelium, 
thereby releasing cytokines and inducing the generation of secondary messengers such 
as prostaglandins and nitric oxide (101-103); 3) carrier-mediated transport of cytokines into 
the brain across the blood-brain barrier (104); 4) activation by cytokines of peripheral 
afferent nerve terminals, which then relay cytokine signals to relevant brain regions (100, 
105, 106); and 5) recruitment of activated cells such as monocytes / macrophages from 
the periphery to the brain, where these cells can produce cytokines (107).  These 
mechanisms are not mutually exclusive, and depend in part on the location of the 
inflammatory stimulus and the disease state of the organism (108).  In addition, most 
cytokines can be synthesized and released within the CNS (108) such as by microglia that 
are a primary source of pro-inflammatory cytokine production in the brain (2). However, the 
brain circuitry that mediates the various behavioural responses to cytokines remains 
elusive (59).   
Clinical and experimental studies indicate that stress and depression are also associated 
with increased circulating concentrations of cytokines, such as TNF-α and IL-1 (109).  
Increased levels of these cytokines have the potential to impair synaptic plasticity 
(structurally and functionally), modulate long-term potentiation (LTP) and glutamatergic-
dependent synaptic plasticity (110-117), and to induce fear learning, thus contributing to 
progression of a depressive disorder (4). It has also been postulated that antidepressants 
indirectly modulate synaptic plasticity as a mechanism of antidepressant action, and that 
selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants may induce 
changes in TNF-α expression and function in the brain (4). 
Cytokines influence on biological pathways of depression 
Cytokines affect biological pathways that have been associated with depression, and so 
the cytokine theory in depression can be viewed as complimentary rather than competitive 
to other hypotheses of depression, such as the monoamine theory of depression. 
Tryptophan is an essential amino acid required for protein synthesis and is a precursor for 
the monoamine serotonin and a lowered availability of plasma L-tryptophan has been 
associated with depression (118). Interestingly, decreased levels of L-tryptophan are also 
correlated with inflammation, indicating that systemic inflammation may contribute to 
clinical depression via a decrease in the serotonin precursor L-tryptophan (119-121).  
 39 
As depicted in Figure 2-3, pro-inflammatory cytokines induce IDO (indoleamine 2-3-
dioxygenase), an enzyme that mediates the catabolism of tryptophan into kynurenine 
(KYN) (122). KYN is further metabolized into 3-hydroxykynurenine (3-HK), 3-
hydroxyanthranilic acid (3-HAA), and quinolinic acid (QUIN), which may induce neuronal 
damage (123, 124).  Hence, it is suggestive that increased levels and activity of cytokines 
may lead to depressive symptoms by inducing a reduction in important neurotransmitters 
such as serotonin and by stimulating neuronal damage both implicated in clinical 
depression.  
Figure 2-3: Tryptophan pathways 
 
 
Key: 5-HT= 5-hydroxytryptamine; HAA=hydroxyanthranilic acid; HK= hydroxykynurenine; IDO= indoleamine 
2-3-dioxygenase; ↑IDO= increased levels of IDO; IFN= interferon; IL= interleukin; NMDA= N-methyl-D-
aspartate; QUIN= quinolinic acid; TNF= tumor necrosis factor; TRYCATS=tryptophan catabolites along the 
IDO pathway 
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As cytokines, among other humoral and cellular immune factors, have the potential to 
influence systems heavily implicated in depression (97), it is a clinically relevant question 
to determine if a genetic predisposition, or environmental factors that frequently associate 
with depression, or a combination of both, contribute to the pathophysiology of depression. 
It has been frequently reported that stress elevates levels of pro-inflammatory cytokines by 
activating their signaling pathways (125-128). Moreover, cytokines influence the 
hypothalamic pituitary axis (HPA)(129) and IL-1, IL-6, TNF-α, and IFN-α may increase 
corticotrophin-releasing hormone (CRH) release and disrupt the function of the 
glucocorticoid receptor (reviewed by (130)). Indeed, since a hyperactive HPA axis has 
been reported in a proportion of patients with MDD (129), it is plausible that such 
hyperactivity could be a consequence of an elevation in cytokines, attributable to 
potentially both environmental and genetic moderators. Particularly genetic variants of 
cytokines have been suggested to be associated with clinical depression as recently 
reviewed by Bufalino et al. (62). However, the likely important interaction between these 
genetic variants and environmental factors such as stress and maltreatment has not been 
considered yet in original studies. 
Other genes of potential relevance are polymorphisms of the glucocorticoid receptor gene 
(NR3C1), involved in the regulation of the HPA axis. While some studies have reported 
that genetic variants of NR3C1 influence susceptibility to MDD and depressive symptoms 
(131), three further reports found no association, or associations that failed to withstand 
correction for multiple testing (132, 133). In addition, multiple genome-wide studies have 
presented no evidence for genome-wide significance (134). Failure to replicate may reflect 
insufficient power, due to insufficient sample size, heterogeneity of the phenotype of 
depression, or interaction with unidentified environmental factors. Indeed, evidence for 
gene-environment interaction has been reported with variation in the NR3C1 gene and 
childhood maltreatment (135), and altered methylation of the NR3C1 gene has been 
associated with stress exposure (136, 137).  These findings may lead to the speculation 
that depression could be a consequence of the effect of elevated cytokine levels in 
response to a stressor, occurring in the context of an NR3C1 system that was already 
dysregulated due to genetic or epigenetic effects earlier.  Hence, levels of pro-
inflammatory cytokines would be elevated in the context of the dysregulated HPA axis. 
Recent work on the HPA axis and depression has also been conducted by Solomon et al., 
who showed a sex difference in the role of forebrain glucocorticoid receptors in regulating 
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HPA axis activity and depression-like behavior in mice (138).  Specifically, in mice with 
selective deletion of glucocorticoid receptors in forebrain cortico-limbic sites (forebrain 
glucocorticoid receptor knockout mouse – FBGRKO), female mice did not show basal HPA 
axis dysregulation or exaggerated stress responses. The authors noted that in females, 
glucocorticoid receptor regulation of HPA axis function and behavior may be from other 
brain areas than those targeted in the FBGRKO mouse (138). 
Another biological pathway associated with depression might be a stress-induced 
decrease in neurogenesis influenced by cytokines. Pro-inflammatory cytokines, such as IL-
1β, have been shown to inhibit cell proliferation and promote cell death in the 
hippocampus (139).  Furthermore, there is evidence that neurodegeneration and the 
defects in neurogenesis in depression are caused by inflammatory processes, related to 
the production of oxidative and nitrosative stress molecules and pro-inflammatory 
cytokines (74).  Glutamate has also been implicated in MDD (140, 141), and glutamate 
neurotoxicity represents a pathway leading to increased apoptosis enhanced by pro-
inflammatory cytokines via various pathways: (a) activation of the kynurenine pathway in 
microglia, with glutamate release and increased quinolonic acid; (b) reducing glial 
glutamate transporter activity, resulting in decreased glutamate removal from the 
extracellular space; and (c) by inducing long-term activation of microglia, which releases 
TNF-α and IL-1 (reviewed in McNally et al 2008) (4, 142).  
In summary, cytokines exert wide-ranging influences on neuronal structure, function, and 
directly on the stress-response system, as well as in response to stress.  Evidence for the 
role of cytokines in the brain in depression is building, and seems tantalizing, yet remains 
largely circumstantial.  Still needed is to clarify whether effects are causal in humans, to 
better specify the actual molecular mechanisms operating in human depression related to 
cytokines, and in particular to clarify the effects in adolescence.    
II. The Role of Cytokines in Depression in Adolescents  
 
Emerging literature has examined a possible role of cytokines in adolescent depression. A 
total of twenty-four articles examining the role of immune markers in depression in 
adolescents were identified for this review. Of these, eighteen studies report empirical data 
as summarized in Tables 2-1, 2-2, and 2-3. Twelve publications present case-control 
studies which have relatively small sample sizes; the largest study consisted of 134 cases 
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and 149 controls.  Four studies used a prospective design (30, 32, 143, 144), assessing 
N=135, N=141, N=147, and N=1420 individuals respectively for depressive symptoms. 
The two remaining studies are a cross-sectional representative community sample (145), 
and an observational study of youths with diabetes (146). Key results from the studies are 
included in the relevant sections below.  Of the remaining 6 articles examining the role of 
immune markers in depression in adolescents, some did not measure cytokines (for 
example cytokine genes were genotyped but not circulating cytokine levels (147); Pandey 
et al. measured serotonin receptors postmortem and discussed the interaction between 
the HPA axis and serotonergic system (148)).  Two of these remaining 6 articles measured 
inflammatory markers or cytokines only when the cohort had reached adulthood (29, 53).  
Of these 6 articles, the studies by Danese et al. (29, 53), and Pandey et al. (148) are 
discussed in more detail later in the review. 
Stress Response, Neurogenesis and Neurodevelopment 
Increased levels of pro-inflammatory cytokines in response to acute stress has been 
described as characteristic (96), involving an activated HPA axis that may lead to a further 
rise in pro-inflammatory cytokines through complex positive feedback loops (64). These 
mechanisms could be particularly important during adolescence, as brain structures such 
as the hippocampus appear susceptible to adverse effects of prolonged periods of excess 
corticosteroids with consequences such as atrophy of the apical dendrites of the pyramidal 
cells (66). Therefore, chronic unpredictable stress in the environment is regarded as an 
important factor in the development and onset of depression (96).  
The variation in how an individual responds to stress, including their vulnerability to 
depression, may be influenced by an inflammatory response of the immune system. In a 
recent review, Fagundes et al. proposed a model of early adversity leading to greater 
stress sensitivity, and so placing an individual at greater risk for immune dysregulation 
(149).  Elevated levels of inflammatory markers, specifically C-reactive protein (CRP), 
have been reported not only in depressed adults exposed to childhood maltreatment (28, 
53, 150), but also in adolescence (28).  CRP is an acute phase protein that promotes 
resistance to infection and repair of damaged tissues (53). In these studies, CRP levels 
showed a linear increase depending on depression and/or maltreatment exposure (28, 
29). Individuals with a history of depression or current depression exhibited higher CRP 
levels relative to individuals with no depression or exposure to maltreatment; those with a 
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history of maltreatment and no depression exhibited even higher levels of CRP, and finally 
those that had experienced both maltreatment and depression presented the most 
elevated profile of all the groups. The elevation in CRP levels was significant in the 
combined depressed and maltreated group, relative to those with no exposure to 
maltreatment or depression. The authors concluded that a history of childhood 
maltreatment has a significant role in explaining the co-occurrence of depression and 
inflammation through the lifespan with “biological embedding” already seen at adolescence 
(28, 29). The findings in adolescents (Danese et al) (28) are particularly important, as 
increased inflammatory markers in adulthood has been linked to increased risk of both 
mental and physical illness (2, 29).  
In adolescents, pro-inflammatory cytokines have also been implicated in the stress 
response with a higher number of stressful life events associated with higher TNF-α levels 
(151).  In support of these findings is an 18-month longitudinal study of adolescent females 
who showed increased IL-6 responses to two different types of threatening stimuli on the 
background of exposure to a harsh family environment (143).  An extension of this study 
that investigated circulating levels of IL-6 and CRP found that among those exposed to 
higher levels of childhood adversity, the transition to depression was also accompanied by 
relative increases in both CRP and IL-6 (30).  Furthermore, the authors noted that higher 
CRP levels remained in these subjects 6 months later, even after the episode of 
depression had abated. Importantly, this coupling of depression and inflammation was not 
apparent in those without a history of childhood adversity (30).   
Cytokines also appear to be involved in neurodevelopmental processes (152); for 
example, IL-6 has demonstrated both neuroprotective (153, 154) and neurodegenerative 
properties (155).  In support of a possible neuroprotective effect of IL-6 is a recently 
published neuroimaging study conducted in healthy individuals that showed increased 
hippocampus volumes associated with genetic variants of the IL-6 gene (156). There is 
also some preliminary evidence suggesting that maternal psychopathology and HPA 
function influences fetal, infant, and adolescent HPA axis function resulting in a higher 
tonic setting of the HPA axis through epigenetic programming (157, 158). Psychiatric 
epigenetics is a relatively new field, however it does provide a biological mechanism by 
which stress might influence the immune response, and ultimately predispose to 
depression. Moreover, such mechanisms could lead to atypical early neurogenesis and 
vulnerable neural systems in the post-pubertal adolescent brain (50). Such a sensitization 
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of the neurobiological systems implicated in stress adaptation and response (as is seen in 
childhood maltreatment) may increase the risk of developing depression (159). Therefore, 
as individuals move through different stages of adolescence, the risk for depression as a 
consequence of stress exposure may change, and arguably so might the inflammatory 
stress-response profile. To date little gene-environment work has focused on stress 
exposure and depression onset in adolescents specifically – the stress exposure has 
primarily focused on either adulthood or childhood (although this at times spans 
adolescent years) (e.g. (54, 160)). 
Cytokines and onset of Depression during Adolescence 
Similarly to adult MDD, immune system dysregulation with a pro- and anti-inflammatory 
imbalance has been proposed in MDD in adolescents (161). The first study to examine 
cytokines in adolescent MDD, reported increased pro-inflammatory cytokines IFN-γ and 
IFN-γ/IL-4 as well as a trend for increased IL-6 in adolescents with MDD compared to 
healthy controls (161).   
In an attempt to examine the neurobiology of clinical subtypes of depression in 
adolescence, Gabbay et al. examined whether adolescent MDD with melancholic features 
(M-MDD) has distinct biological features in the kynurenine pathway. As previously 
reported, pro-inflammatory cytokines induce IDO, which metabolizes tryptophan (TRP) into 
kynurenine (KYN), eventually decreasing TRP availability in the brain (162). The authors 
reported decreased plasma TRP levels and an increased KYN/TRP ratio (estimating IDO 
activity) in adolescents with M-MDD compared to both non M-MDD and a control group. 
Interestingly, the severity of episodes as measured by Children’s Depression Rating 
Scale-Revised (CDRS-R) was associated with several KYN pathway measures (e.g., KYN 
and 3-hydroxyanthranilic acid (3-HAA)/KYN) in the M-MDD group (162).   
Investigating the relationship between early onset of depression and anxiety, IL-10 levels 
have been associated with increased anxiety and depression scores, and IFNα2 levels 
with anxiety scores only (163). The association between IFNα2 levels and anxiety scores 
remained significant after controlling for familial risk of MDD, gender, current stress, and 
childhood trauma (163), suggesting an independent effect of cytokines in anxiety. 
Of clinical relevance is the potential that cytokine levels are modified during treatment with 
antidepressants (64). In a clinical sample of adolescent females with MDD and/or anxiety 
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disorder the effects of antidepressant treatment with SSRIs on cytokine levels was 
compared to healthy controls (164). The overall sample showed significantly increased 
levels for IL-1β, IL-2 and IL-10 as compared to healthy controls, with SSRI-treatment 
associated with IL-6 levels in the clinical sample (164). The non-SSRI subgroup showed 
significantly higher levels of IL-1β, IL-2, and IL-6 compared to healthy controls. The 
authors concluded that pro-inflammatory cytokines are likely to be part of the 
pathophysiology of emotional disorders in adolescent females, and that SSRIs may exert 
anti-inflammatory properties in this patient group (164). 
Cytokine interactions with gonadal hormones 
The prevalence of major depression is known to increase during periods of changes in 
gonadal hormones (165). While the male-to-female ratio is 1:1 during childhood, the 1:2 
sex ratio that characterizes adult MDD first emerges during adolescence (39). The timing 
of the change in male-to-female prevalence ratios for depression has important 
implications for theories about the relationship between depression and puberty.  Angold 
et al. reported early the role of secondary sex characteristics in the development of 
depression (166). Characteristics of gender development (sex characteristics) as 
expressed in Tanner stages ranging from I-prepubertal to V-adult level of development 
have been suspected to better associate with the development of depression rather than 
age.  It also appeared that this transition in gender prevalence ratios was a mid-pubertal 
event, occurring in Tanner stage III, generating theories about a role of gonadal hormones 
in the etiology of depression (166). 
Research in pre-menopausal women indicates that gonadal hormones may modulate 
immune function (167, 168). The cytokine response of peripheral blood monocytes after 
LPS stimulation in premenopausal women appears to be modulated by the phase of the 
menstrual cycle (167). Specifically, a lower release of TNF-α (p<0.05) and IL-6 (not 
significant) during the luteal phase compared to the follicular phase was reported (167). 
Overall, however, findings on cytokine production across the normal menstrual cycle have 
been inconsistent (169) requiring further investigations. In addition, it remains to be 
examined as to whether such findings derived in adult women would generalize and apply 
to younger age groups such as adolescents. Systematic research is required to determine 
if a relationship exists in adolescence between cytokines and hormones that are important 
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for brain development. If such a relationship does exist, it will be important to determine if 
cytokines modulate gonadal hormones or vice versa. 
Differences in the Role of Cytokines in Depression between Adolescents and Adults 
In this section, we aim to identify evidence for possible differences and similarities on the 
role of cytokines in adolescent and adult MDD. It is worthwhile to summarise the findings 
on the possible involvement of natural killer (NK) cells in adult and adolescent depression 
as an expression of immune activity in this psychiatric condition. While studies in adult 
MDD when compared to age consistent controls consistently demonstrate lower NK cell 
activity (170-172) and reduced number of major lymphocyte subclasses (173), studies of 
NK cell activity and lymphocyte subpopulations in adolescent MDD as compared to age 
consistent controls have yielded contradictory findings (174-178). Some of these 
inconsistencies in adolescent MDD might be related to methodologies such as accounting 
for adverse life events in some studies (175), or sampling of younger age groups (i.e. 
inclusion of both  children and adolescents) (174), or gender specific findings in girls (144).  
The inconsistent results in adolescents may also indicate a lack of any real association. 
However, the sample sizes for most of these studies are relatively small (174-178), and 
only one of the studies (144) used a longitudinal design.  
Table 2-1: Studies of Immune Markers in Depression in Adolescents 
Study Objectives Design Immune 
markers  
Results 
Targum et al., 
1990 (178)  
 
Determine if hospitalized 
adolescents with MDD or 
conduct disorder (CD) show 
reduced lymphocyte 
populations compared to 
controls, and whether there 
is an association between 
reduced lymphocyte nos / 
subpopulations and cortisol 
dysregulation in 
hospitalized adolescents 
 30 (11 patients with 
MDD, 5 males, 6 females, 
ages 15.5+/-1.6 yrs; 11 
with conduct disorder 
(CD), 7 males, 4 females, 
ages 15.3+/-1.2 yrs; 8 
controls, 4 males, 4 
females, ages 14.1+/-1.5 
yrs); structured diagnostic 
interviews using DSM-III 
criteria for MDD or 
conduct disorder; cross-
 Total T cells, 
CD4+, CD8+, 
CD16, total B 
cells 
 
No significant differences on 
any lymphocyte measure 
between patients and 
controls 
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sectional study 
Shain et al., 
1991 (177)  
 
 
To compare natural killer 
(NK) cell activity in 
depressed adolescent 
patients with NK cell activity 
in age- and sex-matched 
controls 
32 (16 patients with MDD, 
16 controls; 6 males, 10 
females in each group), 
ages 13-18 yrs; interview 
by child psychiatrist, 
using the Schedule for 
Affective Disorders and 
Schizophrenia (SADS) 
Present Episode version 
(179); cross-sectional 
study 
NK cell activity 
 
No significant differences 
between patients and 
matched controls.  Age 
significantly correlated with 
NK cell activity. 
Birmaher et 
al., 1994 
(175) 
 
 
Determine whether 
adolescents with MDD have 
disturbances in their cellular 
immunity, and to study 
whether the immunological 
changes detected are 
specific to depression or are 
general responses to stress 
54 (20 patients with MDD, 
5 males, 15 females; 17 
non-depressed patients 
with conduct disorder 
(CD), 7 males, 10 
females; 17 sex matched 
healthy controls), ages 
11-18 yrs, Tanner stage 
III or more; SADS Present 
Episode version; cross-
sectional study 
NK cell activity, 
lymphocyte 
subtypes 
 
Patients with CD 
significantly higher absolute 
number of B cells than 
healthy controls (p=0.02), 
and a significantly greater % 
of B cells than MDD group 
(p=0.05) and controls 
(p=0.02).   
Patients with CD (who had 
significantly more adverse 
life events) showed a trend 
for lower NK cell activity 
than those in the MDD 
group (p=0.08) and the 
control group (p=0.08). 
Bartlett et al., 
1995 (174)  
 
To examine for differences 
in immunity between 
children with MDD and 
healthy controls 
36 (18 patients, 18 
controls; 13 males, 5 
females in each group), 
ages 8-12 yrs; Diagnostic 
Interview Schedule for 
Children- Revised (DISC-
R) (180); cross-sectional 
study 
 
Total white 
blood cells 
(wbc), 
lymphocytes, T 
cells, B cells, 
monocytes, NK 
cells, CD4+, 
CD8+ cells 
Lowered NK cell activity in 
depressed subjects 
compared to healthy 
controls (p<0.001). 
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Schleifer et 
al., 2002  
(176) 
 
To determine if immune 
changes in MDD are age-
related 
72 (36 patients, 13 males, 
23 females; 36 sex 
matched healthy 
controls), ages 14-20 yrs; 
Diagnostic Interview 
Schedule for Children 
DSM-III-R criteria; cross-
sectional study 
 
Total wbc, 
lymphocytes, 
granulocytes, 
monocytes, T 
cells, B cells, 
CD4+, CD8+, 
CD29+, 
CD45RA+, NK 
cells, HLA-DR+ 
cells 
Increased levels of 
lymphocytes, T cells, B 
cells, CD4+, and CD29+ 
lymphocytes in depressed 
group compared to controls 
(p<.05).    Increased NK cell 
activity in MDD adolescents 
(p< .001)  
 
Caserta et al. 
2011 (144)   
To test the hypothesis that 
self-reported efficacy and 
depression would predict 
immunity and rate of 
illnesses.    
141 children, 76 males, 
65 females; assessed on 
3 occasions, 6 months 
apart; depression 
symptoms (Children’s 
Depression Inventory – 
Short Form) (181) and 
self-efficacy measured by 
self-report; parents 
recorded illness (mental 
health problems were not 
coded as illness); 
longitudinal study; age 7-
13 years (median age 9.3 
years) 
IL-6, NK cell 
functional assay 
Negative association 
between self-efficacy and 
IL-6 (p=0.03); depression 
was associated with 
increased NK cell function 
(p=0.02) and higher rates of 
illness (p<0.01) in girls older 
than 9.3 years of age; 
Key: CD= Conduct Disorder; CD cells= Cluster of Differentiation; MDD= Major Depressive Disorder; NK 
cells= natural killer cells; wbc= white blood cells; reference numbers for studies are included in study column 
(in brackets) 
A meta-analysis of studies examining the association between depression in adults and 
elevated levels of the inflammatory marker CRP have also yielded inconsistent results 
(182).  In adolescents, a large population-based study has found no apparent association 
between CRP and depressive symptoms (145). Although this first study indicates there 
may be a difference between adult and adolescent levels of CRP in depression, problems 
with this study include a lack of clinical diagnosis. In a meta-analysis of the associations of 
depression with CRP, IL-6, and IL-1, Howren et al. noted the importance of the method 
used to assess depression, with larger associations noted in clinical samples and when 
standard clinical interviews were used to assess depression (7).  Copeland et al. used a 
49 
 
structured interview to assess depression in a study examining longitudinal pathways 
between CRP and depression in adolescents and young adults (32). The authors found 
that cumulative depressive episodes predicted later CRP levels after adjusting for 
important covariates (covariates of sex, age, body mass index (BMI), current nicotine/ 
alcohol/ illicit drug use, current medication use, recent health ailments, and current low 
socioeconomic status) (32).   
Heterogeneity in results from both adult and adolescent studies may be due to no 
consideration of other variables that influence inflammation, such as stressful life events 
(28, 30) . Addressing such a potential confounder, Brambilla et al examined the immune 
function of children with a first episode of MDD unlikely to have been preceded by stressful 
events. Contrary to that seen in depressed adults, those children without the experience of 
stressful life events with MDD had normal IL-1β levels (183). However, it is likely that 
several depression studies in adults have not accounted for stressful life events, limiting a 
direct comparison with the study by Brambilla.   
Many studies in adult MDD have reported increased TNF-α compared to controls 
suggesting a role in the pathophysiology of depression (6, 184-187).   However, when 
studying suicidality in adult MDD, studies on its relationship with cytokines have not always 
included assessment of TNF-α (188, 189). A study which did include measurements of 
TNF-α in suicidal adults found increased levels of TNF-α (and IL-6) in suicide attempters 
compared to non-suicidal depressed patients and healthy controls (190).  In adolescents, 
contrasting findings were reported. Gabbay et al found that plasma levels of TNF-α were 
significantly decreased in suicidal adolescents with MDD compared to a nonsuicidal MDD 
group (191).  However, the authors noted their findings should be considered preliminary 
in view of the small sample size (30 patients, 15 controls), and the substantial percentage 
(57%) of patients receiving psychotropic medications (191). The authors also noted that 
due to the small sample size, in order to preserve statistical power, a multiple comparison 
correction was not applied (191).  
If these findings in vivo hold true, postmortem studies suggesting the serotonergic system 
of the prefrontal cortex (PFC) is implicated in suicide in both adolescents and adults (148, 
192), provide a possible pathway linking TNF-α levels to suicidality (191).  A proposed 
mechanism to explain how cytokines may affect behavior is through activation of the 
enzyme IDO, which results in altered serotonin metabolism (193, 194). Specifically, 
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increased 5-HT2A receptor binding has been observed in the PFC of teenage (148) and 
adult suicide victims (195).  In addition, serotonin has been observed to be depleted in 
multiple brain regions, including the frontal cortex, in rodents acutely administered IFN-α 
by intracerebroventricular injection (196).   
Importantly, cytokines in the brain of suicide victims, or subjects with depression, have not 
been systematically studied (197), and the direction of their association remains to be fully 
understood.  For example, Pandey et al. observed that the mRNA levels of TNF-α, IL-1β, 
IL-6, and protein levels of TNF-α and IL-1β were significantly increased in Brodmann area 
10 of the PFC of teenage suicide victims (compared to controls) (197).  Interestingly, 
Tonelli et al. found no significant change in TNF-α in male or female adult suicide victims, 
however observed increased IL-4 in female suicide victims and increased IL-13 in male 
suicide victims (193). It is possible that these studies are not directly comparable (Pandey 
et al. (197); Tonelli et al. (193)), as the pathophysiology of teenage suicide and the role of 
cytokines in teenage suicide may differ from that in adults (197).   
Table 2-2: Clinical Studies of Cytokines / Inflammatory Markers in Depression in Adolescents 
Study Objectives Design Inflammatory 
Markers 
Results 
Brambilla et 
al., 2004  
(183) 
To determine whether 
cytokine secretion is 
impaired at an early phase 
of development of 
depression, possibly 
involvement in the course of 
the disease 
33 (22 patients, 17 
males, 5 females; 11 
psychologically healthy 
age and sex matched 
controls), ages 6-14 
yrs; DSM IV criteria 
using the Kiddie SADS 
interview (198); cross-
sectional study 
Plasma IL-1β, 
TNF-α 
 
IL-1β levels significantly higher 
(p<0.0003, z= -2.95) and TNF-
α lower (p<0.01, z= -2.53) in 
dysthymic patients than in 
controls; IL-1β and TNF-α not 
significantly different between 
MDD and controls.  
Gabbay et al., 
2009 (161)  
To examine immune system 
dysregulation in 
adolescents with MDD 
45 (30 patients, 19 
females; 15 healthy 
controls, 8 females), 
ages 12-19 yrs; DSM-IV 
diagnostic criteria, then 
interview by child 
psychiatrist using the 
Plasma IFN-γ, 
TNF-α, IL-6, IL-
1β, IL-4 
Significantly increased plasma 
level of IFN-γ (p<0.003, 
Bonferroni corrected p<0.02) 
and IFN-γ/IL-4 ratio (p=0.007, 
Bonferroni corrected p<0.05) in 
adolescents with MDD; 
Trend for increased IL-6 in 
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Schedule for Affective 
Disorders and 
Schizophrenia – 
Present and Lifetime 
Version for Children (K-
SADS-PL) (199); cross-
sectional study  
adolescents with MDD 
compared to controls (p=0.09) 
Gabbay et al., 
2009 (191)  
To examine the role of 
cytokines in suicidal 
symptomatology in 
adolescent MDD 
Patient group as above 
(30 patients – 12 
suicidal, 18 non-
suicidal; 15 controls); 
cross-sectional study 
Plasma IFN-γ, 
TNF-α, IL-6, IL-
1β, IL-4 
Suicidal adolescents had 
significantly decreased plasma 
levels of TNF-α compared to 
non-suicidal adolescents with 
MDD (p=0.03); Increased IFN-γ 
in both suicidal (p<0.02) and 
non-suicidal (p=0.005) 
adolescents with MDD 
compared to controls; 
Gabbay et al., 
2010 (162)  
To examine whether MDD 
in adolescents has distinct 
biological features in the 
kynurenine pathway in MDD 
cases with (M-MDD) and 
without (Non M-MDD) 
melancholic features; 
20 adolescents with M-
MDD, 11 females; 30 
adolescents with non 
M-MDD, 16 females; 22 
healthy controls, 13 
females.  Ages 12-
19yrs. Interview by child 
and adolescent 
psychiatrist using the K-
SADS-PL. Cross-
sectional study 
Plasma TRP, 
KYN, 3-HAA 
KYN/TRP ratios significantly 
elevated and TRP 
concentrations significantly 
reduced M-MDD group 
compared to non M-MDD 
adolescents (p=0.001; p=0.006 
respectively), and controls 
(p=0.008; p=0.02 respectively); 
Significant positive correlation 
between 3-HAA/KYN and MDD 
severity in the M-MDD group 
(p=0.03); 
Blom et al. 
2012  (164) 
To study effects of 
antidepressants on 
systemic cytokines in post 
pubertal adolescent females 
with anxiety disorders 
and/or MDD compared to 
healthy controls 
42 adolescent females 
with MDD, 60 healthy 
controls; age 14 – 18 
years. Assessment by 
child and adolescent 
psychiatrist or 
psychologist and the 
Development and 
Wellbeing Assessment 
(DAWBA)-interview 
Plasma IL-1β, 
IL-2, IL-6, IL-
10, IFN-γ, TNF-
α 
Unmedicated subgroup of 
clinical sample showed 
significantly higher IL-2, IL-1β 
and IL-6 compared to controls 
(adjusted Z= -3.3, p<0.001; 
adjusted Z= -2.2, p<0.05; 
adjusted Z= -2.3, p<0.05 
respectively); in the medicated 
subgroup, only IL-2 was 
significantly higher as 
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(200); cross-sectional 
study 
compared to controls (adjusted 
Z= 2.3, p<0.05).  Unmedicated 
subgroup of clinical sample 
showed significantly higher IL-6 
and IL-6/IL-10 compared to 
medicated subgroup (adjusted 
Z= 2.8, p<0.001, adjusted Z= 
2.5, p<0.05 respectively);  
Pandey et al. 
2012 (197)  
To examine the role of pro-
inflammatory cytokines in 
suicide 
24 suicide victims (14 
males, 10 females), 24 
controls (17 males, 7 
females).  Cause of 
death for the controls 
varied (e.g heart 
disease, motor vehicle 
accident); unclear if 
controls ever attempted 
suicide; Ages 12-20 
years; cross-sectional 
study 
Protein and 
mRNA levels of 
TNF-α, IL-1β 
and IL-6 in 
prefrontal 
cortex 
Significantly increased mRNA 
levels of TNF-α, IL-1β and IL-6 
in Brodmann area 10 of the 
PFC in suicide victims 
(p<0.01).  Significantly 
increased protein levels of 
TNF-α and IL-1β in Brodman 
area 10 of the PFC in suicide 
victims (p<0.01) 
Quinones et 
al. 2012 (163)  
To further understand the 
role of specific immune 
mediators early in the 
development of depression 
and anxiety 
A group at high familial 
risk for MDD (n=134), 
and an age and sex 
matched low-risk group 
(n=149); no previous 
mood disorder or 
substance abuse 
diagnosis.  Ages 12-15 
years; cross-sectional 
study 
Plasma 
cytokine levels 
IL-10 was significantly 
associated with anxiety and 
depression scores; IFNα2 
levels were correlated with 
anxiety scores independent of 
familial risk for mood disorders 
and environmental stressors 
 
Key: CRP= C-reactive protein; HAA= hydroxyanthranilic acid; IFN= interferon; IL= interleukin; KYN= 
kynurenine; LPS= lipopolysaccharide; MDD= Major Depressive Disorder; M-MDD= Major Depressive 
Disorder with melancholic features; NK cell = natural killer cell; TNF= tumor necrosis factor; TRP= 
tryptophan; reference numbers for studies are included in study column (in brackets) 
In summary, studies that provide empirical data for a role of cytokines in adolescent MDD 
currently show similarities and differences between adolescents and adults, not allowing 
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definite conclusions at this stage. Similarities include increased IL-6 levels, and decreased 
plasma TRP levels (161, 162).  Differences in IL-1β variation have been reported, with 
normal levels in “un-stressed” children with MDD (183) and elevated levels in adults with 
MDD (201). Plasma TNF-α was noted to be significantly decreased in adolescents with 
MDD and suicidality (191), yet mRNA levels of TNF-α were significantly increased in the 
PFC of teenage suicide victims (197).  A meta-analysis in adults with MDD, regardless of 
suicidality, suggests a consistent association between circulating levels of TNF-α and adult 
MDD (6). Therefore, results for TNF-α are inconsistent between studies, however 
cytokines have been measured from different sites (for example, plasma in Gabbay et al. 
(191), versus postmortem brain tissue in Pandey et al. (197)).  In addition, it remains to be 
clarified, if suicidality alone could account for the differences in cytokines reported in MDD 
studies in adults and adolescents.  
Small sample sizes in most of the studies on adolescents limit conclusions (e.g. 33 
individuals in the Brambilla et al. study (183), and 45 individuals in the studies by Gabbay 
et al. (161, 191)). In addition to small sample sizes, there are a range of ages of study 
participants (i.e. pre-pubertal and post-pubertal) in the studies. The youngest study 
participant was 6 years old in the Brambilla et al. study (183), and 7 years old (median age 
9.3 years) in Caserta et al. (144). 
There are significant differences between many of the study protocols, such as cross-
sectional studies of hospital inpatients (e.g. a proportion of patients in Gabbay et al. (161, 
191) were inpatients) versus longitudinal population-based observational studies (e.g. 
Copeland et al. (32), Miller and Cole (30)), prohibiting a formal meta-analysis.  Another 
significant difference between study protocols is the method used to assess for MDD or 
assess depressive symptoms.  Some studies used DSM criteria (e.g. Gabbay et al. (161, 
191), however others used self-report questionnaires (e.g. Chaiton et al. (145) used a 
depression subscale, Caserta et al. (144) measured depression symptoms and self-
efficacy using self-report).  These differences in the assessment of depression symptoms 
limit comparisons between studies, particularly as there are currently no diagnostic 
biomarkers for MDD.  A further issue is the problem of an unknown number of negative 
results not being published.  If these unpublished results are not included in meta-
analyses, this acts as a source of bias. Further research using epidemiological approaches 
(202) in well-powered and well-designed cohorts is required to provide empirical data to 
consolidate and build on these results. 
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Table 2-3: Population based Epidemiological Studies of Cytokines / Inflammatory Markers in 
Adolescents 
Study Objectives Design Inflammatory 
Markers 
Results 
Miller and 
Chen, 2010 
 (143) 
To evaluate if a harsh 
environment engenders a pro-
inflammatory phenotype in 
children that is marked by 
exaggerated cytokine 
responses to bacterial stimuli 
and the anti-inflammatory 
properties of cortisol 
135 adolescent females, 
assessed at 4 occasions 
over an 18 month period 
(prospective study).  No 
history of chronic medical 
or psychiatric disorders; 
Ages 15-19 yrs at time of 
study entry; UCLA Life 
Stress Interview – 
Adolescent Version (203) 
administered at each visit. 
Circulating serum 
IL-6, production 
of IL-6 following 
LPS stimulation, 
and resistance to 
glucocorticoids  
Those raised in a harsh 
environment showed 
increased IL-6 response 
to 2 different types of 
threatening stimuli - in 
vitro LPS (p=0.01) and a 
stressful life event 
(p=0.001).  Over this 
time, subjects also 
showed progressive 
desensitization of the 
glucocorticoid receptor 
(p=0.04) 
 Chaiton et 
al., 2010  
(145) 
To study the association 
between high-sensitivity C-
reactive protein 
concentrations and 
depressive symptoms in youth 
1,535 (721 aged 13 yrs, 
814 aged 16 yrs); self-
report questionnaires 
(depression subscale of 
the Psychological Distress 
Scale (204)); cross-
sectional study 
CRP No apparent association 
between depressive 
symptoms and serum 
CRP (p=0.81) 
Copeland et 
al., 2012 (32)   
To test 1. Effect of CRP levels 
on later depression status; 2. 
Effect of depression status on 
later CRP levels; 3. Effect of 
cumulative episodes of 
depression on later CRP 
levels 
1,420 children, ages 9, 11, 
and 13 years at intake; 
48.7% of total sample 
female. Longitudinal study, 
with annual assessments 
to age 16 years, and again 
at ages 19 and 21 years; 
depression assessed by a 
structured interview: Child 
and Adolescent Psychiatric 
Assessment (205) until age 
16, the Young Adult 
Psychiatric Assessment 
CRP (measured 
in dried blood 
spot samples) 
CRP levels were not 
associated with later 
depression status.  CRP 
levels increased with 
number of prior 
depressive episodes.  
Only cumulative 
depressive episodes 
predicted later CRP 
levels after controlling 
for covariates (p= 0.02) 
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(206) at later ages 
Miller and 
Cole, 2012  
(30) 
To aim to clarify the direction 
of the association between 
depression and inflammation 
To determine whether other 
kinds of childhood adversity 
(besides childhood 
maltreatment) also promote 
clustering of depression and 
inflammation 
147 adolescent females, 
assessed every 6 months 
over 2.5 years.  Ages 15-
19 years at time of study 
entry; Structured Clinical 
Interview for DSM-IV-TR 
(SCID) Axis I Disorders -
Non-Patient Edition (207); 
longitudinal study 
Serum CRP, IL-6 High levels of IL-6 
predicted risk of 
depression 6 months 
later in those with a 
history of childhood 
adversity (serum IL-6 
odds ratio 1.50, 95% CI 
1.10-2.06, p=0.01).  
Higher CRP levels 
remained 6 months after 
depressive episode had 
abated in those subjects 
exposed to higher levels 
of childhood adversity. 
Hood, 
Lawrence et 
al. 2012 (146) 
 
To provide preliminary 
evidence that the increased 
risk for depression in youth 
with diabetes is associated 
with metabolic and 
inflammatory markers 
To inform future examinations 
of the directionality of these 
associations 
2,359 youths with diabetes 
from the SEARCH study – 
an observational study of 
US children diagnosed with 
diabetes at <20 years of 
age.  Mean age of study 
participants 15.2 +/- 3.1 
yrs, 53% of sample female; 
depression measured with 
the Centre for 
Epidemiologic Studies 
Depression (CES-D) Scale 
(208). 
CRP, IL-6 CRP was significantly 
(p<0.006) associated 
with depression in youth 
with diabetes in 
bivariate analysis.  In 
regression models 
stratified by diabetes 
type and accounting for 
demographic and 
clinical characteristics, 
only higher levels of 
apoB remained 
associated with higher 
levels of depression in 
youth with type 1 
diabetes. 
Key: CRP= C-reactive protein; IL= interleukin; LPS= lipopolysaccharide; reference numbers for studies are 
included in study column (in brackets) 
A summary of the differences in immune and inflammatory markers between adults and 
adolescents with MDD is provided below in Table 2.4. 
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Table 2-4: Summary of Differences in Immune and Inflammatory Markers in Adult versus 
Adolescent Depression 
Study Age group Immune or 
Inflammatory marker 
Results 
Kronfol et al., 1989 (170), 
Nerozzi et al., 1989 (171), 
Irwin et al., 1990  (172) 
Adult  NK cell activity Decreased NK cell activity in 
patients suffering an episode of 
MDD  
Shain et al., 1991 (177) Adolescent NK cell activity No significant differences in NK 
cell activity between patients with 
MDD and matched controls.  
Bartlett et al., 1995 (174) Adolescent NK cell activity Lowered NK cell activity in 
depressed subjects. 
Schleifer et al., 2002 (176) Adolescent NK cell activity Increased NK cell activity in 
adolescents with MDD. 
Maes et al., 1991 (201) Adult IL-1β Elevated IL-1β levels in adults 
with MDD 
Brambilla et al., 2004 (183)  Adolescent IL-1β Normal IL-1β levels in children 
with MDD 
Dowlati et al., 2010 (6) Adult TNF-α Elevated TNF-α in adults with 
MDD 
Gabbay et al., 2009 (191) Adolescent TNF-α Decreased TNF-α in suicidal 
adolescents with MDD  
Key: IL= interleukin; MDD = Major Depressive Disorder; NK cell = natural killer cell; TNF= tumor necrosis 
factor 
 
III. Clinical Implications  
 
Antidepressant drugs appear to have some action on pro-inflammatory cytokines (209, 
210), with  attenuation of an imbalance between pro- and anti-inflammatory cytokines in 
patients with MDD treated with the antidepressants fluoxetine, sertraline, or paroxetine 
(184, 187, 211-213).  Furthermore, patients who fail to respond to antidepressants have 
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been found to demonstrate increased plasma concentrations of IL-6 and acute phase 
reactants when compared to treatment-responsive patients (214-216).   
Other agents and treatment programs that have anti-inflammatory actions or block actions 
of cytokines, such as physical exercise and omega-3 polyunsaturated fatty acids, may 
have a role in the treatment of depression. It is possible that physical exercise may exert 
similar anti-inflammatory effects beneficial to improving depressive symptoms, which are 
believed to be more globally mediated through various pathways of the neuroimmune 
system (96).  As recently extensively reviewed by these authors, consistent exercise / 
physical activity has been shown to reduce levels of IL-1β, TNF-α, IL-6, and CRP (96), 
whereas studies examining the cytokine levels during or immediately after exercise have 
shown an upregulation of IL-6 and IL-8 (217, 218). The short-term effects of exercise with 
an acute transient upregulation of IL-6 appears to induce a rise in IL-10 (219), and to 
negate neurotoxic changes of TNF-α (220).  Further research has been recommended to 
enhance alternative treatment approaches to depression, such as physical exercise, that 
might improve depression via the immune system (96). 
A meta-analysis of 10 double-blind, placebo-controlled studies in adult patients with mood 
disorders receiving omega-3 PUFAs, indicated an antidepressant effect of omega-3 
PUFAs (221). However, the authors noted that it is premature to draw firm conclusions 
based on the findings due to the heterogeneity of the different study methodologies (221). 
Similar effects have also been reported for children in a small randomized controlled trial 
study showing that long chain omega-3 PUFAs supplementation in the treatment of 
children with a first episode of depression had a benefit in reducing depressive symptoms, 
however not in achieving remission (222). Given the implication of omega-3 PUFAs in 
depression, it is therefore interesting that omega-3 PUFAs have the capacity to decrease 
the production of pro-inflammatory cytokines, and exert strong anti-inflammatory effects 
(74); studies in adolescents could add valuable knowledge to the literature.   
In studies of adults with depression, cytokine antagonists have also been found to have 
antidepressant-like effects (223-227).  TNF-α blockers such as etanercept and infliximab 
have been found to attenuate the depressive symptoms that accompany immune system 
activation in psoriasis (223-225, 227).  However, conflicting results have been reported for 
TNF-α antagonists such as infliximab in that depressed patients with higher levels of CRP 
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prior to treatment may benefit from such treatment as opposed to a general benefit in 
depression (226).  
Anti-inflammatory medications have also been found to have antidepressant-like effects.  
For example, acetylsalicylic acid added to fluoxetine led to increased remission rates in 
depressed patients previously unresponsive to fluoxetine alone (228).   Furthermore, in 
patients with MDD adding the cyclooxygenase-2 (COX-2) inhibitor celecoxib to treatment 
with reboxetine (229) or sertraline (230) induced an antidepressant response. Interestingly, 
Abbasi et al. also showed a significantly greater reduction in serum IL-6 concentrations in 
the group treated with celecoxib and sertraline (compared to the group treated with 
sertraline) (230).      
It has been noted that selectively targeting COX-2 in the treatment of depression may be 
problematic (231).  Consistent with determining the mechanism of action of COX-2 
inhibitors in depression, Maes reviewed possible detrimental effects of COX-2 inhibitors 
targeting pathways involved in depression.  He concluded that treatments with COX-2 
inhibitors may aggravate the pathophysiology of depression, through involvement in 
pathways which include lowering of antioxidant defenses and inducing neuroinflammation 
(231).  As anti-inflammatory treatments and the use of cytokine antagonists are less 
common in adolescents than in adults, further research is required to determine if 
interventions that act on immune responses are effective interventions for depression in 
adolescent populations.  
Conclusion 
 
A substantial body of literature has now focused on the association between cytokines and 
depression, primarily in adults with less extensive research in adolescents (73).  However, 
this review shows that the role of cytokines in adolescent depression is characterized by 
many similarities with adult MDD, although important differences of cytokines in 
depression between these age groups may be emerging.  
The relatively small number of studies on the role of cytokines in adolescent MDD has to 
be taken into account alongside with several methodological issues, which limit their 
comparability among studies in adolescents but also with research in adults. In general, 
the sample sizes of these studies are small and few have employed a prospective design. 
This could particularly be an issue if altered cytokine levels are a consequence of illness, 
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rather than a cause. If this is the case, altered cytokine levels in adolescence would be 
more subtle, and so larger sample numbers would be required to detect them statistically, 
compared to adult studies where changes might be more established and pronounced. 
Depression in children and adolescents show some different immune and inflammatory 
changes to those seen in adult depression in the current literature, with contradictory 
findings of NK cell activity, and differences in pro-inflammatory cytokines such as IL-1β 
and TNF-α (177, 183, 191, 197). In adults with MDD, NK cell activity has been found to be 
decreased (170-172), however in adolescents with MDD, NK cell activity has been found 
to be increased (176), unchanged (177), and decreased (174). The elevated levels of IL-
1β seen in adults with MDD have not been found in adolescents (183). Decreased levels 
of TNF-α have been found in adolescents with MDD (191), however many studies in adults 
(including a meta-analysis) have found elevated levels of TNF-α in MDD (6, 184-187). 
Some of the reported differences between the role of cytokines in depression could be 
influenced by neurodevelopment, hormonal changes, stress, and trauma, with more direct 
effects in young individuals as they experience developmental changes compared to 
adults. An improved understanding of the role of cytokines in adolescent MDD also in 
relation to stress, maltreatment, hormonal changes and genetic background may inform 
aetiology and treatment options in adolescent depression.   
Further research is warranted to explore more broadly the role of cytokines in depression 
of adolescents considering adequately the neurobiological, hormonal and environmental 
changes young individuals are undergoing. Moreover, additional treatment options might 
be suitable in some forms of inflammation associated depression in adolescents.  Initially, 
the field could be progressed with the inclusion of measurements of circulating cytokines, 
such as IL-1β, IL-6, and TNF-α, in intervention studies in adolescent MDD. Later, 
interventions that change levels of circulating plasma cytokines in adolescents with MDD 
may prove worthy of investigation. Importantly, future research requires well-designed, 
well-powered clinical studies that consider environmental factors (in particular stressful life 
events), in addition to using genetic, developmentally, and physiologically sensitive 
designs with prospective community-based studies, as well as psychiatric samples (50). 
 
 
60 
 
Acknowledgements 
This work was supported by grants from the Australian Research Council (FT0991360) 
and Australian Rotary Health. 
Conflict of Interest 
None 
 
 
 
 
 
 
 
 
Chapter review 
 
This chapter addressed aim 1 of the thesis: to review systematically the literature so as to 
identify differences in the role of cytokines in depression in adolescents compared to 
adults.  This review helped to inform the design of studies described in the chapters that 
follow.  The literature review also identified challenges in accurately measuring cytokines 
and inflammatory markers.  Significant gaps in the literature were also identified by 
undertaking this review.  
 
 
 
 Cytokines mediate key steps in cellular and humoral immunity  
 Immune system dysregulation / pro- inflammatory cytokines have been 
implicated in adult major depressive disorder (MDD) 
 Studies on the role of cytokines in adolescent MDD are few; the immune / 
inflammatory changes seen in adolescent MDD show specific similarities 
and differences to those seen in adult MDD 
 Cytokines may influence neurodevelopment during adolescence 
 Potential treatments that modify inflammation require further research, as 
this may lead to better outcomes in the treatment of adolescent MDD 
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CHAPTER 3 
 
In this chapter I report analyses of measures of cytokines, inflammatory markers, and 
other blood measures involved in immune regulation in a pilot study of healthy adolescent 
twins.  The purpose of the pilot study was to determine if these biomarkers could be 
measured accurately, to provide important preliminary data for an intended larger study in 
twins and for the clinical study reported in Chapter 4. Part 1 of this chapter, published in 
the Journal Twin Research and Human Genetics (February 2015), reports the 
measurement and investigation of genetic variance of two of the measured cytokines and 
Vitamin D.  In fact, the pilot study highlighted important difficulties in the measurement of 
cytokines.  Part 2 of this chapter reports the measurement and investigation of genetic 
variance of cytokines (measured in dried blood spots (DBS)), neurotrophins and antibodies 
(gliadin antibodies and antibodies to infectious agents) and the analytical steps that led to 
my conclusions that most of the pilot data could not be presented for publication.  As a 
result of the analyses of this pilot study we decided that we should not progress to the 
intended larger study. 
 
PART 1: Heritability of Transforming growth factor-β1 and Tumour 
necrosis factor-receptor type 1 expression and Vitamin D levels in 
healthy adolescent twins 
 
Total Word Count: 6,759 
Word count excluding abstract, acknowledgements, references, and tables: 4,337 
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Abstract 
 
Cytokines and vitamin D both have a role in modulating the immune system, and are also 
potentially useful biomarkers in mental illness such as major depressive disorder and 
schizophrenia. Studying the variability of cytokines and vitamin D in a healthy population 
sample may add to understanding the association between these biomarkers and mental 
illness.   
To assess genetic and environmental contributions to variation in circulating levels of 
cytokines and vitamin D (25-hydroxy vitamin D: 25(OH)D3), we analysed data from a 
healthy adolescent twin cohort (mean age 16.2 years; standard deviation 0.25). Plasma 
cytokine measures were available for 400 individuals (85MZ, 115DZ pairs), dried blood 
spot sample vitamin D measures were available for 378 individuals (70MZ, 118DZ pairs).  
Heritability estimates were moderate but significant for the cytokines transforming growth 
factor-β1 (TGF-β1), 0.57 (95% CI 0.26 – 0.80) and tumour necrosis factor-receptor type 1 
(TNFR1), 0.50 (95% CI 0.11 – 0.63), respectively. Measures of 25(OH)D3 were within 
normal range and heritability was estimated to be high (0.86, 95% CI 0.61 – 0.94). Assays 
of other cytokines did not generate meaningful results. 
These potential biomarkers may be useful in mental illness, with further research 
warranted in larger sample sizes. They may be particularly important in adolescents with 
mental illness where diagnostic uncertainty poses a significant clinical challenge.  
 
Keywords: cytokines, vitamin D, major depression, psychosis, heritability 
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Introduction 
 
Emerging evidence suggests a range of blood measures may be useful biomarkers in 
mental health disorders such as Major Depressive Disorder (MDD) and schizophrenia. 
Potential blood biomarkers include measures of Vitamin D, cytokines, C-reactive protein 
(CRP), and antibodies to infectious agents (7, 13, 232). Blood biomarkers may be 
particularly relevant in adolescence, where depression is often comorbid with other 
disorders (17) resulting in diagnostic uncertainty. Genetic and environmental influences 
both contribute to the aetiology of psychiatric disorders (233). Heritability is estimated 
around 40% for MDD (234, 235) and around 80% for schizophrenia (236).  The presence 
of  plasma pro-inflammatory cytokines (20, 161) and variation in Vitamin D levels  (13)  in 
adolescents with mental illness is especially interesting, with both also having a role in the 
modulation of the immune system (12). At present these biomarkers are not specific to a 
particular mental illness (MDD or schizophrenia). However, understanding how putative 
biomarkers vary in a healthy population of adolescents may help in guiding the study of 
these blood measures in psychiatric disorders in adolescents. Examining the link between 
psychiatric disorders and immune system dysregulation (161), and the genetic contribution 
to these biomarkers, are both required to understand the role of plasma cytokines and 
vitamin D levels in adolescent psychiatric disorders.  
Cytokines: 
Cytokines are small proteins that mediate key steps in cellular and humoral immunity (64), 
and have been shown to act as neuromodulators. Examples of pro-inflammatory cytokines 
include Interleukin-1β (IL-1β), Interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-α) (6, 
15), (with tumour necrosis factor-receptor type 1 (TNF-R1) the key mediator of TNF 
signalling in most cells) (237). Some cytokines, such as transforming growth factor-beta 
(TGF-β) and TGF-β1, have both pro-inflammatory and anti-inflammatory effects (5, 238). 
Cytokines, in particular pro-inflammatory cytokines, have been associated with both MDD 
and schizophrenia. MDD is thought to be associated with immune system dysregulation (1, 
28, 53, 161). In adults, a recent meta-analysis reported an association between elevated 
levels of two pro-inflammatory cytokines, IL-6 and TNF-α, and MDD (6). It is also possible 
that symptoms of depression may be a result of natural variation between individuals in 
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levels of circulating cytokines even in the absence of specific immune challenge such as 
infection. 
A role for immune system dysregulation in schizophrenia has also been hypothesized 
(239, 240). Levels of circulating cytokines have been associated with acute exacerbations 
of schizophrenia. Specifically, a recent meta-analysis reported an increase in the cytokines 
IL-1β, IL-6, and TGF-β during acute relapse and/or first episode psychosis which 
normalised with antipsychotic treatment (15). The same meta-analysis found IL-12, TNF-α, 
Interferon-γ (IFN-γ) and soluble IL-2 receptor (sIL-2R) appeared to be trait markers, with 
levels elevated in first episode psychosis, and remaining so following antipsychotic 
treatment. Levels of IL-12, TNF-α, and IFN-γ were also found to be elevated in acute 
relapses of schizophrenia, and remained elevated following antipsychotic treatment (15).  
Some studies have measured cytokine response in stimulated cells, for example ex vivo 
stimulation with amyloid-β in whole blood (241), or antigen-stimulated whole-blood assays 
(242).  This is likely to reflect the heritability of the immune response rather than natural 
variation. Few studies have estimated the heritability of circulating levels of cytokines, 
particularly in adolescents. Heritabilities of circulating levels of the cytokines IL-1β, IL-6, IL-
10 and TNF-α have been estimated in adult females, with the cytokines IL-1β and IL-10 
found to be moderately heritable (range 0.27 – 0.32 and 0.3 for IL-1β and IL-10, 
respectively), and the cytokines IL-6 and TNF-α found to be less heritable (range 0.15 – 
0.16 and 0.17 – 0.23 for IL-6 and TNF-α, respectively) (80). It should also be noted that 
measurement of cytokines is known to present difficulties and quantification of cytokine 
levels has been found to depend on a number of factors. For example, concentrations of 
several inflammatory markers have been found to change depending on whether serum or 
plasma is collected (243), and healthy adolescents should have very low levels of 
circulating inflammatory cytokines (15). Furthermore, circulating levels of some cytokines 
vary throughout a 24 hour period (for example IL-2) (21), or a 7 day period (for example 
TNF-α) (169).  These challenges all need to be considered in the design of studies 
involving the measurement of cytokines. 
Vitamin D: 
Vitamin D is best known for its role in skeletal health. More recently, vitamin D has also 
been implicated in non-skeletal health such as cancers, immunology and psychiatric 
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disease (12, 244, 245). Activation of cells of the immune system results in upregulation of 
the Vitamin D receptor (246). Furthermore, Vitamin D is a direct inhibitor of the pro-
inflammatory cytokine IL-17 (247). With regard to psychiatric disease, an increased risk of 
depression has been associated with low Vitamin D in cross sectional studies (248), yet 
this may reflect individuals with depression spending less time outdoors with less sun 
exposure. However, a prospective study of 2,759 individuals found a significant 
association between low Vitamin D measured at 9 years of age, and higher scores on 
depressive symptoms at 11 and 14 years of age (13). With regard to schizophrenia, an 
association has been observed with increased risk of this syndrome later in life in 
neonates who had either low levels or high levels of Vitamin D (249).  
Heritability estimates for Vitamin D show much variation and some also seem to vary 
across season of measurement and sex. Heritability of Vitamin D ranges from 0.43 in 
European adult twins (98.3% of these twins were female) (250) to as high as 0.80 in the 
German Asthma Family Study Group (251). A study of male twins found Vitamin D levels 
to be highly heritable during winter, but not heritable in summer (252), whilst a study of 
male and female twins found Vitamin D to be heritable in summer, but not during winter 
(253).  Sex differences have been observed with a study of Vitamin D in rural Chinese 
adolescent twins estimating heritability at 0.86 for males and 0.17 for females (254).  
With the clinical diagnosis of both MDD and schizophrenia likely to represent a biological 
heterogeneous group of disorders, identification of biomarkers that stratify patients for 
application of “stratified medicine” is a direction worthy of further research (18). The study 
reported here represents preliminary research towards the goal of understanding the role 
of potential blood biomarkers (specifically plasma cytokine and vitamin D measures) of 
depression and psychosis. We could not find prior published heritability estimates for some 
of these cytokines. We use a population based sample of healthy adolescent twins to 
assess the genetic and environmental contributions to variation in circulating levels of 
these potential biomarkers. 
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Methods 
 
Samples:  
Participants were 16 year old twins (mean 16.2 years, standard deviation (SD) 0.25 years) 
from the Brisbane Adolescent Twin Study (255). In this sample, both plasma cytokine and 
dried blood spots (DBS) Vitamin D measures were collected as part of a study focussing 
on health and well-being in an adolescent population sample. Plasma cytokine measures 
were available for 400 individuals (48.25% males, 51.75% females, 85 MZ twin pairs and 
115 DZ twin pairs), DBS Vitamin D measures were available for 378 individuals (50.13% 
males, 49.87% females, 70 MZ twin pairs and 118 DZ twin pairs, two twin pairs were 
incomplete). Of these twin pairs, 49 MZ twin pairs and 74 DZ twin pairs had data available 
for both plasma cytokine and Vitamin D measures.  
Blood was collected when twins came in for testing as close as possible to their 16th 
birthday. To explore impact of age of biological sample in this pilot study we selected 
individuals who participated either between the years of 1997 – 2000 (wave 1) or between 
the years of 2006 – 2009 (wave 2). Blood samples were available from these years both 
as plasma (for measurement of cytokines) and DBS (for measurement of Vitamin D). DBS 
for the measurement of Vitamin D were stored on Whatman 903 filter paper for wave 1, 
and on Whatman FTA cards impregnated with antibacterial agents to preserve DNA for 
wave 2. Blood of two members of a twin pair (i.e. co-twins) was always collected within the 
same wave.  
Assay of plasma cytokine and Vitamin D measures  
Plasma cytokine measures: A total of 25 plasma cytokines and inflammatory markers were 
measured at the James Cook University, Townsville, Australia. Of these 25 markers, TGF-
β1 and TNFR1 were assayed successfully. Specifically, plasma cytokines and 
inflammatory markers were divided into 4 separate groups, based on multiplexing 
compatibility with other cytokines and inflammatory markers with the groups as follows: 
Group 1: TGF-β1; Group 2: Interleukin-2 (IL-2), IL-4, IL-7, IL-11, IL-12, IL-13, TNF-α, IL-
17A, IL-21, Exotaxin, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). 
Group 3: IL-1α, IL-1β, IL-3, IL-5, IL-6, IL-8, IL-9, IL-10, IFN-γ-inducible protein 10 (IP-10), 
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Monocyte Chemo-attractant protein-1 (MCP-1), Macrophage inflammatory protein-1a (Mip-
1a), IFN-γ; Group 4: TNFR1.  
TGF-β1 and TNFR1 were measured individually (not part of the multiplex) due to not being 
compatible with other cytokines. For TGF-β1 (560429) we used the Human TGF-β1Duoset 
ELISA kit (R&D). We used BD Biosciences flex set multiplex assays at half strength 
(allowing double the number of samples) compared to the manufacturers 
recommendations, supported by pilot analyses. Plasma samples were diluted 4 times 
before testing, consistent with observations from the kit manufacturer (and our own pre-
experiment measurements) that undiluted plasma causes high background signal that 
interferes significantly with specific signals. Standard curves were generated using 
technical controls of lyophilised standard protein at a known concentration. In addition, for 
all cytokines and inflammatory markers an intra-assay experiment (to evaluate accuracy of 
the method) was run on 20 samples created from tissue culture medium spiked with 
standards. The experimental design for the plasma samples ensured that co-twins (two 
members of a twin pair) were randomised across plates.  
Of the cytokines measured in plasma we found that only the two assays conducted for 
individual cytokines (TGFβ1 and TNFR1) not included in the multiplex, generated 
meaningful results. For the multiplexed cytokines (groups 2 and 3) we found that although 
the technical controls (the intra-assay experiment) were measured accurately, the assay 
was not sufficiently sensitive to the low circulating levels in healthy adolescents following 
the recommended dilution of sample.  
Given the poor outcome of cytokine assays from plasma samples we also attempted to 
assay cytokines from DBS (256). Inflammatory markers are more stable in DBS, with 
measurable concentrations of cytokines found to be stable in DBS stored at different 
temperatures for many days when compared to DBS frozen immediately after preparation 
(although long-term storage at -20°C is considered optimal) (256). Whilst measurable 
amounts of most cytokines have been found to be nearly constant in DBS stored up to 23 
years, a marked decrease over time has been noted in measurable concentrations of IL-
1β, IL-8, sIL-6ra, Matrix Metallopeptidase-9 (MMP-9), Triggering Receptor Expressed on 
Myeloid cells 1 (TREM-1), CRP, Brain-derived Neurotrophic Factor (BDNF), and 
Neurotrophin-4 (NT-4) in stored DBS (257). We found that the cytokine measures were 
sensitive to paper type (often generating null reads for one or other paper) and were 
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subject to plate effects which could not be adjusted appropriately in an experimental 
design in which co-twins within a twin pair were present on the same plate. We also 
attempted to measure antibodies to infectious agents (258), another potential biomarker 
for MDD, but also found the assays to be highly sensitive to paper type and plate effects, 
and few individuals had non-null measures.  
Vitamin D measures: the main circulating form of Vitamin D is 25 hydroxyvitamin D3 
(25[OH]D3) (244). In our study, 25(OH)D3 was measured from DBS by liquid 
chromatography tandem mass spectroscopy (249, 259) at the University of Queensland, 
Brisbane, Australia. The assay method is highly sensitive, and can measure 25(OH)D3 in 
DBS stored for between 8 to 22 years (259). With this method, assay calibrants are 
extracted and derived in the same way as clinical samples, using multi-point calibration 
curves (259). Co-twins were plated in adjacent wells on the same plate. As Whatman FTA 
paper is thicker than 903 and therefore absorbs more blood, standards were prepared on 
both paper types in accordance with previous studies (260).  
For the measurement of 25(OH)D3 the experimental design for the DBS was not ideal for 
partitioning of variance as co-twins of the same pair were plated in neighbouring wells of 
the same plate. Under this design, batch effects are common to the twin pair so will be 
partitioned into the common environmental component. In contrast, if co-twins of a twin 
pair are plated randomly, batch effects will partition into the unique environment variance 
component. The DBS plating layout had been established for a different study interested in 
differences between twin pairs in blood markers. The static associated with tiny blood 
spots meant that replating was not practical. However, the extensive technical controls 
implemented in the 25(OH)D3 assay eliminated plate effects and so confounding of plate 
and twin pair was not an issue. 
Statistical analyses:  
To account for non-normality of the data, a square root transformation was applied to 
TGFβ1. Subsequently, TGFβ1 and TNFR1 were standardized and effects of plate and 
year of blood sampling were regressed out. For 25(OH)D3, which is largely affected by 
seasonal differences in ultra violet exposure, a cosinor regression model was fitted to the 
data to adjust for seasonality, additionally possible effects of sex, year of blood sampling, 
and paper type (261) were regressed out. Year of blood sampling did not have a 
significant effect on any measure.  
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A saturated model was fitted to the residuals to estimate MZ and DZ twin correlations for 
cytokines TGFβ1 and TNFR1 and for 25(OH)D3. A saturated model does not hold any 
assumptions regarding the underlying variance components model. Means and variances 
were constrained to be equal across zygosity groups and twin correlations were 
constrained to be equal for same-sex DZ and opposite-sex DZ twin pairs to improve 
stability of the genetic model. Within the saturated model, differences in means and 
variances between first and second born twins and between zygosity and sex (and BMI for 
25(OH)D3) were tested using likelihood ratio tests.  
To investigate the relative contributions of genetic and environmental factors to the 
observed variation in TGFβ1, TNFR1, and 25(OH)D3 univariate variance components 
models were specified. The analysis of 25(OH)D3 was done in the full sample as well as 
separately including individuals which had their blood collected in summer or winter (where 
the months May through October inclusive were considered winter and November through 
April inclusive were considered summer in the Southern hemisphere). Within these 
models, the variance was partitioned into additive genetic (A), common environmental (C), 
and unique environmental (E) variance components. ‘A’ represents the additive genetic 
effects of alleles summed up over all genetic loci in the genome, ‘C’ represents shared or 
common environmental factors that render offspring of the same family more alike, and ‘E’ 
represents environmental factors that result in differences between family members, ‘E’ 
also includes measurement error.  
To examine the significance of estimated variance components, the fit of a nested 
(increasingly more restricted) model was compared to the fit of the full model. Two sub 
models were considered, (i) a model including A and E and (ii) a model including C and E. 
Goodness-of-fit of these sub models was assessed using likelihood ratio tests. The 
difference in log-likelihoods between the full (ACE) model and the reduced (AE or CE) 
model follows a χ2-distribution and was evaluated using a χ2-difference test. If the χ2-
difference test is significant the estimate of the variance component that is removed from 
the model (e.g., C in an AE-model) is considered significantly larger than zero. If the χ2-
difference test is not significant, the estimate of the variance component that is removed 
from the model is not significantly larger than zero. Twin correlations and variance 
components were estimated in the statistical software package Mx (262).  
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Results 
 
Means and variances of raw values for TGFβ1, TNFR1, and 25(OH)D3 are shown in Table 
3-1. For TGFβ1 and TNFR1 we were not able to find an agreed normal reference range to 
which we could compare our results, Vitamin D levels were within the normal range (263). 
For TNFR1, we observed a significant difference in means between males and females 
with males having higher levels than females (p <0.001). For 25(OH)D3, we observed 
significant differences in variances (p=0.001) between MZ and DZ twins (with MZ twins 
having on average higher levels and larger variance compared with DZ twins) and a birth 
order effect in both means (p<0.05) and variances (p<0.01) (with first born twins having on 
average lower levels of vitamin D and smaller variance). We expect the effects of zygosity 
and birth order to be a result of the sampling variance. The phenotypic correlations 
between the Vitamin D and the two cytokine measures were not significantly different from 
zero. 
MZ correlations were significantly higher than DZ correlations for TGFβ1 and 25(OH)D3, 
and approached significance for TNFR1 (Table 3-1) suggesting a genetic component in 
the variance decomposition. Given the small sample size we did not estimate heritability 
separately for males and females. Twin correlations, however, were very similar for males 
and females suggesting no differences in heritability estimates across sex in our data 
(Table 3-1).  
Table 3-1: Means, Variances (of raw values), and Twin Correlations (with 95% Confidence 
Intervals) for transformed values of TGFβ1, TNFR1, and 25(OH)D3. 
 Mean  Variance rMZ (95% CI) rDZ (95% CI) 
TGFβ1 
A: 30.54 
M: 29.66 
F:  31.45 
A: 327.75 
M: 339.30 
F: 316.41 
A: 0.72 (0.62,0.80) 
M: 0.68 (0.50,0.79) 
F: 0.77 (0.63,0.85) 
A: 0.45 (0.29,0.58) 
M: 0.60 (0.30, 0.76) 
F: 0.54 (0.31, 0.70) 
TNFR1 
A: 809.25 
M: 890.70  
F:  725.01 
A: 85039.67 
M: 82972.81  
F: 73712.50 
A: 0.52(0.35, 0.65) 
M: 0.53 (0.23, 0.70) 
F: 0.52 (0.29, 0.67) 
A: 0.21 (0.04,0.37) 
M: 0.27 (0.00, 0.48) 
F: 0.25 (-0.10, 0.52) 
25(OH)D3 
A: 69.51 
M: 71.84  
F: 67.16 
A: 752.87 
M: 824.77 
F: 673.56 
A: 0.91 (0.87,0.94) 
M: 0.92 (0.87,0.95) 
F: 0.91 (0.84,0.94) 
A: 0.49 (0.33,0.62) 
M: 0.76 (0.60,0.85) 
F: 0.71 (0.49, 0.82) 
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Key: rMZ = monozygotic twin pair correlation; rDZ = dizygotic twin pair correlation;  
        A=males and females combined; M=males; F=females 
Notes: TGFβ1and TNFR1: Measured in ng/ml; Number twin pairs = 85 MZ, 115 DZ  
            25(OH)D3: Measured in nmol/L; Number twin pairs = 70 MZ, 118 DZ 
 
Sex was included as a covariate in the means model in the genetic analyses. We did not 
include sex as a covariate in the variance model, neither did we consider birth order 
effects in our genetic models. Including those effects in our genetic models would greatly 
reduce power given the current sample size, which in turn would probably lead to spurious 
results.  
Within the genetic model, the two cytokines were found to be moderately heritable (Table 
3-2), with heritabilities estimated at 0.57 (95% CI 0.26 – 0.80, χ2 =12.49, p=<0.001) and 
0.50 (95% CI 0.11 – 0.63, χ2 =5.9, p=0.008) for TGFβ1 and TNFR1, respectively. 
Heritability of 25(OH)D3 (all months combined) was estimated to be high (0.86, 95% CI 
0.61 – 0.94, χ2 = 55.98, p=<0.001) (Table 3-2). Heritability of 25(OH)D3 for individuals who 
had blood collected in the summer months was also high (0.90, 95% CI 0.60 – 0.94, χ2 = 
25.43, p=<0.001), whilst heritability for individuals who had blood collected in winter was 
moderate (0.56, 95% CI 0.31 – 0.92, χ2 = 23.023, p= 0.001). For the cytokines TGFβ1 and 
TNFR1, any plate or batch effects would tend to increase the unique environment variance 
component.  
Table 3-2: Heritabilities of TGFβ1, TNFR1, and 25(OH)D3 (with 95% Confidence Intervals) 
 A C E 
TGFβ1 0.57(0.26,0.80) 0.16(0.00,0.42) 0.27(0.20,0.38) 
TNFR1 0.50(0.11,0.63) 0.00(0.00,0.29) 0.50(0.37,0.66) 
25(OH)D3 - overall 0.86(0.61,0.94) 0.06(0.00,0.30) 0.09(0.06,0.13) 
25(OH)D3 - summer 0.90 (0.60,0.94) 0.00 (0.00,0.30) 0.10(0.06,0.17) 
25(OH)D3 - winter 0.56(0.31,0.92) 0.36(0.00,0.60) 0.08(0.05,0.14) 
 
Key: A= standardized additive genetic variance; C= standardized common environmental variance; E= 
standardized unique environmental variance 
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Discussion  
 
We set out to determine if potential biomarkers for MDD and schizophrenia were heritable 
in a community cohort of healthy adolescent twins. Mean levels of circulating Vitamin D, 
measured as 25(OH)D3, were in the normal range for healthy Australian adolescents 
(263). The differences in variances observed for 25(OH)D3 may have been due to chance. 
The heritability estimates of the two cytokines that could be measured in plasma were 
found to be moderate (57% and 50% for TGFβ1 and TNFR1, respectively) whilst the 
heritability of vitamin D was found to be high (86%).  
The heritability estimate for the standardised values of Vitamin D was similar to the 
heritability of 0.80 found for Vitamin D (specifically also 25(OH)D3) in the German Asthma 
Family Study Group (251), and 0.86 found for 25(OH)D (as 25(OH)D3) in male rural 
Chinese adolescent twins (254), but greater than the estimate of 0.43 estimated in adult 
twins from the St Thomas UK Adult Twin Registry (Hunter, De Lange et al. 2001). Similar 
to Snellman et al. (253), we found the heritability estimate of Vitamin D to be higher in the 
summer months. This was in contrast to another study, which observed heritability of 
Vitamin D to be higher in winter months (252). The only previous published report we 
could find estimating the heritability of TGFβ1 found a heritability of 0.28, however the 
levels of this cytokine were estimated in an antigen-stimulated whole-blood assay (242). 
We could not find published reports of heritabilities of TNFR1 to which to compare our 
results.  
A genetic contribution to variation in circulating levels of cytokines TGFβ1 and TNFR1 and 
Vitamin D is potentially relevant in the aetiology of MDD and schizophrenia, as each of 
these biomarkers may contribute to a role in the aetiology of these disorders. Here we 
show the variance of these biomarkers is largely genetic, whilst changes in environmental 
factors appear to have less influence. Variants in the Major Histocompatibility Complex 
(MHC) region have been associated with schizophrenia (240, 264), and many of the genes 
of this region code for cytokines (265). This association does not appear to be driven by 
the high linkage disequilibrium in the extended MHC (240). With the complexity of the 
MHC region presenting challenges in understanding its role in schizophrenia (266), further 
study of shared genetic factors between these biomarkers and schizophrenia is warranted. 
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The possibility of shared genetic factors between these biomarkers and MDD could also 
be investigated in future studies.  
It should also be noted that although we did not find a strong positive phenotypic 
association between cytokines and vitamin D measures, this was to be expected. 
Stimulation of human CD4+CD25- T lymphocytes in the presence of 1,25(OH)2D3 has 
been shown to inhibit production of pro-inflammatory cytokines, including IFN-γ and IL-17 
(267). Low levels of plasma 25(OH)D3 have been associated with chronic disease where 
inflammation has been found to play an important role, such as type 2 diabetes (268). This 
finding may not diminish the potential usefulness of these blood biomarkers, rather it 
suggests that the role of Vitamin D deficiency in inflammation may be an area where 
further research is warranted (12).  
A limitation of our study is that healthy adolescents are expected to have very low levels of 
circulating inflammatory cytokines (15). This may explain why our initial ELISA multiplex 
assay performed on plasma samples was not sufficiently sensitive (i.e. did not generate 
useable results) to the circulating levels of cytokines in our healthy community cohort of 
adolescents.  This was despite the assay being calibrated to standardised adult samples 
(269). To address the limitation of assay sensitivity, high-sensitivity assays (such as ELISA 
single assays or high sensitivity kits based on the Luminex 200 system) can be used. 
ELISA assays utilize undiluted samples, but they usually need high volume of sample (up 
to 500µL per sample). A limitation of the TGF-β1 assay was the volume of sample 
required. The human TGF-β1 Duoset ELISA used required 100 µl of sample. This was 
higher than the volume of aliquots available, so we decreased the sample volume used to 
50 µl. In addition, the release of TGF-β1 from platelet granules upon platelet activation 
also needs to be considered. Our protocol should remove platelets from the plasma 
sample but incomplete removal of platelets, which can cause variable and irreproducible 
results (270), would serve to reduce estimates of heritability.  
Recommendations for future studies could include extending this research to adolescents 
with MDD or schizophrenia (or psychotic symptoms) and conducting both univariate and 
bivariate analyses to investigate to what extent genetic impact on circulating levels of 
cytokines and vitamin D are heritable and whether the same genes affect these measures 
in people with psychiatric disorders such as MDD and schizophrenia. However, high 
sensitivity assays (such as ELISA single assays), with larger sample sizes would be 
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required. This could be followed by investigating the role of other potential blood 
biomarkers (such as CRP and antibodies to infectious agents) in adolescents with MDD or 
psychosis.  
Conclusion 
 
This study reports heritability estimates of cytokines/inflammatory markers and Vitamin D 
in a community based cohort of adolescent twins. The heritability estimate for Vitamin D 
was high whereas the two cytokines that could be measured in plasma showed moderate 
heritabilities. As presented in the published literature, we found measurement of cytokines 
at the levels circulating in healthy adolescents to be difficult, perhaps limiting their utility. 
Further research (which takes into account the limitations of our present study) is 
warranted to explore the potential uses of these biomarkers, in particular in adolescents 
with mental health disorders.  
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PART 2: Evidence of genetic variance in putative biomarkers for 
depression in a cohort of healthy adolescent twins  
 
Abstract  
 
Introduction: Part one of this chapter reported on two cytokines measured in plasma and 
vitamin D measured in dried blood spots (DBS) in a pilot study of healthy adolescent twins. 
Other cytokines were measured (in both plasma and DBS) in the same samples of twins, 
as were other potential biomarkers (measured in DBS) that may be associated with MDD, 
including neurotrophins, gliadin antibodies, and antibodies to infectious agents.  Here I 
report on the analysis of these data.  
Methodology: Study participants are 16 year old twins (mean age 16.2 years, standard 
deviation 0.25 years) from the Brisbane Adolescent Twin Study.  For cytokines, 
neurotrophins, and antibodies measured in DBS, there were 87 monozygotic (MZ) twin 
pairs and 126 dizygotic (DZ) twin pairs.  Of these twin pairs, 65 MZ twin pairs and 81 DZ 
twin pairs (total of 146 twin pairs) had plasma measures of cytokines and inflammatory 
markers (reported in part one of this chapter), and 128 individuals were participants in the 
Brisbane Systems Genetics Study.   
Results: All cytokines, neurotrophins, and antibodies measured in DBS suffered from 
batch effects and from confounding of plate and twin pair. Common and unique 
environmental factors were not able to be estimated. Cytokines and neurotrophins 
measured through gene expression showed large unique environmental effects. 
Conclusions: The study highlighted important limitations to consider when further 
exploring the potential use of these biomarkers in adolescent mental illness.  Due to these 
limitations, variance component estimations of the data were not reliable, and hence 
heritability estimates are not able to be reported.    
 
Introduction 
 
Identifying potential blood biomarkers of Major Depressive Disorder (MDD) is a direction 
worthy of further research (18).  Reasons for this include the potential to assist in 
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diagnosis, and to improve treatment by re-classifying illness (19). As discussed in part one 
of this chapter, a range of blood measures may be useful as biomarkers of illness not only 
in MDD, but also in other mental illnesses such as psychosis.  Potential blood biomarkers 
include cytokines, neurotrophins, antibodies to infectious agents, and Vitamin D (13, 232, 
271, 272).  A preliminary question is how putative biomarkers vary in a healthy population 
of adolescents. Since genetic factors are important in MDD (heritability 0.37) (234) and 
particularly adolescent onset MDD, the contribution of genetic factors to natural variation in 
biomarkers is of interest. 
Evidence that MDD may be associated with immune system dysregulation has been 
provided for both adults (1, 6) and adolescents (28, 53), although there are considerably 
fewer studies on the immune system in adolescent MDD (161, 164, 273).  It is possible 
that natural variation between individuals in levels of circulating cytokines or other 
inflammatory markers, even in the absence of specific immune challenge (such as 
infection), is associated with depression.  Evidence for this comes from a recent meta-
analysis that reported an association between elevated levels of two pro-inflammatory 
cytokines, Interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), and MDD in adults 
(6).   
Neurotrophins regulate differentiation and survival of neurons, neurotransmitter release 
and synaptic plasticity (274). Examples of neurotrophins include brain-derived 
neurotrophic factor (BDNF),Neurotrophin-3 (NT-3), and Neurotrophin-4 (NT-4) (275).  
Plasma and serum BDNF levels have been found to be reduced in adults with MDD (272).  
In adolescents with MDD, one study investigated BDNF, and found lower levels of BDNF 
in those with MDD (276).  With regard to the role of NT-3 and NT-4 in MDD, one study in 
adults investigated expression levels of NT-3 mRNA and NT-4 mRNA in peripheral blood.  
The study found reduced expression of NT-3 mRNA in those with a current episode of 
MDD, but did not find a significant difference in expression levels of NT-4 mRNA (277).  
Exposure to infectious agents during childhood and adolescence may influence the 
development of mental illness in adult life (278).  A recent systematic review and meta-
analysis found significant associations between schizophrenia and the viruses Human 
Herpes Virus 2, Borna Disease Virus, and Human Endogenous Retrovirus W (HERV-W) 
(232).  Among the bacteria and parasites examined in this systematic review and meta-
analysis, there was a statistically significant association between schizophrenia and 
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infection by Toxoplasma gondii, Chlamydophila pneumonia, and Chlamydophila psittaci  
(232).  Prenatal depression and anxiety have also been associated with latent 
toxoplasmosis (10, 279).  The associated immune response following exposure to 
infectious agents such as T. gondii has been postulated to be a factor in the development 
of mental illnesses such as schizophrenia (280).  For example, astrocyte activation during 
toxoplasma infections increases brain kynurenic acid production (281, 282).  Furthermore, 
it has been hypothesized that dopamine is increased by activated pro-inflammatory 
cytokines (such as IL-2) (283) as a consequence of toxoplasma infection (284).  With 
regard to MDD, activated pro-inflammatory cytokines are part of the body’s immune 
response to infection (59).  
The body’s immune response to non-infectious agents has also been hypothesized as a 
possible link with mental disorders such as MDD and schizophrenia.  For example, the 
presence of antibodies to gliadin signifies an immune response to glutens in dietary cereal 
grains, and usually indicates celiac disease or wheat allergy (285).  Celiac disease has 
been associated with a subsequent risk of MDD, and MDD has been associated with a 
subsequent diagnosis of celiac disease (11).  With regard to schizophrenia, an increased 
risk has been reported in patients with celiac disease (286).  An association has been 
observed between gliadin antibodies and schizophrenia (287), and between high levels of 
maternal gliadin antibodies and the subsequent development of non-affective psychosis in 
offspring (288).   
Previous heritability estimates for cytokines have sometimes been estimated on stimulated 
cells, reflecting the heritability of the immune response (241) rather than natural variation.  
A twin study estimating heritabilities of circulating levels of the cytokines IL-1β, IL-6, IL-10 
and tumour necrosis factor-α (TNF-α) found heritabilities to be moderate for IL-1β (range 
0.27 – 0.32) and IL-10 (0.30), and low for IL-6 (range 0.15 – 0.16) and TNF-α (range 0.17 
– 0.23) (80).  Heritability estimates for antibodies to infectious agents have shown a strong 
influence of shared environment, presumably from exposures shared by twins living in the 
same family.  However, genetic factors have also been found to have a strong influence on 
antibody levels for some pathogens (289).    
The objectives of this study are i) to measure cytokines / inflammatory markers, 
neurotrophins, antibodies to common infections, and gliadin antibodies in a community 
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based population of adolescent twins and ii) to determine genetic contribution to the 
variation of these biomarkers in a cohort of healthy adolescent twins. 
 
Methods 
 
Samples:  
Participants are 16 year old twins (mean 16.2, standard deviation (SD) 0.25 years) from 
the Brisbane Adolescent Twin Study. Blood was collected either between the years of 
1997 – 2000 (blood collected during these years was stored on Whatman 903 filter paper), 
or between the years of 2006 – 2009 (blood collected during these years was stored on 
Whatman FTA® cards impregnated with antibacterial agents to preserve DNA).  For dried 
blood spot (DBS) cytokine, other inflammatory markers, neurotrophin, and antibody 
measures, the sex distribution of the sample was 49.77% male and 50.23% female, with 
87 monozygotic (MZ) twin pairs and 126 dizygotic (DZ) twin pairs.  Of these twin pairs, 65 
MZ twin pairs and 81 DZ twin pairs (total of 146 twin pairs) previously had cytokines 
measured in plasma (two of which were reported in part one of this chapter).  Of the twins 
who had cytokines and other inflammatory markers measured in DBS, 128 individuals are 
also participants in the Brisbane Systems Genetics Study (290).  The study was approved 
by the Human Research and Ethics Committee of the QIMR Berghofer Medical Research 
Institute. 
Assay of cytokines / inflammatory markers, neurotrophins and antibodies 
The cytokines measured in plasma (not reported on in part one of this chapter) were 
measured at the James Cook University, Townsville, Australia.  The cytokines were 
measured in a multiplex assay, where they were grouped based on compatibility with other 
cytokines as follows:  Multiplex 1: Interleukin-2 (IL-2), IL-4, IL-7, IL-11, IL-12, IL-13, TNF-α, 
IL-17A, IL-21, Exotaxin, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). 
Multiplex 2: IL-1α, IL-1β, IL-3, IL-5, IL-6, IL-8, IL-9, IL-10, Interferon-γ-inducible protein 10 
(IP-10), Monocyte Chemo-attractant protein-1 (MCP-1), Macrophage inflammatory protein-
1a (Mip-1a), Interferon-γ (IFN-γ).  The preparation of plasma samples, generation of 
standard curves, and intra-assay experiment (to evaluate accuracy of the method) are 
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described in part one of this chapter.  The experimental design for the plasma samples 
ensured that co-twins (two members of a twin pair) were randomised across plates. 
A multiplex immunoassay (25-plex xMAP assay for analysis of DBS) was used to measure 
cytokines and other inflammatory markers in DBS (243).  Measurement was completed by 
the Statens Serum Institut, Copenhagen, Denmark.  Cytokines, other inflammatory 
markers, and neurotrophins measured in DBS were: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, 
IL-12, IL-17, IL-18, Interleukin receptor antagonist of IL-6 (IL-6ra), TNF-α, TNF-β, 
transforming growth factor-β (TGF-β), IFN-γ, Regulated and Normal T-cell Expressed and 
Secreted (RANTES), MCP-1, NT-4, BDNF, C-reactive protein (CRP), Macrophage 
inflammatory protein-1a (Mip-1a), Matrix Metallopeptidase-9 (MMP-9), Granulocyte 
Macrophage-Colony Stimulating Factor (GM-CSF), Triggering Receptor Expressed on 
Myeloid cells-1 (TREM-1).  
Antibodies were measured in DBS, using enzyme immunoassays (ELISA) at the John 
Hopkins University (258, 291).  Antibodies to the following infectious agents were 
measured: Toxoplasma (Toxo), Cytomegalovirus (CMV), Herpes Simplex Virus 1 (HSV1), 
Herpes Simplex Virus 2 (HSV2), and Human Herpes Virus 6 (HHV6).  In addition, gliadin 
antibodies were measured.   
Preliminary statistical analysis 
Preliminary analyses of the biomarkers assayed from DBS identified biomarkers that had 
failed or generated no or very limited variation between individuals. These biomarkers 
were excluded from analyses and included MMP-9 and IL-2. Biomarker measures from 
DBS were sensitive to paper type, often generating null reads for one or other paper, and 
were subject to plate effects as twin pairs were plated in adjacent wells on the same plate.  
Specifically, only measures from paper type 2 for IL-12, IL-18, IL-6ra, BDNF, CRP, HSV1, 
HHV6, CMV, and toxoplasma were variable between individuals.  Therefore, measures 
from paper type 1 of these corresponding biomarkers were excluded from analyses.  
Paper type influenced both mean and variance of measures and so analyses were 
conducted on winsorised residuals after regression of within-paper rank normalised 
measures on sex and plate (Figure 3-1, Figure 3-2).  
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Estimation of Genetic Parameters:   
As described in part one of this chapter, a saturated model was fitted to estimate MZ and 
DZ twin correlations for all cytokines, other inflammatory markers, neurotrophins, and 
antibodies.  Within the saturated model, differences in means and variances between first 
and second born twins and between zygosity, sex and body mass index (BMI) were tested 
using likelihood ratio tests.  The univariate variance component models described in part 
one of this chapter were used to investigate the relative contributions of genetic and 
environmental factors to the observed variation in the cytokines, other inflammatory 
markers, neurotrophins, and antibodies.  Twin correlations and variance components were 
estimated using the statistical software package Mx (262).  
For those individuals who are participants in both the Brisbane Adolescent Twin Study and 
stage II of the Brisbane Systems Genetics Study (BSGS), the correlation of cytokines 
measured in DBS with those measured by gene expression was calculated.  BSGS is a 
family based study, which provides genome-wide expression and genotype data for 962 
extensively phenotyped individuals (290). In stage II of BSGS,  transcript expression levels 
in whole blood for 862 individuals were measured with over 47,000 genome-wide probes 
using the Illumina HT-12 v4.0 microarray chip (290). 
Results 
 
For the cytokines measured from plasma in a multiplex, the assay was not sufficiently 
sensitive to the low levels of circulating cytokines in healthy adolescents. This was despite 
the technical controls having been measured accurately (the intra-assay experiment).  
Therefore, no cytokines measured from plasma in either multiplex generated meaningful 
results.   
Of the biomarkers measured in DBS, MMP-9 and IL-2 failed the assay. For MMP-9, the 
same value was obtained for every study participant. IL-2 was a tri-modal distribution, 
which could not be transformed to a more normalised distribution.   
Figure 3-1 and Figure 3-2 show the distribution of the cytokines TNF-α, TNF-β, MCP-1, 
TGF-β, Mip-1a, and the inflammatory marker TREM-1. The diagonal shows the distribution 
of each of these cytokines and TREM-1.  The off-diagonals contain all the pairwise scatter 
plots of the cytokines and TREM-1, with each row and column defining a single scatter 
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plot.  Each single scatter plot shows the correlations between a pair of cytokines (or 
between a cytokine and TREM-1).  So in Figures 3-1 and 3-2, the plot on the intersection 
of the 4th row and 5th column is a plot showing the correlation between the cytokines TGF-
β and Mip-1a. Owing to the skewed distributions (Figure 3-1), measures were rank-
normalised within paper, and then regressed on sex and plate (Figure 3-2).  The residuals 
that were more than 3 standard deviations from the norm were winsorised, with the 
resulting distribution shown in Figure 3-2.  Analyses were conducted on residuals after the 
regression (on sex and plate).  The distribution of other cytokines, inflammatory markers, 
and biomarkers are presented in the Appendix section of the thesis (pages 178-185).     
Figure 3-1: Distribution and correlations of TNF-α, TNF-β, MCP-1, TGF-β, Mip-1a, and TREM-1 
(measured in DBS)  
 
Key: MCP-1=Monocyte Chemo-attractant protein-1; Mip-1a=Macrophage inflammatory protein-1a; TGF-
b=transforming growth factor-β; TNF=tumour necrosis factor; TREM-1=Triggering Receptor Expressed on 
Myeloid cells-1  
Note: diagonal shows distribution of each cytokine and the inflammatory marker TREM-1; off-diagonals 
show correlations between a pair of cytokines (or between a cytokine and TREM-1, for example, the plot on 
the intersection of the 4th row and 5th column is a plot showing the correlation between the cytokines TGF-β 
and Mip-1a). 
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Figure 3-2: Distribution and correlations of TNF-α, TNF-β, MCP-1, TGF-β, Mip-1a, and TREM-1 
after regression of within-paper rank normalised measures on sex and plate (measured in DBS) 
 
Key: MCP-1=Monocyte Chemo-attractant protein-1; Mip-1a=Macrophage inflammatory protein-1a; TGF-
b=transforming growth factor-β; TNF=tumour necrosis factor; TREM-1=Triggering Receptor Expressed on 
Myeloid cells-1 
Note: diagonal shows distribution of each cytokine and the inflammatory marker TREM-1; off-diagonals 
show correlations between a pair of cytokines (or between a cytokine and TREM-1, for example, the plot on 
the intersection of the 4th row and 5th column is a plot showing the correlation between the cytokines TGF-β 
and Mip-1a). 
 
Figure 3-3 represents the phenotypic correlations of the transformed cytokines, other 
inflammatory markers, neurotrophins and antibodies in DBS.  Several pro-inflammatory 
cytokines and other inflammatory markers correlated highly with each other.  IL-6 had high 
correlations with IL-17 (0.72) and TREM-1 (0.72). GM-CSF correlated highly with TNF-β 
(0.77), and BDNF correlated highly with TGF-β (0.74).  The anti-inflammatory cytokine IL-
10 had negative or very low correlations with pro-inflammatory cytokines, with correlations 
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of -0.15 with IL-18, and 0.07 with both TNF-α and CRP.  Correlations of Vitamin D with the 
cytokines and inflammatory markers are not represented in Figure 3-3, as Vitamin D is 
discussed in part one of this chapter.  However a negative correlation between Vitamin D 
and IL-18 (-0.14) was not significant (p=0.054). 
 
Figure 3-3: Phenotypic correlations of transformed cytokines, other inflammatory markers, 
neurotrophins, and antibodies 
 
Key: BDNF=brain-derived neurotrophic factor; CMV=cytomegalovirus; CRP=C-reactive protein; 
GMCSF=Granulocyte Macrophage-Colony Stimulating Factor; HHV6=Human Herpes Virus 6; HSV=Herpes 
Simplex Virus; IFNg=Interferon-γ; IL=interleukin; MCP1=Monocyte Chemo-attractant protein-1; 
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Mip1a=Macrophage inflammatory protein-1a; NT4=neurotrophin-4; RANTES= Regulated and Normal T-cell 
Expressed and Secreted; TGFb=transforming growth factor-β; TNF=tumour necrosis factor; 
Toxo=toxoplasmosis; TREM1=Triggering Receptor Expressed on Myeloid cells-1   
 
The study design, which saw co-twins of the same pair plated in neighbouring wells of the 
same plate, had been established for another study (where interest was differences 
between co-twins).  This meant that plate effects were common to the twin pair, and 
therefore partitioned into the common environmental component.  Re-plating was not 
practical due to the static between blood spots. Despite these concerns about batch 
effects that could not be removed by statistical methods because of confounding, we 
continued on to conduct the variance component analysis. As will become clear, the 
conclusion of the analysis was that the batch effects compromised the results and extreme 
caution is needed in interpreting the results. For completeness, the analyses conducted 
that led to these conclusions are detailed below.  
In the model assumption testing prior to the estimation of variance components, for the 
cytokine RANTES there was a significant difference in means between males and 
females, with females having higher levels than males (p=0.04).  For the antibody HSV-2, 
a birth order effect was observed in means (p=0.006, with first born twins having on 
average lower levels of HSV-2).  Means were able to be constrained to equal for all other 
cytokines, inflammatory markers, neurotrophins, and antibodies.  For IL-8 and BDNF a 
birth order effect was observed in variances (p=0.014 and p=0.036 respectively), with first 
born twins having on average larger variance.  Variances were able to be constrained to 
equal for all other cytokines and biomarkers.  These effects of birth order are likely to be a 
result of the sampling variance.   
For the majority of the DBS measures both MZ and DZ correlations were of similar 
magnitude, and the DZ correlation was significantly higher than the MZ correlation for IL-
17 (Table 3-3).  Hence the estimates of the common environmental variance effects for 
these biomarkers were large (Table 3-4).  These results reflect technical confounding 
factors (in particular plating of co-twins of the same pair in neighbouring wells), which 
mean the variance component estimations are not reliable. 
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Table 3-3: Twin Correlations (with 95% Confidence Intervals in brackets) 
  MZ DZ MZF MZM DZF DZM DZO 
A GM-CSF 
0.47  
(0.29,0.60) 
0.65 
(0.54, 0.73) 
0.50  
(0.30, 0.65) 
0.39  
(0.04, 0.61) 
0.75  
(0.59, 0.84) 
0.61  
(0.39,0.75) 
0.59  
(0.38,0.73) 
A TNF-β 
0.50  
(0.33,0.63) 
0.49 
(0.35, 0.61) 
0.50 
(0.28, 0.65) 
0.51 
(0.19, 0.69) 
0.53 
(0.28, 0.70) 
0.54 
(0.26,0.71) 
0.43 
(0.20,0.60) 
A IL-6 
0.39 
(0.20,0.54) 
0.53  
(0.40,0.64) 
0.44  
(0.17,0.62) 
0.34  
(0.06,0.55) 
0.64  
(0.44, 0.77) 
0.60  
(0.37,0.74) 
0.35 
(0.05,0.57) 
A IL-17 
0.31 
(0.11,0.47) 
0.61 
(0.49, 0.70) 
0.37  
(0.10,0.57) 
0.23 
(-0.07, 0.48) 
0.65  
(0.44, 0.77) 
0.62  
(0.39,0.75) 
0.58 
(0.37,0.71) 
A IL-5 
0.53 
(0.35,0.66) 
0.53  
(0.40,0.64) 
0.62 
(0.42, 0.75) 
0.36 
(-0.06, 0.61) 
0.57 
(0.36, 0.71) 
0.56  
(0.33,0.71) 
0.46 
(0.20,0.63) 
A TREM-1 
0.54 
(0.38,0.66) 
0.51 
(0.37, 0.63) 
0.55 
(0.34, 0.69) 
0.51 
(0.26, 0.68) 
0.58 
(0.36, 0.73) 
0.51 
(0.25,0.68) 
0.52 
(0.24,0.69) 
A NT-4 
0.47 
(0.29,0.61) 
0.51 
(0.38, 0.62) 
0.61 
(0.40, 0.74) 
0.30 
(-0.02, 0.54) 
0.48 
(0.24, 0.65) 
0.40 
(0.14,0.59) 
0.69 
(0.50,0.80) 
A Mip-1a 
0.48 
(0.29,0.62) 
0.54 
(0.41, 0.64) 
0.50 
(0.24, 0.67) 
0.45 
(0.16, 0.64) 
0.71 
(0.52, 0.82) 
0.48 
(0.26,0.64) 
0.47 
(0.23,0.64) 
A IL-10 
0.24  
(0.04,0.42) 
0.38 
(0.22, 0.52) 
0.35  
(0.06,0.56) 
0.15 
(-0.14, 0.39) 
0.38 
(-0.01, 0.61) 
0.34  
(0.06,0.55) 
0.42 
(0.17,0.60) 
A IL-1β 
0.49 
(0.33,0.62) 
0.58 
(0.46,0.68) 
0.52  
(0.30,0.68) 
0.46  
(0.18, 0.64) 
0.52  
(0.27, 0.68) 
0.68  
(0.48,0.79) 
0.56 
(0.33,0.71) 
A IFN-γ 
0.25 
(0.03,0.44) 
0.44 
(0.29, 0.56) 
0.42 
(0.13, 0.62) 
0.10 
(-0.20, 0.37) 
0.62 
(0.37, 0.76) 
0.38 
(0.15,0.56) 
0.39 
(0.11,0.59) 
B IL-12 
0.49  
(0.24,0.66) 
0.42 
(0.18, 0.61) 
0.50  
(0.18,0.70) 
0.46  
(0.02, 0.71) 
0.65 
(0.31, 0.82) 
0.17  
(-0.40,0.58) 
0.38 
(-0.02,0.64) 
A MCP-1 
0.56 
(0.40,0.67) 
0.59 
(0.47, 0.69) 
0.47 
(0.23, 0.64) 
0.68 
(0.48, 0.79) 
0.74 
(0.57, 0.84) 
0.67 
(0.47,0.79) 
0.45 
(0.22,0.62) 
A RANTES 
0.68 
(0.56,0.77) 
0.57 
(0.43, 0.67) 
0.81  
(0.70,0.88) 
0.56 
(0.32, 0.71) 
0.53 
(0.26, 0.70) 
0.68 
(0.48,0.79) 
0.51 
(0.25,0.68) 
A IL-8 
0.80  
(0.72,0.86) 
0.70 
(0.60, 0.77) 
0.84  
(0.75,0.90) 
0.74  
(0.59, 0.83) 
0.83 
(0.73, 0.89) 
0.59  
(0.25,0.75) 
0.63 
(0.41,0.76) 
A TGF-β 
0.65 
(0.53,0.74) 
0.66 
(0.55, 0.74) 
0.69  
(0.53,0.79) 
0.60 
(0.38, 0.74) 
0.74 
(0.57, 0.84) 
0.64 
(0.42,0.77) 
0.62 
(0.41,0.74) 
A IL-4 
0.34  
(0.12,0.51) 
0.17 
(0.00,0.32) 
0.34 
(0.06,0.55) 
0.34 
(-0.03,0.58) 
0.08 
(-0.19, 0.35) 
0.13 
(-0.12,0.35) 
0.41 
(0.06,0.62) 
A TNF-α 
0.23 
(0.03,0.41) 
0.43 
(0.27,0.55) 
0.20 
(-0.06,0.43) 
0.27 
(-0.04, 0.51) 
0.47 
(0.19, 0.65) 
0.50 
(0.24,0.68) 
0.30 
(-0.02,0.54) 
B Toxo 
0.37 
(0.09,0.58) 
0.36 
(0.11, 0.55) 
0.60 
(0.26,0.78) 
0.16 
(-0.23, 0.49) 
0.19 
(-0.29, 0.55) 
0.36 
(-0.03,0.62) 
0.53 
(0.11,0.75) 
B CMV 
0.68 
(0.49,0.80) 
0.64 
(0.47, 0.75) 
0.77 
(0.54, 0.88) 
0.59 
(0.27, 0.77) 
0.60 
(0.22, 0.79) 
0.50 
(0.08,0.72) 
0.78 
(0.59,0.88) 
B HHV6 
0.32 
(0.05,0.53) 
0.26 
(-0.02,0.48) 
0.78 
(0.56, 0.88) 
0.04 
(-0.28, 0.35) 
0.36 
(-0.45, 0.71) 
0.27 
(-0.09,0.54) 
0.19 
(-0.29,0.56) 
A Gliadin 
0.15 
(-0.07,0.34) 
0.21 
(0.04, 0.36) 
0.34 
(-0.01,0.57) 
0.05 
(-0.21, 0.30) 
0.18 
(-0.17, 0.46) 
0.39 
(0.01,0.62) 
0.16 
(-0.07,0.37) 
A HSV2 
0.32 
(0.13,0.48) 
0.43 
(0.27, 0.56) 
0.32 
(0.09, 0.51) 
0.33 
(-0.02, 0.56) 
0.32 
(0.00, 0.55) 
0.51 
(0.18,0.70) 
0.46 
(0.23,0.63) 
B HSV1 
0.37 
(0.09,0.58) 
0.51 
(0.29, 0.66) 
0.71 
(0.43, 0.84) 
0.12 
(-0.25, 0.45) 
0.56 
(0.12, 0.78) 
0.54 
(0.20,0.74) 
0.38 
(-0.14,0.69) 
B CRP 
0.53 
(0.25,0.70) 
0.41 
(0.19, 0.58) 
0.67 
(0.35, 0.82) 
0.38 
(-0.09, 0.66) 
0.56 
(0.02, 0.78) 
0.43 
(0.05,0.67) 
0.35 
(0.02,0.59) 
B BDNF 
0.56 
(0.32,0.71) 
0.52 
(0.30, 0.67) 
0.68 
(0.42, 0.82) 
0.35 
(-0.19, 0.66) 
0.64 
(0.26, 0.81) 
0.45 
(-0.02,0.70) 
0.47 
(0.11,0.70) 
B IL-6ra 
0.46 
(0.21,0.64) 
0.57 
(0.36, 0.71) 
0.65 
(0.35, 0.80) 
0.30 
(-0.07, 0.57) 
0.67 
(0.23, 0.84) 
0.51 
(0.17,0.72) 
0.57 
(0.15,0.77) 
B IL-18 
0.45 
(0.19,0.64) 
0.62 
(0.43,0.75) 
0.69 
(0.42, 0.83) 
0.18  
(-0.24, 0.52) 
0.55 
(-0.06, 0.78) 
0.54 
(0.24,0.73) 
0.78 
(0.54,0.88) 
 
Key: MZ = monozygotic twin pairs; DZ = dizygotic twin pairs; MZF = monozygotic female twin pairs; MZM = 
monozygotic male twin pairs; DZF = dizygotic female twin pairs; DZM = dizygotic male twin pairs; DZO = 
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opposite sex dizygotic twin pairs; BDNF=brain-derived neurotrophic factor; CMV=cytomegalovirus; CRP=C-
reactive protein; GM-CSF=Granulocyte Macrophage-Colony Stimulating Factor; HHV6=Human Herpes Virus 
6; HSV=Herpes Simplex Virus; IFN-γ=Interferon-γ; IL=interleukin; MCP-1=Monocyte Chemo-attractant 
protein-1; Mip-1a=Macrophage inflammatory protein-1a; NT-4=neurotrophin-4; RANTES= Regulated and 
Normal T-cell Expressed and Secreted; TGF-β=transforming growth factor-β; TNF=tumour necrosis factor; 
Toxo=toxoplasmosis; TREM-1=Triggering Receptor Expressed on Myeloid cells-1                                   
Notes: A: Number twin pairs = 87 MZ, 126 DZ; B: Number twin pairs = 41 MZ, 61 DZ  
 
Table 3-4:  Estimates of the proportion of variance attributable to additive genetic effects (A) or 
heritabilities, common environmental effects of families (C) and unique environmental effects (E) 
(Univariate model), with 95% Confidence Intervals in brackets:  
  A C E 
A GM-CSF 
0.00  
(0.00,0.12) 
0.57  
(0.44,0.65) 
0.43  
(0.35,0.53) 
A TNF-β 
0.02  
(0.00,0.39) 
0.48  
(0.18,0.59) 
0.50  
(0.37,0.62) 
A IL-6 
0.00 
(0.00, 0.19) 
0.47  
(0.30, 0.57) 
0.53  
(0.43,0.64) 
A IL-17 
0.00  
(0.00, 0.11) 
0.48  
(0.36, 0.58) 
0.52  
(0.42,0.63) 
A IL-5 
0.01  
(0.00,0.35) 
0.52  
(0.24,0.62) 
0.47  
(0.34,0.58) 
A TREM-1 
0.00  
(0.00,0.35) 
0.53  
(0.24,0.62) 
0.47 
(0.35,0.57) 
A NT-4 
0.00  
(0.00,0.31) 
0.49  
(0.23,0.59) 
0.51 
(0.39,0.62) 
A Mip-1a 
0.00  
(0.00,0.26) 
0.51  
(0.30,0.61) 
0.49  
(0.38,0.59) 
A IL-10 
0.00  
(0.00,0.27) 
0.32  
(0.09,0.43) 
0.68  
(0.56,0.81) 
A IL-1β 
0.00  
(0.00, 0.20) 
0.54 
(0.36,0.63) 
0.46  
(0.37, 0.56) 
A IFN-γ 
0.00  
(0.00,0.22) 
0.37  
(0.17,0.48) 
0.63  
(0.52,0.76) 
B IL-12 
0.12 
(0.00,0.63) 
0.36 
(0.00,0.59) 
0.52  
(0.34,0.71)  
A MCP-1 
0.00  
(0.00,0.26) 
0.58  
(0.36,0.66) 
0.42  
(0.32,0.52) 
A RANTES 
0.23  
(0.00,0.53) 
0.45  
(0.18,0.67) 
0.32  
(0.23,0.44) 
A IL-8 
0.19  
(0.00,0.39) 
0.61  
(0.41,0.76) 
0.21  
(0.15,0.29) 
A TGF-β 
0.00  
(0.00,0.26) 
0.65  
(0.43,0.73) 
0.35  
(0.25,0.43) 
A IL-4 
0.34  
(0.00,0.50) 
0.00  
(0.00,0.31) 
0.66 
(0.51, 0.87) 
A TNF-α 
0.00  
(0.00,0.21) 
0.34  
(0.15,0.45) 
0.66  
(0.55,0.79) 
B Toxo 
0.00 
(0.00,0.53) 
0.36 
(0.00, 0.52) 
0.64 
(0.44, 0.82) 
B CMV 
0.10 
(0.00, 0.49) 
0.58 
(0.22, 0.74) 
0.33 
(0.21, 0.48) 
B HHV6 
0.11 
(0.00, 0.52) 
0.20 
(0.00, 0.45) 
0.69 
(0.48, 0.90) 
A Gliadin 0.00 0.18 0.82 
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(0.00,0.34) (0.00, 0.31) (0.65, 0.95) 
A HSV2 
0.00 
(0.00, 0.25) 
0.36 
(0.14, 0.47) 
0.64 
(0.53, 0.76) 
B HSV1 
0.00 
(0.00,0.37) 
0.44 
(0.11, 0.59) 
0.56 
(0.41, 0.73) 
B CRP 
0.20 
(0.00,0.67) 
0.31  
(0.00,0.58) 
0.49  
(0.31,0.71) 
B BDNF 
0.06  
(0.00,0.57) 
0.49  
(0.05,0.66) 
0.45 
(0.29,0.62) 
B IL-6ra 
0.00  
(0.00, 0.34) 
0.52 
(0.20, 0.65) 
0.48  
(0.35, 0.64) 
B IL-18 
0.00  
(0.00, 0.24) 
0.54  
(0.30,0.66) 
0.46  
(0.34,0.62) 
 
Key: A=additive genetic variance; C=common environmental variance; E=unique environmental variance; 
BDNF=brain-derived neurotrophic factor; CMV=cytomegalovirus; CRP=C-reactive protein; GM-
CSF=Granulocyte Macrophage-Colony Stimulating Factor; HHV6=Human Herpes Virus 6; HSV=Herpes 
Simplex Virus; IFN-γ=Interferon-γ; IL=interleukin; MCP-1=Monocyte Chemo-attractant protein-1; Mip-
1a=Macrophage inflammatory protein-1a; NT-4=neurotrophin-4; RANTES= Regulated and Normal T-cell 
Expressed and Secreted; TGF-β=transforming growth factor-β; TNF=tumour necrosis factor; 
Toxo=toxoplasmosis; TREM-1=Triggering Receptor Expressed on Myeloid cells-1                                      
Notes: A: Number twin pairs = 87 MZ, 126 DZ; B: Number twin pairs = 41 MZ, 61 DZ 
 
Estimates of heritabilities of the cytokines RANTES and the inflammatory marker TREM-1 
when measured through gene expression were moderate (0.31 and 0.23 respectively, 
Table 3-5).  Heritability estimates of the other cytokines and neurotrophins measured 
through gene expression were low (Table 3-5).  The BSGS investigated heritability 
distribution of all gene expression probes, and showed that the majority of genetic 
variance is additive (292).  Estimation of the common environmental variance effect of 
IFN-γ was very large (Table 3-5), with the remaining cytokines and neurotrophins 
measured through gene expression showing very large unique environmental effects. 
Table 3-5: Estimates of proportion of variance attributable to additive genetic effects (or 
heritabilities), and common environmental effects (measured through gene expression); and 
correlation of cytokines and other biomarkers measured in DBS with those measured by gene 
expression 
 A C r N 
TREM-1 0.23 0.05 -0.04 126 
Mip-1a 0.13 0 0.08 85 
IL-10 0.11 0 -0.04 128 
IL-1β 0.17 0 0.03 128 
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IFN-γ 0 0.82 N/A 6 
RANTES 0.31 0 -0.07 128 
IL-4 0 0 -0.06 22 
TNF-α 0.17 0.05 0.07 126 
BDNF 0 0 -0.28 21 
IL-18 0.06 0.1 0.08 126 
 
Key: A=additive genetic variance; C=common environmental variance; N = number of individuals with 
cytokines and other biomarkers measured in both DBS and by gene expression; r = correlation between 
cytokines / other biomarkers measured in DBS and cytokines / other biomarkers measured by gene 
expression; BDNF=brain-derived neurotrophic factor;  IFN=interferon; IL=interleukin; Mip-1a=Macrophage 
inflammatory protein-1a; RANTES= Regulated and Normal T-cell Expressed and Secreted; TNF=tumour 
necrosis factor; TREM-1=Triggering Receptor Expressed on Myeloid cells-1                             
 
Discussion 
 
Important limitations in the measurement of these biomarkers were encountered in this 
study, to the extent that the variance component estimations from these data are not 
reliable.  Hence, heritability estimates are not able to be reported.   
For the cytokines, other inflammatory markers, neurotrophins, and antibodies measured in 
DBS, common environmental components were high.  While high estimates of common 
environment may reflect factors such as a response to exposures common to family 
members such as infection, here we believe the low heritability estimates and high 
common environment estimates reflect deficiencies in the experimental design, detailed 
below.  
This study has highlighted important technical problems with the measurement of 
circulating cytokines and other biomarkers in healthy adolescents.  The DBS plating layout 
had been established for another study examining differences between twin pairs in blood 
markers, however this experimental design is not appropriate for partitioning of variance as 
twin pairs were plated in neighbouring wells of the same plate. Hence, batch effects are 
partitioned into the common environmental component, and interpretation of the twin 
correlations and variance components is unclear.  The high estimates of common 
environmental components of variance for most biomarkers may reflect inflation of 
common environmental effects because of this experimental design or it may reflect an 
important common environmental contribution reflecting shared family environment in 
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which immune and bacterial challenges may be shared between family members.  A 
further problem was the limited variation between individuals in circulating levels of some 
biomarkers (IL-12, IL-18, IL-6ra, BDNF, CRP, HSV1, HHV6, CMV, and toxoplasma), which 
led to these biomarkers from paper type 1 being excluded from further analyses.    
There are advantages as well as disadvantages with measuring biomarkers in DBS.  The 
multiplex assays for DBS allow measurement of the concentrations of several 
inflammatory markers simultaneously in small amounts of sample, and the use of internal 
assay markers may improve the analysis (243).  However, the potential interactions in 
bead-based multiplex assays between multiple antibodies and cytokines can be a 
disadvantage.  Specifically, these antibodies can then prevent binding of the capture ± 
detection antibody, and so produce a falsely low result (243).  A further limitation of this 
method is that the extraction of analytes may be less complete from old DBS (257).  
In view of the limitations of measuring biomarkers in a multiplex, an alternative method is 
high sensitivity Enzyme-linked immunosorbent assay (ELISA).  ELISA is the most widely 
used analytical method for measuring circulating inflammatory markers, where the 
concentrations measured depend on the antibodies and curve-fits that are used for 
calibration curves (293, 294).  Results of high sensitivity ELISA are highly quantitative 
(295).  However, ELISA allows only a single cytokine to be measured at a time, often 
requires higher volumes of sample, and generally costs more (295).  Further sources of 
uncertainty within the ELISA methodology include pipetting and plate variation (22).     
Another study, which measured the cytokines IL-1β, IL-6, IL-10, and TNF-α in serum, 
found heritabilities of IL-1β and IL-10 to be moderate, but also found unique environmental 
effects to be important (80).  Interestingly, the authors also found that heritability of some 
cytokines changed with age, with heritability of TNF-α increasing with age, and heritability 
of IL-1β decreasing with age (80).  With regard to antibody levels, the low heritability 
estimates measured were in contrast to the observations of another study.  Specifically, 
heritabilities for CMV and HHV-6 antibody levels were observed to be 0.39 and 0.28 
respectively, with small common environmental contributions to the variance of levels of 
these particular antibodies (289).   
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Conclusion 
 
This study has reported on DBS measurements of cytokines, other inflammatory markers, 
neurotrophins, antibodies to common infectious agents, and gliadin antibodies in a 
community based cohort of adolescent twins. Important limitations in the measurement of 
these biomarkers were encountered in the study, reflecting poor experimental design 
(confounding of plate and twin pair), batch and DBS paper effects. We concluded that the 
variance component estimation from these data were not reliable. These challenges and 
limitations need to be addressed in further research that explores the potential uses of 
these biomarkers in adolescents with mental health disorders.  
 
Chapter review 
 
The chapter addressed the aim of investigating the genetic variance of cytokines, other 
inflammatory markers, and biomarkers altered in inflammatory states in healthy 
adolescents.  This chapter also explored the difficulties in measuring cytokines and other 
inflammatory markers.  Those cytokines that were able to be measured in plasma 
generated meaningful results, and provided evidence of cytokines that could be measured 
(individually, using ELISA) in low concentrations.  It was important to have established that 
cytokines could be measured prior to attempting to measure these in a clinical sample in 
the following chapter.  However, most of the pilot data in part 2 of this chapter suffered 
from important limitations, making the variance component estimations from the data not 
reliable.    
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CHAPTER 4: Measuring cytokines in inpatients of an adolescent mental 
health unit: study design and lessons learned 
 
This chapter describes a study undertaken in a clinical sample of adolescents.  The design 
of the study, particular challenges encountered in implementing the study, and potential 
solutions to overcome these challenges (when planning future studies) are all discussed. 
Introduction: 
 
Mental disorders are highly prevalent in youth (296) however their assessment and 
management during this developmental period is complicated by the presence of 
considerable co-morbidity.  Depression and anxiety disorders commonly co-occur or 
emerge sequentially (17) and psychotic symptoms frequently accompany these disorders 
(297).  This phenotypic overlap challenges diagnosis and management (297, 298).   
These challenges in diagnosis are also considered in the Research Domain Criteria 
(RDoC) project of the National Institute of Mental Health (NIMH) (299).  RDoC uses 
dimensional constructs, which include symptoms and potential biomarkers of mental 
illness (300).  RDoC is currently a framework for organising research (299), and by 
attempting to link symptoms of mental illness to underlying neurobiology, recognises that 
identifying potential biomarkers is a direction worthy of further research (18).  
These potential biomarkers include cytokines, small proteins with immune modulating 
activity (75).  Increasingly, cytokines have been associated with Major Depressive 
Disorder (MDD) in adults through immune system dysregulation, even in the absence of 
infection (1).  A meta-analysis of 24 studies reported an association between elevated 
levels of 2 pro-inflammatory cytokines (tumour necrosis factor-α (TNF-α) and interleukin-6 
(IL-6)) and MDD in adults (6).  Emerging evidence suggests that circulating levels of blood 
cytokines may also be a useful biomarker of MDD in adolescents (20, 301), with immune 
system dysregulation also observed in adolescent MDD (161).   
A systematic review identified 18 studies measuring cytokines or immune markers in 
adolescents with depression or depressive symptoms (20).  A more recent systematic 
review of inflammatory markers in MDD in children and adolescents identified 27 (including 
7 longitudinal) studies (301).  Compared to studies of adults, some differences in the 
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immune response of adolescents with depression have been identified.  For example, 
Brambilla et al. (2004) examined the immune function of children with a first episode of 
MDD unlikely to have been preceded by stressful events.  Contrary to that seen in 
depressed adults, those children with MDD who had not experienced stressful life events 
had normal IL-1β levels (183). Furthermore, in contrast to adults with MDD, plasma TNF-α 
was noted to be significantly decreased in adolescents with MDD and suicidality (191). 
At the time of commencing the study that forms the basis of this thesis chapter, only three 
studies (30, 31, 143) of cytokines in adolescent MDD had included measures of childhood 
adversity.  The paucity of studies of cytokines in adolescents is an important issue for 
further investigation, as a coupling of depression and inflammation has been noted during 
this developmental phase (28, 30), with ‘biological embedding’ of stress already seen in 
adolescence (28, 29).   Specifically, individuals with MDD or a history of MDD have been 
found to have higher levels of C-reactive protein (CRP) compared to those with no 
depression or maltreatment, those with a history of maltreatment and no MDD have been 
found to have even higher levels of CRP, and those with a history of maltreatment and 
MDD have been found to have the highest CRP levels (28, 29).   
Circulating levels of cytokines can be measured from serum, plasma and dried blood spots 
(DBS). For measurement in plasma or serum, the most widely used analytical method is 
Enzyme-linked Immunosorbent Assay (ELISA), where the concentrations measured 
depend on factors such as the antibodies used for calibration curves (294).  For 
measurement of circulating levels of some inflammatory markers, DBS are superior to 
plasma or serum if samples cannot be prepared and frozen quickly (256).  Cytokines can 
also be measured through gene expression in peripheral blood cells (302).  White blood 
cells have been proposed as a useful peripheral model to study inflammatory processes in 
the central nervous system (CNS) (302), especially for genes encoding stress mediators 
and cytokines (302, 303).      
Many factors affect circulating levels of cytokines and / or gene expression of cytokines.  
Circulating levels of some cytokines and other inflammatory markers vary both throughout 
a 24 hour period, and a 7 day period (21, 169).  Levels of circulating cytokines are also 
influenced by medications such as selective serotonin re-uptake inhibitors (SSRIs) (212) 
and infections such as influenza.  Furthermore, measurement of cytokines is complex, with 
particular cytokines degrading or alternatively increasing if blood is not separated and 
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stored by the laboratory within several hours (256).  In addition, the same pattern of 
change in the concentration of cytokines is not seen for all individuals, with production and 
/ or release of antigens and the subsequent degradation of antigen affecting concentration 
of cytokines (243).  Therefore, whilst cytokines are potential biomarkers for adolescent 
MDD, many challenges exist in the measurement of these fragile proteins.   
As there are a paucity of studies examining cytokines in adolescents (not only in MDD, but 
also in anxiety disorders and psychosis), we aimed to measure the levels of circulating 
plasma cytokines in adolescents admitted to an Adolescent Inpatient Unit (AIU).  We 
hypothesised that levels of circulating IL-6 would be higher in adolescents with MDD 
compared to a control group, whilst circulating levels of the pro-inflammatory cytokine 
TNF-α may be lower in adolescents with MDD (consistent with the findings of Gabbay et 
al. (191)).  We also hypothesised that circulating levels of the inflammatory marker CRP 
would be higher in adolescents with MDD compared to a control group, and would be 
higher in adolescents with a history of early childhood adversity (irrespective of diagnosis) 
compared to a control group.  
However methodological challenges were encountered in recruiting subjects and collecting 
samples from this population of adolescent inpatients.  As such, this chapter describes the 
study methodology and some of the practical limitations in conducting this research in an 
Australian acute adolescent inpatient psychiatric unit.  Furthermore, we aimed to provide 
suggestions for future researchers in order to avoid or overcome some of the challenges 
encountered.  
Methods: 
 
The study was approved by the Royal Children’s Hospital Human Research Ethics 
Committee (RCH-HREC) and the QIMR Berghofer Medical Research Institute Human 
Research Ethics Committee (QIMRB-HREC).  Patients were recruited from the Royal 
Brisbane and Women’s Hospital (RBWH) Adolescent Inpatient Unit.  Inclusion criteria for 
recruitment to the study were patients who had been admitted with a diagnosis (primary or 
co-morbid) made by a Child and Adolescent Psychiatrist, according to ICD 10 criteria of a 
depressive, anxiety or psychotic disorder between June 2012 and May 2013.   
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The Adolescent Inpatient Unit is a 12 bed psychiatric unit which services the state of 
Queensland, north of the Brisbane River accepting admissions for assessment and 
management of adolescents with acute and serious mental illness. Prior to commencing 
the study, meetings were held with clinical staff on the Adolescent Inpatient Unit (AIU), to 
discuss the aims and methodology of the project.  Staff identified individuals who met 
inclusion criteria and had capacity to consent. Written consent was also obtained from 
their legal guardian or parent by associate investigators of the study, or AIU staff.  Charts 
were reviewed to determine previous episodes of depression, anxiety or psychosis, family 
history of mental illness, concurrent medical illnesses, and prescribed medications. Height 
and weight data were also collected from charts (to allow calculation of body mass index 
(BMI)).  A sample size of 50 patients was needed to detect a difference of 0.5 standard 
deviation units between the clinical group and the control group for circulating levels of 
cytokines and inflammatory markers (304).  The significance threshold assumed in the 
power calculation (based on a two sample t-test) was 0.05 for a single test.  However, this 
threshold would be smaller for multiple testing.  
Blood sample: 
Bloods were collected for measurement of cytokines, cytokine genes, and routine 
biochemistry (2x10ml EDTA tubes, 1x10ml serum tube, and 1x1ml PAX tube).  With the 
exception of 1 study participant, all blood samples were collected in the morning.  Where 
possible, the blood sample was collected at the same time as clinical samples for 
investigations (e.g., thyroid function tests) ordered by medical staff in order to minimise 
venepuncture of patients.  To preserve the cytokines, samples were immediately 
transported to the laboratory of QIMRB located on the same hospital campus.  On arrival, 
the EDTA tubes were placed and processed on ice, separating plasma and serum before 
freezing at -80 degrees Celsius (256).    
Psychological measures: 
Participants completed the Somatic and Psychological Health Report (SPHERE) (305), the 
Junior Eysenck Personality Questionnaire (JEPQ) (306), and the Child Post-traumatic 
stress disorder Symptom Scale (CPSS) (307).  We combined these questionnaires and 
scales into a single questionnaire, which we named the “Adolescent Behaviour and 
Lifestyle Questionnaire”. 
 96 
 
The SPHERE, a 34-item questionnaire (305), measures symptoms of depression, anxiety, 
fatigue and somatic illness (308).  The ‘PSYCH-6’ is the 6-item subscale of the SPHERE 
assessing psychological symptoms of depression and anxiety (308). For the 34 item 
SPHERE, each item is scored as “0”, “1” or “2” to correspond with responses of 
“sometimes / never”, “often”, or “most of the time” respectively (305, 308). We used the 
same coding employed in previous research in adolescent and young adult twins (255), 
where “sometimes / never” is scored as “0”, and “often” or “most of the time” are both 
scored as “1” (309).  The SPHERE has been found to be reliable in identifying depression 
in young persons, where co-morbid physical disease has a low prevalence (308).      
The JEPQ assesses the 3 major dimensions of personality, namely Psychoticism, 
Extraversion, and Neuroticism (310).  A fourth dimension of the JEPQ (the Lie scale) acts 
as a measure of social desirability (310).  A negative correlation has been found between 
Extraversion and depression, and a positive correlation between Neuroticism and 
depression (311).  We used the 81-item questionnaire (full version), which includes 20 
items on the Neuroticism scale, as short forms have less reliability (312).  The maximum 
score possible for the Neuroticism scale of the JEPQ is 20, as each ‘yes’ answer is scored 
as 1.  Maximum scores possible for the Extraversion, Psychoticism and Lie scales are 24, 
17 and 20 respectively.   
Both the SPHERE and the JEPQ have also been administered to study participants in the 
Brisbane Adolescent Twin Study (255), a community sample of twins, enabling 
comparison of age-matched controls.  These control samples were comprised of 
adolescent and young adult twins aged 12 – 25 years (mean age 15.5 years (standard 
deviation (SD) 2.9 years), 1,168 complete twin pairs, 53% females) for the SPHERE (309), 
and 16 year old twins (525 males and 570 females) for the JEPQ (313). 
The CPSS assesses Post-traumatic stress disorder (PTSD) symptoms based on the 3 
symptom clusters of DSM-IV (re-experiencing, avoidance and arousal).  Answers to each 
question are scored as “0” (“not at all”), “1” (“once a week or less”), “2” (“2 to 4 times a 
week”), or “3” (“5 or more times a week”), producing a total symptom severity score 
ranging from 0 to 51.  Seven additional items assess functional impairment  (307).  We 
asked participants if they had experienced a major loss, a life threatening event, and / or 
interpersonal violence in the past. Those participants who endorsed any of these 
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questions were then given the CPSS. The CPSS has high internal consistency for both the 
total score and the three subscales / symptom clusters (307).  
Statistical analyses: 
Responses to the combined questionnaires were analysed using the computer programme 
R.  Means and standard deviations of each of the SPHERE, JEPQ, and CPSS were 
calculated for the total sample, and for each of the primary or co-morbid diagnoses (MDD, 
anxiety disorder, psychotic disorder, and anorexia nervosa).  As 80% of the clinical sample 
was female, all traits in the clinical sample and community samples were corrected for sex 
prior to comparing mean scores of the clinical and community samples.  Correlations were 
calculated between the SPHERE, JEPQ, and CPSS (for the total sample, as numbers 
were too small to allow calculations within disorders).  
Results: 
 
During the study period, 220 individuals were admitted to the Adolescent Inpatient Unit.  A 
total of 39 individuals (31 females, 8 males) participated in the study. Reasons for non-
participation included brief admissions, refusal for venepuncture and challenges accessing 
parents to gain consent prior to a patient’s discharge. The age of study participants ranged 
from 14 years 3 months to 17 years 6 months (mean 16.1 years; SD 1.2 years), with the 
majority of study participants attending school (92%) and living at home (95%).  Thirty-four 
of the 39 study participants provided a blood sample for the measurement of circulating 
cytokine levels and cytokine genes, three requested to complete questionnaires only 
(because of fear of venepuncture), and in two participants we were unable to process the 
blood sample within the time-frame required to avoid changes in cytokine levels.  Thirty-
eight of the 39 study participants completed the Adolescent Behaviour and Lifestyle 
Questionnaire resulting in complete data for 33 patients.   
Of the 39 participants, 13 had a primary diagnosis of an anxiety disorder, 11 met criteria 
for major depressive disorder and 4 were diagnosed as having a psychotic disorder. 
Eleven participants had a primary diagnosis of anorexia nervosa but had co-morbid 
anxiety and so were also included in the study.   
To detect a difference of 0.5 standard deviation units in circulating levels of cytokines and 
inflammatory markers between the clinical sample and the community sample of twins, the 
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sample size required from the Adolescent Inpatient Unit was at least 50 individuals (304).  
Therefore due to the small sample size, as yet cytokines and inflammatory markers have 
not been measured in the blood samples.   
Exposure to trauma and loss were common in study participants, with 29 of the 38 (76.3%) 
participants endorsing at least one event.  Of the 29 adolescents who endorsed exposure 
to trauma or loss, 20 (71%) endorsed exposure to more than one event.  Twenty-eight of 
the 29 participants exposed to any trauma or loss then completed the CPSS based on the 
most distressing event they had experienced.  The most common distressing events were 
interpersonal violence (which included being bullied; n=25), major loss (e.g. death of a 
parent, parental divorce; n=17) and life-threatening events (n=10).   
Table 4-1 shows the average SPHERE, JEPQ (Neuroticism, Extraversion, Psychoticism 
and Lie scales), and CPSS scores by primary diagnosis in the clinical sample, and the 
JEPQ scores from the community twin sample.  Compared to the community sample, the 
clinical samples had significantly higher scores on the Neuroticism scale (10.7 versus 16.7 
respectively, p=1.8x10-13) with the group with a primary diagnosis of psychosis scoring 
highest (mean 19, SD 0.8) (Table 4-1).  Conversely, study participants had lower scores 
on the Extraversion scale of the JEPQ compared to the community sample (13.8 versus 
19.4 respectively, p=6.7x10-8) (Table 4-1).   
Table 4-1: Mean (SD) for SPHERE, JEPQ (Neuroticism, Extraversion, Psychoticism and Lie 
scales), and CPSS scores (by diagnosis): 
  
Clinical Sample 
 
 
Community Twin Sample 
 Total 
Sample 
(n=38) 
Anxiety 
Disorder 
(n=12) 
MDD  
(n=11) 
Psychotic 
Disorder 
 (n=4) 
AN 
(n=11) 
Total 
(n=1095) 
Males 
(n=525) 
Females 
(n=570) 
SPHERE 20.6(7.1) 21.2 (7.7) 20.2 (6.9) 20.3 (3.8) 20.5 (8.2) n/a n/a n/a 
JEPQ-N 16.7(3.3) 16 (3.9) 17.1 (2.5) 19 (0.8) 16.2 (3.8) 10.7(20.3) 8.7 (21.1) 11.2 (20.1) 
JEPQ-E 13.8(5.7) 13.8 (6.9) 14.3 (4.3) 9.3 (5.9) 14.8 (5.3) 19.4(16.4) 19 (13.1) 19 (17.2) 
JEPQ-P 3.5(2.7) 4.5 (3.7) 4.4 (2.2) 2 (0.8) 1.9 (1.5) 2.6(4.2) 3.9 (6.0) 2.2 (3.8) 
JEPQ-L 8.1(3.7) 7.5 (4.3) 6.8 (3.3) 8.8 (3.9) 9.7 (3.0) 7.1(12.4) 6.2 (11.2) 7.3 (12.7) 
CPSS 25.0(14.0) 
25.8 (18.6) 
(n=10) 
26.6 (9.5) 
(n=8) 
36* 
(n=1) 
21.6(12.6) 
(n=9) 
n/a n/a n/a 
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Key: AN = Anorexia Nervosa; CPSS = Child PTSD (post-traumatic stress disorder) scale; JEPQ-E = JEPQ 
Extraversion scale; JEPQ-L = JEPQ Lie scale; JEPQ-N = JEPQ Neuroticism scale; JEPQ-P = JEPQ 
Psychoticism scale; MDD = Major Depressive Disorder; n = number of individuals; SPHERE = Somatic and 
Psychological Health Report; n/a = not available 
*SD not applicable as only one individual completed the CPSS from this subgroup 
 
Mean SPHERE scores were significantly higher in the clinical sample compared to the 
community sample of twins (20.6 versus 8.52 respectively, p=<4.4x10-16). To examine 
these measures further, we correlated scores from the clinical sample between the 
SPHERE (including the PSYCH-6 subscale), the 4 scales of the JEPQ, and the CPSS.  
Results of correlations between the SPHERE, JEPQ, and CPSS are listed in Table 4-2. 
Table 4-2: Correlations between SPHERE, JEPQ, and CPSS:  
 SPHERE JEPQ - N JEPQ-E JEPQ-P JEPQ-L CPSS 
SPHERE 1.00 0.53 -0.04 0.34 -0.55 0.74 
JEPQ - N 0.53 1.00 -0.45 -0.01 -0.36 0.56 
JEPQ-E -0.04 -0.45 1.00 0.08 0.16 -0.23 
JEPQ-P 0.34 -0.01 0.08 1.00 -0.61 0.32 
JEPQ-L -0.55 -0.36 0.16 -0.61 1.00 -0.53 
CPSS 0.74 0.56 -0.23 0.32 -0.53 1.00 
 
Key: CPSS = Child PTSD (post-traumatic stress disorder) scale; JEPQ-E = JEPQ Extraversion scale; JEPQ-
L = JEPQ Lie scale; JEPQ-N = JEPQ Neuroticism scale; JEPQ-P = JEPQ Psychoticism scale; SPHERE = 
Somatic and Psychological Health Report 
The correlation between the measures was high for SPHERE and PSYCH-6 (0.75, as 
expected for a whole-part relationship) and moderate between SPHERE and JEPQ-N 
(0.53), JEPQ-N and CPSS (0.56), and PSYCH-6 and JEPQ-N (0.67).  Hansell et al. found 
the correlation between the PSYCH-14 (the 14-item subscale of the SPHERE) and the 
JEPQ-N to be 0.64 in the community sample of twins (309). In the clinical sample, we also 
found that scores on the SPHERE correlated highly with scores on the CPSS (correlation 
0.74).   
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Discussion: 
 
This chapter describes the study methodology and the challenges that arose in attempting 
to collect samples that would enable measurement of circulating cytokines in a clinical 
sample of adolescents admitted to an inpatient unit. The study suffered a number of 
challenges worthy of discussion. These challenges can be broadly divided into patient 
factors, blood collection factors, and other data collection factors.    
Patient factors include patient selection bias, the degree of morbidity / co-morbidity of 
patients, and the length of admission to the unit.  The selection bias of patients 
participating in clinical studies is systemic. Adolescents who were due to have other blood 
tests as part of their clinical assessment were more likely to consent to participate in the 
study, as potential subjects were understandably reluctant to endure extra venepuncture 
for research purposes.  Additionally, patients were not approached about the study until 
they were well enough to consent. Because of pressure to ensure patient flow through 
acute psychiatry units, patients were already being placed on leave or on the cusp of 
discharge at the time they had capacity to consent to participate. Time constraints 
prevented consent being obtained from those patients in crisis admitted for brief 
admissions as other clinical priorities such as detailed assessments, psychoeducation and 
family meetings were prioritised ahead of research.  The net effect of these selection 
biases was that patients with illnesses requiring extended inpatient care (with multiple 
medical investigations) such as anorexia nervosa and treatment refractory psychotic and 
affective disorders were more likely to participate in this project. 
The fragility of the cytokine proteins presented a challenge to blood collection. Rapid 
transport, processing and freezing of blood samples were necessary in order to avoid 
significant changes in cytokine levels.  The study used the hospital pathology service to 
collect the samples as funding and staff were unavailable for the exclusive collection and 
strict adherence to such a rigorous protocol of blood collection as used in this study. The 
study was able to achieve the co-operation of the pathology service in a large tertiary 
hospital although frequent communication was required to ensure the protocol was 
maintained.   
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Other challenges arising from data collection factors included the identification of patients 
and the time required to obtain consent particularly from parents.  Many of the adolescents 
admitted to an inpatient unit have considerable family distress (314). They are more likely 
to come from families who are socio economically disadvantaged and access to transport, 
affordable parking and demands of caring for other children limit the time many parents 
can spend visiting their child who is unwell. Thus, when they visit, gaining a clinical 
understanding or spending time with their child becomes the main focus of their visit and 
consenting to research is understandably not a priority.  As such, our observation was that 
those parents whose children had more persistent or treatment refractory disorders were 
again more likely to consent to the research. 
As a result of these challenges, the sample collected was disproportionately small and 
biased, especially when considering the effort that went into establishing the protocol and 
attempting to collect the data.  Although inpatient units would appear to be an ideal place 
to collect data from patients, especially where biological samples are required, our 
experience has been that the high level of clinical activity, short lengths of stay and the 
severity and acuity of the patients clinical presentations present significant challenges to 
conducting such studies in these settings.  Due to the small number of study participants, 
the follow-up component of the study which we had planned (consisting of repeat 
measurement of circulating cytokines and repeat psychological measures) was not 
conducted. 
It should be noted that other groups conducting research in an Adolescent Inpatient Unit 
have encountered similar challenges.  A study exploring strategies to enhance patient 
recruitment in research involving patients with first episode mental illness noted 
recruitment of research participants often represents the most labour intensive component 
of a study (315).  Furthermore, the authors noted in their study examining the benefit of 
citalopram in adolescents with depression that 50% of eligible participants declined 
enrolling in the study due to concerns from parents or family members (315).  A study 
examining the use of Clonidine for intrusive symptoms of PTSD among patients on a 
Paediatric Mental Health Inpatient Unit also noted the time required to identify study 
participants and obtain consent from parents to be a barrier to participant recruitment 
(314). 
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As a direct result of this experience, methodology employed in current studies has 
changed. At the Royal Brisbane and Women’s Hospital Mental Health Service, assent is 
now routinely used when collecting plasma samples on admission from patients. Informed 
consent is obtained from parents over the telephone and then later obtained from 
participants when they have capacity. This is done close to discharge or over the 
telephone once the patient has left hospital. The Human Research and Ethics Committees 
have approved this process of consent, having understood (including through the reporting 
process to the HREC) the challenges experienced in this study. This was therefore a good 
outcome of the study. 
The findings in the clinical sample of higher scores on the Neuroticism scale (JEPQ) and 
lower scores on the Extraversion scale (JEPQ) (compared to the community sample) were 
to be expected.  Likewise, the finding of higher SPHERE scores across all diagnostic 
groups in the clinical sample (compared to the community sample) were expected, as the 
majority of patients in the clinical sample had been diagnosed with depression or anxiety 
(primary or co-morbid).  The correlation of 0.64 reported between the SPHERE and JEPQ-
N in the community sample of twins (309) was similar to the correlation of 0.53 between 
the SPHERE and JEPQ-N in the clinical sample. 
We remain of the opinion that cytokines have an important role in the mental health of 
adolescents either as biomarkers or as causal factors due to immune dysregulation (161, 
191). It is hoped that further study participants can be obtained at a later date, with a view 
to then measuring cytokines and other inflammatory markers.  Future studies should use 
the RDoC approach rather than diagnostic categories.  For example, study participants 
could be grouped on the basis of domains such as internalizing behaviours or 
immunological profile.  
This research experience alerts others to the challenges of conducting research in 
adolescents where parental consent is generally required.  An awareness of the research 
challenges by the clinical psychiatry community is important in order to develop solutions 
that will progress biological psychiatry research.   
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Chapter review 
 
This study led to changes in the consent process at the Royal Brisbane and Women’s 
Hospital Mental Health Services. Specifically, blood samples for research are now able to 
be collected from patients and stored on admission when other blood samples for routine 
clinical measures are collected.  The patients are then later approached when their mental 
health is stabilized to determine if they consent or refuse for these samples to be used for 
research.  These changes have allowed for collection of samples prior to or just after very 
limited exposure to psychotropic medication and they minimize exposure to venepuncture. 
This has increased participation in clinical projects that have followed on from this study.   
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CHAPTER 5: Investigating the Relationship between Iron and 
Depression  
 
Abstract 
 
Introduction: Measures of circulating levels of iron have been associated with depression.  
Our objective was to investigate the phenotypic and genetic relationship between 
measures of circulating levels of iron (serum iron, serum transferrin, transferrin saturation, 
and serum ferritin) and depressive symptoms using three strategies based on different 
types of analyses of genetically informative data sets. 
Methodology: Data were collected from the ongoing Brisbane Adolescent Twin Study and 
the Health and Lifestyle Survey for Twins, both based at QIMR Berghofer Medical 
Research Institute (QIMRB).  Here, we report data from twin adolescents (mean age 15.1 
years (standard deviation (SD) 3.2 years)), and adult twins (mean age 23.2 years SD 2.2 
years)).  In the adolescent cohort, there were 3,416 participants from 1,688 families.  
Depressive measures were assessed through the Somatic and Psychological Health 
Report (SPHERE).  In the adult cohort, there were 9,035 participants from 4,533 families. 
A quantitative score of depression was measured by the Delusions Symptoms State 
Inventory (DSSI).  First, we estimated heritabilities of, and phenotypic and genetic 
correlations between, traits.  Second, we conducted analyses that linked results from 
published large-scale genome-wide association studies (including iron and Major 
Depressive Disorder (MDD)) with our in-house adolescent and adult samples for which we 
also had genome-wide genotype data. We explored the genetic relationship between the 
traits in our samples and single nucleotide polymorphisms (SNPs) reported as associated 
with iron measures and MDD from published genome-wide association studies.  We 
undertook single SNP and multi-SNP genetic risk score analyses, and LD score regression 
analyses.   
Results: Measures of iron, transferrin, transferrin saturation, and log 10 of ferritin (L10Fer) 
were all found to be highly heritable in both cohorts: Adolescents: iron 0.46 (95% CI 0.15-
0.66), transferrin 0.64 (95% CI 0.42-0.81), transferrin saturation 0.61 (95% CI 0.39-0.70), 
and L10Fer 0.56 (95% CI 0.28-0.72); Adults: iron 0.35 (95% CI 0.25-0.41), transferrin 0.52 
(95% CI 0.38-0.56), transferrin saturation 0.50 (95% CI 0.44-0.55), and L10Fer 0.42 (95% 
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CI 0.27-0.49).  Heritabilities calculated for depressive measures were 0.46 (95% CI 0.29-
0.52) and 0.30 (95% CI 0.11-0.40) for adolescents and adults respectively. In adolescents, 
depression measures were significantly higher in those in the middle 10th percentile versus 
top 10th percentile of transferrin saturation measures (p=0.002).  Genetic profile risk scores 
(GPRS) of the iron measures did not predict depression measures, and MDD GPRS did 
not predict iron measures in study participants of this community sample.  LD score 
analyses showed the expected negative correlations between iron and transferrin, log 
ferritin and transferrin, and between transferrin saturation and transferrin, but no significant 
genetic relationship between iron and depression.   
Conclusions: Genetic factors strongly influence iron measures in adolescents and adults.  
Using several different strategies we find no evidence for a genetic contribution to the 
relationship between measures of iron in circulating blood and measures of depression. 
Keywords: iron, transferrin, transferrin saturation, ferritin, depression 
 
Introduction: 
 
Measures of circulating iron have been associated with depression. In adults, an 
association between iron measures and depressive symptoms has been demonstrated, 
including improvement of depressive symptoms with iron supplementation for iron-
deficiency anaemia in mothers with young infants (316).  Lower levels of serum ferritin (a 
measure of body iron stores) have also been associated with depression in adults (317, 
318) although an association between iron measures and depression is not always evident 
(319).  By contrast, very few studies of adolescents have investigated the relationship 
between iron and depression. 
Iron is an essential component of brain growth and development, and is needed for cell 
differentiation, protein synthesis, hormone production and important aspects of cellular 
energy metabolism (320).  Iron deficiency is a major health problem worldwide, and 
remains the leading cause of anaemia globally (321).  Iron deficiency is also a problem in 
Australia (322), with the World Health Organization estimating the prevalence of anaemia 
in industrialized countries ranging from  5%, to as high as 18% in pregnant women, with 
iron deficiency a major cause (323).   
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Major Depressive Disorder (MDD) is also a major health problem worldwide, with 
considerable morbidity and mortality (36, 324).  Major Depressive Disorder (MDD) has 
also been associated with inflammation (74), and changes in iron measures, such as 
decreased serum transferrin levels, are also seen in inflammatory states (8).  Therefore 
MDD may also be related to iron measures indirectly (325).  In view of the health burdens 
associated with both iron deficiency anemia and MDD, and the association between the 
phenotypes of these disorders, the relationship between iron and depression is an area 
worthy of further investigation. 
It is unknown if the reported phenotypic relationship between blood iron levels and 
depression has a genetic component. The variation between individuals in measures of 
iron in serum is partly under genetic control, with heritability estimated to be ~25%-50% 
(326-328). Furthermore, iron absorption, absorption-diet interactions, and variation in iron 
loss are all potentially subject to genetic influences (327).  Genome-wide association 
studies (GWAS) of iron phenotypes have identified highly associated single nucleotide 
polymorphisms, including 3 independent SNPs in the gene TF (transferrin) (329), and 
more recently SNPs affecting ferritin (330).  Variants in the gene TF, together with the HFE 
C282Y mutation, explain approximately 40% of genetic variation in serum transferrin (329). 
Such large effects are unusual for complex traits (331), but have been reported for other 
measures such as Vitamin D (332). 
Likewise, genetic influences also contribute to individual differences in MDD.  Heritabilities 
are estimated to be approximately 31%-42% for depression (234).  Genetic influences in 
MDD are also found in adolescents (50).  The era of genome-wide association studies 
provides a new experimental paradigm to explore the genetic relationship between traits 
using data sets independently collected for different measures (333). 
The aim of this study is to: 1) investigate the phenotypic and genetic relationship between 
measures of circulating levels of iron and depressive symptoms in two large independent 
community cohorts of twins, and 2) investigate if SNPs that explain variation in iron 
phenotypes are associated with measures of depression. 
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Methods:   
Cohorts: 
 
1) Adolescent Cohort 
Participants are 16 year old twins from the Brisbane Adolescent Twin Study (255).  
Participants completed the Somatic and Psychological Health Report (SPHERE) (334), a 
self-report questionnaire that includes 14 anxiety and depression items.  Items were 
recorded as binary responses, coded as 0 (less anxiety) and 1 (more anxiety) which sum 
to provide a quantitative measure of anxiety and depression (309) giving greater power to 
detect genetic influence (335) than a binary diagnostic code.  Mean age at completion of 
SPHERE was 15.1 years (standard deviation (SD) 3.2 years).  The participants also 
provided a blood sample (mean age at time of blood collection 16.2 years (SD 0.2 years)).  
This allowed quantification of a number of iron phenotypes in the serum: iron (measured in 
µmol/L), transferrin (g/L), transferrin saturation (measured as a percentage of transferrin 
saturated with iron), and ferritin (µg/L).  Transferrin is an iron-binding blood plasma 
glycoprotein that controls the level of free iron (336).  Ferritin is an intracellular protein that 
stores iron and releases it in a controlled manner (336).  A log transformation was applied 
to the ferritin (L10Fer) measures to normalise the distribution.  The sample size comprised 
between 1,363 (49.6% males, 50.4% females) and 2,890 (45.89% males, 54.11% 
females) adolescents from 1,688 families, depending on the measure (see Table 5-2 for 
twin pair numbers).  
2) Adult Cohort  
Participants are adult twins, taken from the Australian Twin Registry (9,035 study 
participants).  In 1989, a Health and Lifestyle Questionnaire (HLQ) was mailed to twins 
born between the years of 1964-1971. The mean age of respondents was 23.2 years 
(standard deviation (SD) 2.2 years), with 37.14% of respondents being male, and 62.86% 
female.  The psychiatric symptom inventory section in the HLQ contained self-report 
questions, consisting of 14 anxiety and depression items from the DSSI (337), as well as a 
19 item subset of the 90-item Symptom Checklist (SCL-90) (338).  When these 33 items 
are factor analysed, 4 factors are derived: depression, anxiety, somatic distress, and sleep 
difficulties.  Study participants provided a blood sample approximately 10 years after, 
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allowing quantification of serum iron (µmol/L), transferrin (g/L), transferrin saturation 
(percentage of transferrin saturated with iron), and ferritin (µg/L).   
All procedures in both the adolescent and adult cohorts were approved by the Human 
Research Ethics Committee of QIMR Berghofer Medical Research Institute (QIMRB). 
Estimation of Genetic Parameters:  
 
Data were analysed using the statistical program Mx.  After standard testing of 
assumptions (equality of means and variances across zygosity and sex), twin correlations 
were calculated.  Heritabilities were calculated initially under a univariate additive genetic 
(A), common environment (C) and unique environment (E) model and then under bivariate 
models considering all pairwise combinations of traits.  To examine the significance of the 
estimated univariate variance components, we also considered AE and CE reduced 
models. Goodness-of-fit of the reduced models were assessed using likelihood ratio tests.  
The sample size gave at least 99% power to estimate additive genetic variance greater 
than zero for iron and depression measures at significance level 0.05 (adolescents and 
adults) (339, 340).  
Percentile analysis:  
 
We hypothesised that the relationship between iron measures and depression measures 
may be non-linear, and that this phenotypic relationship may only be present at the 
extremes of iron measures. Therefore, we also investigated whether there was a 
phenotypic association between the upper and lower range of circulating levels of iron 
measures with depressive symptoms (perhaps representing a non-linear relationship 
between iron and depression), by testing for differences between 1) the lowest 10th 
percentile and middle 10th percentile (i.e. 45th-55th percentile), 2) the highest 10th percentile 
and middle 10th percentile, 3) the lowest 10th percentile and highest 10th percentile, and 4) 
the lowest 5th percentile and highest 5th percentile (Welch Two Sample t-test). These 
choices reflect non-linear models that could be U-shaped (first two tests) as well as 
differences in the extremes (third and fourth tests).  As the phenotypic relationship may 
only be present at the extremes of iron measures, testing for differences between the 
lowest 5th percentile and highest 5th percentile was included.  
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Association Analysis:  
 
Single nucleotide polymorphisms (SNPs) significantly associated with iron phenotypes in 
genome-wide association studies (GWAS) (329, 330, 341, 342) were identified: 
rs2698530, rs1799852, rs1830084, rs2280673, rs3811647, rs1799945, rs8177240, 
rs1800562, rs7787204, rs4820268, rs855791, rs9990333, rs987710, rs744653, 
rs7385804, rs235756, rs4921915, rs651007, rs6486121, rs174577, rs411988.  The 
association statistics of these 21 SNPs (or their proxies, defined as in linkage 
disequilibrium r2 >0.8) were extracted from published GWAS for MDD (134).  The sample 
size of the PGC MDD data gave at least 99% power to detect common (MAF >0.1) 
variants that explain 0.5% of the variance at significance level 0.05 (343).  
Genomic risk profile score analysis:  
 
Genomic profile risk scores (GPRS) for iron, transferrin, transferrin saturation and L10Fer 
were generated for each individual in both the adolescent and adult ‘target’ samples using 
GWAS summary statistics data from the Genetics of Iron Status Consortium (GISC) (330) 
‘discovery’ sample.  The GISC data comprise association statistics between SNP 
genotypes and iron markers (serum iron, transferrin, transferrin saturation, and ferritin) 
from approximately 24,000 individuals from a total of 19 cohorts in 9 participating centres 
(330). QIMRB samples used here were part of the GISC. Since genetic prediction analysis 
requires independence between discovery and target samples, we recalculated effect 
sizes from the GISC cohorts after excluding QIMRB samples.  GPRS were created 
(separately for adolescents and adults) as the sum of associated alleles of quasi-
independent SNPs (pruned so that pairwise linkage disequilibrium between SNPs was less 
than r2=0.25) weighted by their effect size estimated in the GISC meta-analysis.  
GPRS for MDD were generated for individuals in the adolescent and adult target QIMRB 
samples using GWAS data from the Psychiatric GWAS Consortium (PGC) MDD working 
group (134).  The PGC MDD ‘discovery’ sample has 9,240 MDD cases and 9,519 controls 
(134).  QIMRB samples were part of the PGC, so we recalculated effect sizes from the 
PGC MDD cohorts after excluding the QIMRB samples.  GPRS for both iron measures 
and MDD were calculated using varying levels of discovery sample p-value thresholds in 
PLINK (344). The appropriate choice of p-value thresholds depend on the genetic 
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architecture of the trait and the size and hence power of the sample.  For each iron 
measure, we selected the p-value threshold from the GWAS results that maximised 
variance for the same iron measure in our data.  Therefore, different thresholds were 
selected for different traits.  To help in the interpretation of results, one individual per family 
was selected for inclusion in the profile scoring analysis (n= 2,394 individuals for adult 
data; n = 1,028 individuals for adolescent data).   
Linear regression models were then used to predict how much of the variation in each of 
the phenotypes of our samples is explained by the GPRS and the direction of association.  
Age was significantly associated with measures of iron and ferritin, whilst sex was 
significantly associated with measures of iron, transferrin saturation and ferritin.  
Therefore, we used an age and sex adjusted regression model to test for an association 
between the profile scores (iron measures and MDD) and measures in the QIMRB 
samples.  After conducting the profile scoring analyses using one individual per family, we 
subsequently conducted the analyses with relatives included. 
LD score analysis: 
 
Genetic correlations based on genome-wide SNPs between iron phenotypes and 
depression measures were estimated using LD score regression (v1.0.0) (345), based on 
GWAS summary statistics (effect size, direction of effect for each SNP, and sample size).  
The method exploits the expectation that SNPs in high LD regions (with large LD scores) 
will, on average, tag more causal variants than SNPs in low LD regions.  LD score 
regression has previously been used to estimate genetic correlations for a wide range of 
traits, and the resulting estimates were consistent with estimates of genetic correlations 
obtained by bivariate GREML, which uses full genotype data to estimate genetic 
correlation (346). We used LD scores for each SNP calculated from 1000 Genomes, which 
are available on the LD Scores Regression github page (https://github.com/bulik/ldsc ), 
both as the independent variable in LD Score regression, as well as for the regression 
weights (options “--ref-ld-chr" and “--w-ld-chr”). SNPs which were located in or around the 
iron metabolism related genes TF, HFE, and TMPRSS6, which had previously been 
shown to have large effect on variance of serum transferrin levels (329) were excluded 
from the analysis. However, including them in the analysis did not have a large impact on 
the estimates of genetic correlation.  Figure 5-1 shows the strategies / types of analyses 
 111 
 
we used to investigate the genetic relationship between iron measures and depression 
measures. 
Figure 5-1:  Schematic representation of analyses 
 
 
 
 
 
 
 
 
 
 
 
Results:   
 
Numbers of study participants and mean iron and depression measures are shown in 
Table 5-1.  With the exception of transferrin (in the adolescent and adult cohorts), for all 
iron measures males had significantly higher mean measures compared with females 
(Table 5-1).  Mean depression measures were higher in females in both cohorts, however 
this difference was only significant in the adult cohort (Table 5-1). 
In assumption testing analyses that are preliminary to variance component estimation in 
twin samples, means and variances (both within and across zygosity groups) were able to 
be constrained to be equal for each of the iron and depression measures in the adolescent 
cohort.  In the adult cohort, means and variances were able to be constrained to be equal 
for log ferritin and depression measures, but not for other iron measures.  For iron and 
transferrin saturation in adults, we observed significant differences in means (p=0.035 and 
p=0.003 respectively) between MZ and DZ twins (with DZ twins having on average higher 
iron and transferrin saturation levels and larger variance compared with MZ twins), and a 
birth order effect in means (p=0.001 for both traits), with first born twins having on average 
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lower levels.  With transferrin saturation in adults, larger variance in DZ twins (compared to 
MZ) was observed (p=0.049).  For transferrin in the adult cohort, a significant difference in 
means (p=0.004) and variances (p=<9.8x10-6) between MZ and DZ twins (with MZ twins 
having on average higher transferrin levels and larger variance compared with DZ twins) 
was observed.  A birth order effect in variances (p=0.002) was also observed for 
transferrin (adults), with first born twins having on average larger variance.  After 
correction for multiple testing, only the birth order effect in means for iron and transferrin 
saturation, and the differences in variances for transferrin remained significant (Bonferroni 
corrected significance level 0.0017).  In view of the differences in variances for transferrin 
(p=<9.8x10-6), results from analysis of this trait should be considered with more caution.  
Sex effects were significant for all iron measures in the adolescent cohort.  In the adult 
cohort, sex and age effects were significant for all iron and depression measures, so both 
sex and age were fitted as covariates in the estimation of heritability of all traits in both 
cohorts.   
Table 5-1: Means and standard deviations for iron measures and depression measures 
Trait 
(Adolescents) 
Total  Males Females  
p-value* 
Mean SD Mean SD Mean SD 
Iron (µmol/L) 17.47 6.76 19.04 6.64 15.93 6.52 <2.2x10-16 
Transferrin (g/L) 2.96 0.46 2.93 0.41 2.99 0.50 1.8 x10-2 
Saturation (%) 24.05 9.69 26.35 9.60 21.79 9.24 <2.2x10-16  
Log ferritin (µg/L) 1.62 0.34 1.74 0.26 1.51 0.38 <2.2x10-16 
SPHERE 7.60 6.28 8.57 6.34 8.84 6.58 0.21 
Trait 
(Adults) 
Total Males Females 
p-value* 
Mean SD Mean SD Mean SD 
Iron (µmol/L) 19.44 6.63 20.77 6.42 18.69 6.64 < 2.2e-16 
Transferrin (g/L) 2.78 0.49 2.66 0.37 2.85 0.47 < 2.2e-16 
Saturation (%) 28.42 10.59 31.38 10.44 26.73 10.30 < 2.2e-16 
Log ferritin (µg/L) 2.00 0.44 2.27 0.36 1.84 0.41 < 2.2e-16 
Factor 1 0.00 1.06 -0.12 0.95 0.09 1.13 < 2.2e-16 
*p-value for difference between means for males and females; % = units for transferrin saturation = 
percentage of transferrin saturated with iron; Factor 1 = depression measure (adult cohort); SPHERE = 
Somatic and Psychological Health Report (depression measure adolescent cohort) 
 
Adolescents: number individuals iron measures = 1,363 (males=676, females=687); depression measures = 
2,890 (males=1,327, females=1,563) 
Adults: number individuals iron measures = 4,366 (males=1,609, females=2,757); depression measures = 
8,072 (males=2,998, females=5,074) 
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As expected, MZ correlations were higher than DZ correlations for all measures of iron 
(iron, transferrin, transferrin saturation, log of ferritin) in both the adolescent and adult 
cohort (Table 5-2). MZ correlations were also significantly higher than DZ correlations for 
depression measures in the adolescent cohort (Table 5-2).   
Table 5-2: Twin Correlations with 95% Confidence Intervals (CI): 
Trait MZ DZ MZF MZM DZF DZM DZO 
Adolescent sample iron measures: 266 MZ pairs, 380 DZ pairs; SPHERE: 494 MZ pairs, 852 DZ pairs 
Iron 0.56 
(0.44,0.66) 
0.33 
(0.21,0.43) 
0.56 
(0.38,0.68) 
0.56 
(0.37,0.69) 
0.38 
(0.14,0.55) 
0.56 
(0.35,0.69) 
0.21 
(0.04,0.37) 
Transferrin 0.75  
(0.67, 0.81) 
0.47  
(0.34, 0.58) 
0.72 
(0.62,0.80) 
0.82 
(0.71,0.88) 
0.41 
(0.24, 0.54) 
0.64  
(0.44, 0.76) 
0.38  
(0.19, 0.52) 
Saturation 0.62  
(0.51, 0.70) 
0.26 
(0.14, 0.38) 
0.61  
(0.46, 0.72) 
0.63 
(0.47,0.73) 
0.33 
(0.11,0.51) 
0.45  
(0.21,0 .61) 
0.13  
(-0.07,0.30) 
Log ferritin 0.65 
(0.54,0.73) 
0.36 
(0.24,0.46) 
0.58 
(0.43,0.68) 
0.83 
(0.72,0.89) 
0.36  
(0.21, 0.49) 
0.61 
(0.37,0.74) 
0.26 
(0.04,0.44) 
SPHERE 0.46 
(0.39,0.52) 
0.25 
(0.17,0.34) 
0.46  
(0.37, 0.54) 
0.46 
(0.35,0.55) 
0.16 
(0.03,0.28) 
0.35 
(0.23,0.45) 
0.20 
(0.10,0.29) 
Adult sample iron measures: 705 MZ pairs, 957 DZ pairs; depression measures: 1630 MZ pairs, 1742 DZ pairs 
Iron 0.37 
(0.31,0.43) 
0.15 
(0.07,0.22) 
0.36 
(0.29,0.43) 
0.40 
(0.25,0.52) 
0.15 
(0.05,0.23) 
0.16 
(0.01,0.30) 
0.14 
(0.04,0.24) 
Transferrin 0.52 
(0.49,0.56) 
0.25 
(0.18,0.31) 
0.48 
(0.42,0.53) 
0.67 
(0.60,0.73) 
0.20 
(0.13,0.28) 
0.54 
(0.41,0.63) 
0.29 
(0.18,0.39) 
Saturation 0.53 
(0.48,0.58) 
0.17 
(0.09,0.24) 
0.55 
(0.49,0.60) 
0.47 
(0.34,0.57) 
0.17 
(0.07,0.25) 
0.18 
(0.03,0.31) 
0.18 
(0.08,0.28) 
Log ferritin 0.44 
(0.38,0.49) 
0.27 
(0.20,0.34) 
0.41 
(0.34,0.47) 
0.52 
(0.41,0.60) 
0.29 
(0.21,0.36) 
0.23 
(0.09,0.36) 
0.16 
(0.06,0.25) 
Factor 1 0.34 
(0.27,0.40) 
0.19 
(0.11,0.27) 
0.29 
(0.21,0.36) 
0.57 
(0.46,0.66) 
0.18 
(0.08,0.26) 
0.27 
(0.09,0.42) 
0.18 
(0.06,0.29) 
Key: MZ = monozygotic, DZ = dizygotic; F = female, M = male, O = opposite-sex; Factor 1 = depression 
measure (adult cohort); SPHERE = Somatic and Psychological Health Report (depression measure 
adolescent cohort) 
 
Using an ACE model, we found heritability of the iron measures in both cohorts to be 
moderate to high (Table 5-3).  In contrast, estimates of variance attributable to the shared 
family environment (C) were not significantly different from zero. Heritability for depression 
measures in the adolescents (SPHERE) was 0.46 (95% CI 0.29 -0.52), which was in 
keeping with that reported from an analysis from a subset of these samples but with 
measures the mean of scores collected on multiple occasions (309). 
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Table 5-3: Estimates of proportions of variance attributable to additive genetic effects (A) or 
heritabilities, common environmental effects of families (C) and unique environmental effects (E) 
with 95% Confidence Intervals (Univariate model): 
Trait A C E 
Adolescent sample 
 
Iron 0.46 
(0.15,0.66) 
0.10 
(0.00,0.34) 
0.44 
(0.34,0.56) 
Transferrin 0.64 
(0.42,0.81) 
0.11 
(0.00,0.30) 
0.24 
(0.19,0.32) 
Saturation 0.61 
(0.39,0.70) 
0.00 
(0.00,0.18) 
0.39 
(0.30,0.49) 
Log ferritin 0.56 
(0.28,0.72) 
0.09 
(0.00,0.30) 
0.36 
(0.28,0.47) 
SPHERE 0.46 
(0.29,0.52) 
0.00 
(0.00,0.13) 
0.54 
(0.48,0.61) 
Adult sample 
 
Iron 0.35 
(0.25,0.41) 
0.00 
(0.00,0.07) 
0.65 
(0.59,0.71) 
Transferrin 0.52 
(0.38,0.56) 
0.00 
(0.00,0.12) 
0.48 
(0.44,0.53) 
Saturation 0.50 
(0.44,0.55) 
0.00 
(0.00,0.04) 
0.50 
(0.45,0.55) 
Log ferritin 0.42 
(0.27,0.49) 
0.02 
(0.00,0.14) 
0.56 
(0.51,0.61) 
Factor 1 0.30 
(0.11,0.40) 
0.04 
(0.00,0.18) 
0.66 
(0.60,0.73) 
Key: Factor 1 = depression measure (adult cohort); SPHERE = Somatic and Psychological Health Report 
(depression measure adolescent cohort) 
 
Bivariate analyses showed high phenotypic and genetic correlations between the iron 
phenotypes but that the phenotypic and genetic correlations between the iron phenotypes 
and depression measures were not significantly different from zero (Table 5-4).  A 
bivariate AE model was used since the univariate analyses for these measures showed 
estimates of the common environmental components were small and not significantly 
different from zero.   
Table 5-4: Heritabilities (diagonals) from univariate ACE models; phenotypic correlations (above 
diagonals) and genetic correlations (below diagonals) from bivariate AE Models  
(95% CI in parenthesis) 
Adolescents: 
Trait Iron 
 
Transferrin Saturation Log10ferritin SPHERE 
Iron 0.46  
(0.15,0.66) 
-0.03  
(-0.10,0.05) 
0.93  
(0.92,0.94) 
0.17  
(0.10,0.25) 
-0.06  
(-0.14,0.02) 
Transferrin -0.10  
(-0.34,0.07) 
0.64  
(0.42,0.81) 
-0.34  
(-0.41,-0.27) 
-0.43  
(-0.49,-0.36) 
-0.02 
(-0.10,0.06) 
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Saturation 0.94  
(0.90,0.97) 
-0.51  
(-0.78,-0.36) 
0.61  
(0.39,0.70) 
0.28  
(0.21,0.35) 
-0.05  
(-0.13,0.03) 
Log ferritin 0.32  
(0.12,0.69) 
-0.69  
(-0.97,-0.51) 
0.44  
(0.27,0.68) 
0.56  
(0.28,0.72) 
-0.04  
(-0.12,0.04) 
SPHERE -0.19  
(-0.51,0.04) 
0.00  
(-0.19,0.18) 
-0.15  
(-0.36,0.04) 
-0.01  
(-0.22,0.19) 
0.46  
(0.29,0.52) 
 
Adults: 
Trait Iron 
 
Transferrin Saturation Log10ferritin Factor 1 
Iron 0.35 
(0.25,0.41) 
-0.02 
(-0.05,0.02) 
0.90 
(0.90,0.90) 
0.24 
(0.21,0.27) 
-0.03 
(-0.03,-0.02) 
Transferrin -0.15 
(-0.25,-0.05) 
0.52 
(0.38,0.56) 
-0.39 
(-0.40,-0.38) 
-0.39 
(-0.39,-0.36) 
0.00 
(-0.04,0.03) 
Saturation 0.95 
(0.90,0.99) 
-0.57 
(-0.64,-0.57) 
0.50 
(0.44,0.55) 
0.34 
(0.31,0.37) 
-0.03 
(-0.03,-0.03) 
Log ferritin 0.27 
(0.15,0.41) 
-0.33 
(-0.42,-0.24) 
0.38 
(0.28,0.51) 
0.42 
(0.27,0.49) 
0.03 
(0.00,0.07) 
Factor 1 0.02 
(0.02,0.03) 
0.10 
(-0.01,0.24) 
-0.03 
(-0.17,0.10) 
0.00 
(-0.15,0.13) 
0.30 
(0.11,0.40) 
Key: Factor 1 = depression measure (adult cohort); SPHERE = Somatic and Psychological Health Report 
(depression measure adolescent cohort) 
 
Heritabilities in the adolescent and adult cohorts, and SNP heritabilities are also 
represented in graphical format in Figure 5-2.  SNP heritabilities are from GWAS data 
used in the estimation of genetic correlations.  Figures 5-3 and 5-4 represent phenotypic 
correlations (adolescent and adult twin cohorts), genetic correlations (adolescent and adult 
twin cohorts), and genetic correlations obtained through LD score analyses for each 
pairwise combination of iron traits (Figure 5-3) and iron-depression traits (Figure 5-4). 
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Figure 5-2: Heritabilites: adolescent and adult cohorts (univariate ACE models) & SNP heritabilities 
(bars represent 95% Confidence Intervals) 
 
Note: name of file used for MDD SNP heritability estimate: “pgc.mdd.full.2012-04.txt” (contained in 
“pgc.mdd.2012-04.zip”, from https://www.med.unc.edu/pgc/downloads )   
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Figure 5-3: Phenotypic and genetic correlations (adolescent and adult twins), and genetic 
correlations (LD score analyses) for pairwise combinations of iron traits;  
bars represent 95% Confidence Intervals  
 
Key: rp = phenotypic correlation; rg = genetic correlation 
 
 
 
 
 118 
 
Figure 5-4: Phenotypic and genetic correlations (adolescent and adult twins), and genetic 
correlations (LD score analyses) for pairwise combinations of iron-depression traits;  
bars represent 95% Confidence Intervals  
 
Key: rp = phenotypic correlation; rg = genetic correlation 
 
Percentile analysis:  In the adolescent cohort, depression measures were nominally 
significantly higher in those in the lowest 5th percentile of log ferritin measures compared to 
those in the highest 5th percentile of log ferritin measures (p=0.034).  We also found 
depression measures were significantly higher in those in the middle 10th percentile of iron 
and transferrin saturation measures compared to those in the highest 10th percentile of 
iron and transferrin saturation measures (p=0.008 and p=0.002 respectively).  In the adult 
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cohort we did not find a phenotypic association between the upper and lower range of 
circulating levels of iron measures with depressive symptoms. To be conservative we used 
two-sided t-tests.  However, given the multiple testing of 4 traits and 4 tests the Bonferroni 
corrected significance level is 0.0031, so only the association between depression 
measures and transferrin saturation survives multiple testing (p=0.002). 
Association Analysis: Of the 21 independent SNPs associated with iron phenotypes, 
association results from 15 were available in the PGC MDD GWAS.  The smallest p-value 
of association was rs744653 for MDD (p = 0.027), and hence no association was 
significant after correcting for multiple testing. As expected, together the SNPs did not 
explain a significant proportion of the variance.  Results of a sign test of direction of effect 
were consistent with the hypothesis that there was not a significant association between 
iron measures and MDD (p-values 0.94 – 1). 
Genetic Profile Risk Scores (GPRS): Results of testing for an association between the 
profile scores (iron, transferrin, transferrin saturation, and log ferritin) and the measures of 
iron and depression in the QIMRB samples are shown in Table 5-5.  Profile scores 
calculated for each individual in the QIMRB sample using GWAS association results from 
analyses of iron, transferrin, transferrin saturation, and log ferritin were each highly 
significantly associated with their respective trait measures (Table 5-5 column 3).  Marginal 
associations were observed with genetic profile risk scores of iron and transferrin for 
depression measures in adults at p-value thresholds of p<0.05 and p<0.1 respectively, 
however these associations were not significant after correction for multiple testing 
(Bonferroni corrected significance level p=0.0013).  In both the adolescent and adult 
cohort, the direction of effect was not in the expected direction between transferrin genetic 
profile risk scores and depression measures (Table 5-5).  Neither transferrin saturation 
profile scores nor log ferritin profile scores predicted depression status in adolescents or 
adults.  Furthermore, profile scores (iron, transferrin, transferrin saturation, and log ferritin) 
did not predict depression measures in either cohort when relatives were included in the 
analyses (results not shown). 
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Table 5-5: Iron, transferrin, transferrin saturation, and log ferritin genetic profile risk scores – 
prediction of iron / depression measures     
Target Adult/Adolescent P-value Target Variance 
explained 
Target (%) 
Direction of 
effect 
Iron discovery sample; p-value threshold P< 10-3; 212 SNPs  
 
Iron  Adolescent 0.010 1.56 + 
SPHERE Adolescent 0.87 0 - 
Iron discovery sample; p-value threshold P< 10-5; 23 SNPs  
 
Iron Adult 1.81x10-8 5.49 + 
Depression Adult 0.10 0.57 - 
Transferrin discovery sample; p-value threshold P< 10-5; 27 SNPs 
 
Transferrin Adolescent 1.83x10-7 7.09 + 
SPHERE Adolescent 0.50 0 + 
Transferrin discovery sample; p-value threshold P< 10-5; 27 SNPs 
 
Transferrin Adult 8.20x10-10 5.93 + 
Depression Adult 0.85 0.08 + 
Transferrin saturation discovery sample; p-value threshold P< 10-3; 227 SNPs 
 
Transferrin sat Adolescent 4.82x10-5 4.30 + 
SPHERE Adolescent 1.00 0 - 
Transferrin saturation discovery sample; p-value threshold P< 10-5; 32 SNPs 
 
Transferrin sat Adult  4.15x10-13 9.07 + 
Depression Adult 0.20 0.38 - 
Log ferritin discovery sample; p-value threshold P<10-3 ; 212 SNPs 
 
Log ferritin Adolescent 3.24x10-3 2.14 + 
SPHERE Adolescent 0.52 0 + 
Log ferritin discovery sample; p-value threshold P<5x10-4 ; 959 SNPs 
 
Log ferritin Adult  2.26x10-3 1.38 + 
Depression Adult 0.83 0.08 - 
 
The results of testing for an association between MDD profile scores and the QIMRB 
adolescent and adult iron measures are shown in Table 5-6.  The nominal associations 
(p<0.05) listed (Table 5-6) do not survive correction for multiple testing.  Furthermore, 
MDD profile scores did not predict iron measures in the adolescent or adult cohort when 
relatives were included in the analyses (results not shown). 
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Table 5-6: MDD genetic profile risk scores – prediction of iron measures 
P-value of SNPs 
in MDD 
discovery GWAS 
N SNPs Target P-value 
Target 
Variance 
explained Target 
(%) 
Direction of 
effect 
Adolescent sample 
 
P <10-6 11 Iron 0.17 0.24 - 
P <0.05 17,699 Transferrin 0.066 0.61 + 
P <10-6 11 Saturation 0.25 0.08 - 
P <0.10 29,840 Log ferritin 0.46 0 + 
Adult sample 
 
P <10-6 11 Iron 0.022 0.30 + 
P <1.0 119,734 Transferrin 0.43 0 - 
P <10-6 11 Saturation 0.093 0.13 + 
P <10-4 733 Log ferritin 0.048 0.19 - 
 Key: MDD = major depressive disorder 
 
LD Score 
 
Results of LD score analyses showed the same pattern for SNP genetic correlations 
between iron and transferrin, log ferritin and transferrin, and saturation and transferrin 
(Figure 5-5) as expected from the whole genome genetic correlations estimated from the 
twin data (Table 5-4). Estimates of SNP genetic correlations can only be estimated as 
different from zero if they are more than twice the standard error (s.e.) of the estimate. The 
magnitude of the s.e in Figure 5-5, shows that despite the large sample sizes in the 
contributing GWAS, the data was only powered to detect very high correlations.  The SNP-
correlation between transferrin saturation and MDD (0.29 ± se 0.20) was not significantly 
different from zero after accounting for multiple testing.  
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Figure 5-5: Estimate of genome-wide SNP correlations (rG) between traits from LD score analyses 
using GWAS summary statistics  
(vertical lines represent standard error (SE)); these data are also included in Figures 5-3 and 5-4. 
 
Key: lferri = log ferritin; mdd = major depressive disorder; sat = transferrin saturation; trans = transferrin 
 
Discussion: 
 
This study examined the phenotypic and genetic relationship between measures of 
circulating levels of iron and depressive symptoms using different data sets.  In both the 
adolescent and adult cohorts, phenotypic correlations of the iron measures with 
depression measures were not significantly different from zero. We explored the possibility 
of a non-linear relationship between iron and depression by testing the differences in 
adolescents and adults with measures for iron categorised into (i) the lowest 10th, middle 
10th, and highest 10th percentiles, and (ii) the lowest 5th and highest 5th percentiles. In 
adolescents, depression measures were significantly higher (after correcting for multiple 
testing) in those in the middle 10th percentile of transferrin saturation measures compared 
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to those in the highest 10th percentile of transferrin saturation measures (p=0.002).  We 
could not find any studies examining the relationship between iron and depression in 
community samples of adolescents.  However, it is possible that a phenotypic relationship 
of serum ferritin (or iron) with depressive symptoms is more likely to be observed in the 
presence of iron deficiency.  In our study, the lowest iron level in adolescent females was 
2.80 µmol/L, and the lowest iron level in adolescent males was 4.0 µmol/L (normal 
reference range 14-32 µmol/L for males and females (347)).  Similarly, it may be that a 
phenotypic relationship between serum iron and depressive measures is more likely to be 
observed at the lower range of iron scores.  Non-linear relationships have also been 
reported for other biological measures such as Vitamin D, with neonates who had either 
low or high levels of Vitamin D observed to have an increased risk of schizophrenia later in 
life (249).   
To examine the genetic relationship between measures of iron and measures of 
depression, we first used data from a community sample of twins to estimate heritabilities 
and genetic correlations of these measures.  Heritabilities for circulating levels of iron 
measures were moderate to high, and somewhat higher than heritabilities estimated from 
previous studies (328, 348).  These differences from previous studies may simply reflect 
sampling, but may also reflect differences in the ages of subjects between the studies.  
Both previous studies were in adults, but Traglia, Sala et al. 2009 reported the effect of 
age to be significant in the estimation of serum transferrin heritability (328). Here, our 
estimates of heritability were higher in the adolescent than in the adult cohort.  This study 
was well-powered (≥99%) to estimate additive genetic variance greater than zero for iron 
and depression measures at significance level 0.05 (339, 340).  Genetic correlations 
between iron measures and depressive measures were not different from zero, however in 
both twin cohorts negative genetic correlations were found between transferrin and iron, 
transferrin and log ferritin, and transferrin and saturation.   
We used LD score analyses (345) to explore the genome-wide correlation between SNP 
effects for different traits. This is likely the most powerful analysis based on currently 
available data, but still lacked power to detect small correlations as being different from 
zero.  The SNP-correlations between the iron measures were consistent with the genetic 
correlations obtained using a different approach (see Table 4), with negative correlations 
between transferrin and iron, transferrin and log ferritin, and transferrin and saturation. We 
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found a positive correlation between MDD with iron and transferrin saturation, however 
these were not significant after accounting for multiple testing. Using LD score analyses, 
SNP heritability for MDD and transferrin were higher than estimated heritability of these 
traits in the QIMRB twin cohorts. 
We used another independent strategy to explore the hypothesis of a genetic relationship 
between measures of circulating iron and depression.  We undertook analyses using 
published genome-wide association studies of iron and MDD.  Despite these sample sizes 
giving at least 99% power to detect common (MAF > 0.1) variants (343), none of the SNPs 
explaining variation in iron phenotypes showed significant association in the published 
MDD GWAS results (134), and together the SNPs did not explain a significant proportion 
of the variance. We also conducted analyses that linked results from published large-scale 
genome-wide association studies with our in-house adolescent and adult samples for 
which we also had genome-wide genotype data.  In the resulting genetic profile score 
analysis we found no significant association between iron measures and depression.    
A limitation of this study was the time difference between iron measures and depression 
measures, particularly in the adult cohort. While mean age at completion of the SPHERE 
was 15.1 years (SD 3.2 years) for the adolescent cohort, in the adult cohort study 
participants provided a blood sample approximately 10 years after completing the DSSI.  
This time difference was important in the investigation of the phenotypic relationship 
between the iron and depression measures. A further limitation was that the depression 
measures did not use MDD DSM-IV diagnostic criteria.   
Conclusion:  
 
We used multiple approaches to explore evidence for a genetic relationship between 
measures of circulating serum iron and depressive measures. Although each approach 
may have limitations, the results when taken together across the different approaches 
provide no compelling evidence for a genetic relationship between circulating iron and 
measures of depression, even though we were well-powered to detect a relationship 
through estimation of heritabilities, association analyses, and LD score analyses.  The 
reported phenotypic relationship between iron and depression may be more likely to be 
observed at times when the body requires higher amounts of iron, such as during times of 
rapid growth.  In this way it may reflect a highly non-linear relationship, in which those with 
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circulating levels of iron measures below an extreme threshold are more likely to be 
impacted.  
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CHAPTER 6: Investigating the relationship between C-reactive protein, 
depression, and anxiety 
 
Abstract 
 
Background: The inflammatory marker C-reactive protein (CRP) has been associated 
with Major Depressive Disorder (MDD), and a small number of studies have investigated 
the association of CRP with anxiety disorders, with inconsistent results.  It has been 
suggested that body mass index (BMI) mediates the relationship between CRP and MDD, 
since both raised CRP and MDD are associated with higher BMI, but few studies have 
investigated the relationship. 
Objectives:  To investigate the phenotypic and genetic relationship between (i) CRP 
levels, MDD and anxiety, and (ii) CRP levels and childhood sexual abuse (CSA), and to 
test whether those who carry more CRP increasing alleles, are at increased risk to develop 
depression and / or anxiety.  
Methods: Participants were from the Australian Twin Registry, in studies conducted at 
QIMR Berghofer Medical Research Institute.  A total of 14,750 individuals had CRP data 
(mean age at CRP measurement 45.3 years (standard deviation (SD) 10.1 years)), of 
which 8,234 had completed questionnaires using DSM-IV criteria for MDD, 8,679 had 
completed questionnaires using DSM-IV criteria for anxiety disorders, and 8,847 
individuals had genome-wide SNP data. Genetic risk profile scores were estimated for 
each individual based on GWAS summary statistics from the Cohorts for Heart and Aging 
Research in Genomic Epidemiology consortium (for CRP) and the Genetic Investigation of 
Anthropometric Traits Consortium (for BMI). 
Results: Mean BMI of 25.97 kg/m2(standard deviation 4.87 kg/m2) was slightly above the 
normal range of 20-25 for adults.  A point estimate of higher mean log CRP in the group 
(n=942) that met criteria for both MDD and a co-morbid anxiety disorder compared to 
those that met criteria for neither was not statistically significant (p=0.13), but was in the 
same direction found in previous studies of CRP and psychiatric disorders.  A significant 
association between CRP and social phobia (p=0.0045), was not significant after adjusting 
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for BMI (p=0.090). CRP genetic risk profile scores did not predict MDD or anxiety disorders 
in this large community sample.  
Conclusion: The complex relationship between CRP, BMI, MDD and anxiety disorders 
requires further study, but our results suggest that BMI is the key factor that mediates the 
reported relationship between circulating CRP and psychiatric disorders. 
 
Introduction 
 
Major Depressive Disorder (MDD) is associated with considerable morbidity and mortality 
worldwide (36, 324). There is increasing recognition of the role of inflammation in the 
pathophysiology of MDD. This includes the association of C-reactive protein (CRP) (32), 
an acute phase reactant involved in fighting infection and repair of tissue damage (349).  
An association between elevated CRP and MDD has been found in meta-analyses (7, 
271). However, the finding of increased activation of the inflammation system in 
depression has not been consistently demonstrated across studies (182). Known or 
unknown confounding factors may explain this inconsistency, at least in part. Age, female 
gender and diabetes mellitus are possible confounding factors that are all known to 
contribute to low grade inflammation, with elevated plasma CRP levels (79, 350-353). 
Another potential confounder of the association between CRP and MDD is body mass 
index (BMI). BMI has been shown to be significantly correlated with both CRP (354) and 
MDD (355). Adjustment for BMI has reduced the association between MDD and CRP to 
non-significance in several studies (145, 356).  
Other potential confounders are experience of early childhood adversity or comorbid 
anxiety disorders. A history of early childhood adversity is reported to be associated with 
inflammation (including raised CRP in later life) (29, 53, 357).  Individuals with a history of 
early childhood adversity, who also have MDD (or a history of MDD), have been found to 
have even higher levels of CRP than those with MDD alone (28, 29).  These findings are 
particularly important, as persistent inflammation may subsequently contribute to 
increased risk of not only mental health disorders, but also physical disorders in adult life 
(2, 358, 359). Anxiety disorders are often comorbid with MDD and there is evidence of 
shared genetic risk for anxiety and MDD (360). Despite this, the question of whether 
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increased levels of pro-inflammatory markers are also found in those suffering from 
anxiety disorders, or whether this finding is specific to depression has not been addressed.  
There have been several studies investigating the relationship between inflammation and 
psychiatric disorders, but few have evaluated the potential mediation of that relationship by 
genetic factors.  MDD and anxiety disorders as well as CRP levels and BMI have been 
demonstrated to be heritable. A meta-analysis estimate of heritability of MDD in adults is 
37% (234), with evidence that much of the heritability is explained by many common risk 
variants of small effect (134). Both CRP and BMI are also polygenic traits with heritabilities 
estimated to range from 20% to 52% (79, 361-363) for CRP and from 40% to 80% for BMI 
(364, 365).  Worns et al. hypothesized that BMI and adipose tissue mediated a major part 
of CRP heritability (79), but a study of healthy female twins concluded that obesity and 
adipose tissue influence baseline CRP levels independent of genetic influences (350).  
Functional allelic variants of the genes for the inflammatory marker CRP have been 
identified as increasing risk for depression (62).  Specifically, haplotypic variation in the 
CRP locus has been found to moderate an association between CRP levels and 
depressive symptoms, partly through body mass index (366).     
To date, no genome-wide significant loci have been found for either MDD or anxiety 
disorders in Caucasians.  This finding may be due to limitations of sample sizes or 
heterogeneity of these conditions.  Support for heterogeneity as a limitation comes from a 
study conducted by the CONVERGE consortium, which recruited 11,670 Han Chinese 
women (367).  The study aimed to further reduce heterogeneity by recruiting only those 
with recurrent MDD (hence also likely to be a severe illness).  The authors attributed this 
recruiting of more homogeneous cases to the identification (and replication in an 
independent sample) of two loci contributing to MDD risk (367).   
Genetic variants for CRP and BMI have been identified. A recent meta-analysis of GWA 
studies including more than 80,000 individuals identified 18 loci associated with CRP 
levels.  These loci included those implicated in pathways related to the immune system or 
metabolic syndrome (368).  Genetic profile risk scores, calculated to model the effect of 
the identified loci on CRP levels, have been found to explain approximately 5% of the 
variation in CRP levels in independent samples (368). If there is a causal relationship 
between CRP levels and depression and anxiety disorders whereby raised CRP levels are 
a risk factor for development of psychopathology, we would expect to find that alleles that 
 129 
 
increase CRP levels also show evidence of increasing risk to develop these psychiatric 
disorders. Furthermore, among those who have experienced abuse in childhood, 
individuals carrying more CRP alleles may be at greater risk of developing psychiatric 
disorders in adulthood. Assigning causality in the relationship between BMI and CRP from 
observational data is problematic, but Mendelian Randomisation analysis (369) indicates 
that increased BMI leads to increased levels of circulating CRP (370), consistent with the 
hypothesis that the CRP and MDD association is mediated by BMI. Likewise, if there is a 
direct causal relationship between CRP and MDD, then genetic variants that are 
associated with increased circulating CRP may also lead to increased risk of MDD. 
Here, we first investigate the phenotypic relationship between CRP and MDD and anxiety 
disorders, and CRP levels and childhood trauma in a large population-based cohort of 
twins from the Australian Twin Registry. We attempt to elucidate the role of BMI in the 
association by testing how the association changes when accounting for the relationship 
between BMI and CRP. We then investigate the potential association at the genetic level 
by evaluating whether those carrying more CRP-associated alleles are at increased risk 
for MDD or anxiety disorders, under the hypothesis that natural variation between 
individuals in circulating CRP is associated with variation between individuals with respect 
to common mood disorders. We compare the results to those from using BMI genetic risk 
scores to predict MDD or anxiety.    
Methods 
Samples  
 
Overview:  
Our analyses use measures from participants enrolled in studies conducted at QIMR 
Berghofer Medical Research Institute (QIMRB) that drew participants from the Australian 
Twin Registry. All procedures were approved by the Human Research Ethics Committee 
of QIMR Berghofer. Briefly, C-reactive protein (CRP) was measured as part of the protocol 
of three studies, with partly overlapping samples (Figure 6-1).  The protocol of two of those 
studies also involved a telephone-based diagnostic interview for MDD and anxiety 
disorders. All phenotypic analyses of CRP and MDD and anxiety disorders included only 
participants from those two studies. One other study measured CRP as part of the 
protocol, but did not include a diagnostic interview. A number of other waves of data 
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collection also included phone interviews diagnostic for MDD, but did not measure CRP.  
Genetic analyses included anyone with information on lifetime MDD and anxiety and so 
therefore participants were drawn from a larger number of studies.  In total, CRP 
measurements were available on 14,750 participants (37.64% males, 62.36% females) 
from 3,217 families, while BMI was measured on 8,800 participants (43.67% males, 
56.33% females) from 3,206 families.  Across all the studies, a total of 2,609 MDD cases 
and 6,785 controls with genome-wide genotypes were available for analysis.  With regard 
to anxiety disorders, a total of 1,839 cases and 7,849 controls had genome wide 
genotypes for analysis.  From those cases and controls, 1,596 unrelated MDD cases, 
1,856 unrelated MDD controls, 1,172 unrelated anxiety disorder cases, and 1,616 
unrelated anxiety disorder controls were utilised for the profile scoring analysis.  
Details of the contributing studies are as follows: 
The “Anxiety” study and NAG/IRPG study – CRP, diagnostic interview data: 
CRP was measured contemporaneously with assessment of lifetime diagnosis of MDD 
and anxiety disorders as part of two studies. The first study, known as the “Anxiety Study” 
(AX) is described in detail in Kirk et al (371). Based on previous responses to the 12-item 
neuroticism scale from the revised short form of the Eysenck Personality Questionnaire, 
twins and siblings were invited to participate in the study. Participants were selected with 
the purpose of maximising statistical power for a linkage analysis by identifying families 
where twins were highly concordant for high or low neuroticism, or where twins were highly 
discordant for neuroticism. Participants were interviewed over the phone by trained 
interviewers who administered the Composite International Diagnostic Interview (CIDI), 
which assessed DSM-IV diagnostic criteria for MDD, Generalised Anxiety Disorder, Social 
Phobia, Obsessive Compulsive Disorder (OCD), Agoraphobia, and Panic Disorder. 
Interviews were conducted with 2,475 individuals, of whom 1,906 also provided a blood 
sample from which CRP could be measured.  
The second study was conducted between 2003 and 2007 and combines multiple 
separate studies focused on the genetics of alcohol and nicotine addiction measured in 
community samples. These studies are called the NAG and Inter Related Project Grant 
studies (NAG/IRPG). The individual studies are described in detail in Table 2 of Hansell et 
al. (372). A computerised version of the Semi-Structured Interview for the Assessment of 
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the Genetics of Alcoholism (SSAGA) was administered by trained interviewers. A total of 
8,012 individuals completed the sections from which DSM-IV diagnosis of MDD and 
anxiety disorders could be made, and also provided a blood sample for measurement of 
CRP. OCD was not assessed as part of the protocol, so for individuals who had been 
measured in both the AX and NAG/IRPG studies (n = 537) we included only the data from 
the AX study, as the instrument also assessed OCD. Height and weight information were 
collected as part of this study.  The NAG/IRPG study also included a questionnaire about 
childhood trauma that included a section on childhood sexual abuse (373). 
SSAGA and Twin89 – diagnostic interview and GWAS data – no CRP measurement: 
In addition to the AX and NAG/IRPG studies, lifetime diagnosis of MDD and anxiety 
disorders was also assessed in two earlier studies at QIMRB. The studies, which are 
described in detail elsewhere (374) and have non-overlapping samples, are known as the 
SSAGA and Twin89 (TW89) studies. These studies were conducted prior to the AX and 
NAG/IRPG studies.  In both studies, a semi-structured psychiatric interview was conducted 
by telephone between the years of 1996 to 2000.  This telephone interview contained 
lifetime assessments of alcohol and nicotine dependence, drug use, childhood conduct 
disorder, DSM-IV diagnosis of MDD and anxiety disorders, in addition to childhood sexual 
abuse (CSA) and childhood physical abuse (CPA) screening questions.  Both CSA 
screening questions (375, 376) and CPA screening questions have been described 
previously (377). The target sample for the SSAGA study was twin pairs from the 
Australian Twin Registry (ATR) born between 1892 and 1963 and their siblings. The TW89 
study targeted twins from the ATR born between 1964 and 1971.  
The AX and NAG/IRPG studies described earlier drew a substantial proportion of 
participants from the SSAGA and TW89 studies, but also included new participants. 
However, no measures of CRP were taken until the AX study. 
Childhood Sexual Abuse: 
In addition to the SSAGA, TW89 and NAG/IRPG studies, two further studies assessed 
childhood trauma. Where one or more member of the twin pair endorsed either form of 
abuse in the TW89 study, the twins, full siblings and parents went on to be interviewed in 
the Childhood Trauma Study, between the years of 2003 – 2008. Control families (those in 
which twins had not reported either form of abuse in earlier studies) were also interviewed.  
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The Childhood Trauma Study was administered as a computer assisted diagnostic 
interview, and included an evaluation of trauma (both CSA and CPA) prior to age 18 years, 
based on the Christchurch Trauma Assessment (378-380). 
A further study took place between 2010 and 2013, and consisted of a follow-up interview 
of the cohort, constituting the sample for a funded GWAS of alcohol dependence.  Data for 
this survey was initially collected by a structured telephone interview, and later by online 
self-report questionnaire.  The study collected detailed information on environmental 
stressors including childhood sexual and physical abuse, lifetime assessments of PTSD 
(DSM-IV diagnosis) and illicit drug dependence, and updated information on alcohol use 
and alcohol dependence (DSM-IV diagnosis).  
Childhood sexual abuse was defined as any reported instance of unwanted sexual contact 
before the age of 16 years. 
Figure 6-1: Overview of contributing studies  
 
Key: CRP data: from Anxiety Study (AX), NAG and Inter Related Project Grant (NAG/IRPG) studies; MDD / 
anxiety data: from AX, NAG/IRPG, Semi-Structured Interview for the Assessment of the Genetics of 
Alcoholism (SSAGA), Twin89 (TW89) studies; Childhood trauma data: from NAG/IRPG, SSAGA, TW89, 
Childhood Trauma Studies; Genotyped data: from follow-up of SSAGA, TW89, and NAG/IRPG cohort.  
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Notes: Total numbers (in brackets) show total numbers of study participants with CRP data, MDD / anxiety 
data, childhood trauma data, and genotyped data. The numbers immediately above the bracketed total 
numbers are the number of individuals with only that type of data (e.g. 272 individuals have MDD / anxiety 
data but no other type of data; no individuals have only genotyped data). Numbers in overlapping parts of 
circles show numbers of study participants with each type of data represented by the circles that overlap 
(e.g. 8,847 individuals have both CRP data and genotyped data.  Of these 8,847 individuals, 8,162 have 
CRP data, MDD / anxiety data, and genotyped data).   
 
Measurement of CRP  
 
Blood samples were separated into serum at the time of collection.  Samples were stored 
at -70 degrees Celsius until time of measurement. A quantitative measurement of serum 
CRP (in mg/L) was obtained by enzyme-linked immunosorbent assay (ELISA), using a 
high-sensitivity sandwich assay.   
Genotyping 
 
A total of 9,394 individuals had genome-wide SNP data.  Genotype data had been 
generated as part of a number of projects undertaken by the Genetic Epidemiology group 
at QIMRB.  DNA samples were collected in accordance with standard protocols and 
submitted to different genotype centres using different SNP platforms (Illumina 317K, 
IlluminaHumanCNV370- Quadv3, and Illumina Human 610-Quad). SNPs were called 
using the Illumina BeadStudio software. A standard quality control procedure was applied 
to each project individually, prior to imputation (381).  A detailed description of the quality 
control (QC) steps and procedure for detection of ancestry outliers is given elsewhere 
(382). 
A set of 274,604 SNPs that were common to all of the genotyping chips were used for 
imputation, which was performed using the program MACH (383). The imputation process 
uses information on the haplotype structure in the human genome from the HapMap 
project (Release22 Build36) to impute non-genotyped SNPs in the sample. The imputed 
SNPs were screened further for Mendelian errors, minor allele frequency and missingness.  
Only SNPs with an imputation quality score (R2) greater than 0.3 were retained, which 
resulted in a total of 2,380,486 SNPs.  
 134 
 
Association between CRP, MDD and anxiety disorders 
 
Individuals older than 70 years old (n=492) were removed from the analysis because the 
greater risk of physical comorbidities might confound the association of the mood 
disorders with CRP.  Across the AX and NAG/IRPG studies, a total of 2,445 MDD cases 
and 5,786 MDD controls with CRP measures were identified (Table 6-1). A total of 1,783 
individuals met the criteria for an anxiety disorder, and 7,061 individuals were classified as 
controls (Table 6-1). A total of 4,945 individuals did not meet the criteria for either disorder, 
3,301 had either an anxiety disorder or depression, and 942 individuals met the criteria 
both for MDD and an anxiety disorder.  
Table 6-1: Sample sizes for CRP phenotypic analyses  
Phenotype All % Female 
 Families Cases Controls Cases Controls 
CRP – sample size 
MDD 3184 2445 5786 63.3 53.2 
Any Anxiety   3217 1783 7061 60.7 55.3 
Social Phobia 3189 1373 6922 59.4 55.6 
Panic Disorder 3190 359 7996 64.3 56.0 
CSA 2695 1275 6008 73.3 51.3 
Key: CRP = C-reactive protein; MDD = major depressive disorder 
Statistical analysis:  
CRP data were log-transformed to reduce skewness of the distribution. The relationship 
between log CRP levels and psychiatric disorders was evaluated by linear regression, with 
age at CRP measurement and sex included as covariates. We considered models where 
the psychiatric disorder cases used were 1) MDD, 2) anxiety disorders, 3) any disorder, or 
4) both disorders. Only those not meeting the criteria for MDD or an anxiety disorder were 
considered as controls in models 3) and 4).  Further models fitted BMI as a covariate. BMI 
was not measured in the AX study, but had been measured on the participants in previous 
studies; the BMI measurement taken closest to the time of the AX study was used (N 
=1,804). We also constructed linear regression models where log CRP levels in those with 
a history of childhood sexual abuse were compared to those with no history of childhood 
sexual abuse, with age (at time of CRP measurement), sex, and BMI as covariates.  
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Genetic Risk Profile Scoring 
 
Genetic profile risk scores (GPRS) were estimated for each individual with genome-wide 
genotype data as the sum of the number of associated alleles (identified from the 
“discovery” sample) weighted by their estimated effect sizes. The discovery sample GWAS 
studies that identified associated alleles were the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium for CRP (368) and the Genetic 
Investigation of Anthropometric Traits (GIANT) Consortium (384) for BMI. 
Results from the CHARGE meta-analysis of log CRP levels (368) were used to generate 
profile scores for all individuals who had been genotyped and who had either completed a 
telephone-based diagnostic interview or had been asked about childhood sexual abuse.  
The GIANT meta-analysis was conducted with QIMR samples removed so as to ensure no 
overlap between the discovery sample and the target sample in the present study.  
Sample sizes for the genetic profile scoring analyses are provided in the footnotes of 
Tables 6-3 and 6-4.   
The profile scoring methodology has been described in detail elsewhere (333, 385). PLINK 
(344) was used first to perform LD-based clumping so as to make a quasi-independent 
SNP set. SNPs in LD with the most associated SNP in a 1MB region at r2 > 0.25 were 
removed by the clumping algorithm. Then profile scoring was performed using PLINK. 
Genetic profile risk scores were generated for 5 sets of SNPs: SNPs with p-values of 
<0.001, <0.01, <0.1, <0.5, and all clumped SNPs respectively from the CRP and BMI 
meta-analyses. Linear regression was used to see how accurately the CRP and BMI 
profile scores could predict CRP and BMI respectively. Logistic regression was used for 
analysis of the case/control variables. 
To aid in the interpretation of the results, one individual per family was selected for 
inclusion in the profile scoring analyses (n=2,394 individuals for CRP; n=2,396 individuals 
for BMI). For the MDD and anxiety analyses, cases were prioritised from families where 
there were cases and controls in order to increase statistical power. We subsequently 
conducted the profile scoring analyses with relatives included. 
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Initially, the CRP profile scores were used to predict CRP, MDD and anxiety disorders 
across the entire sample, and also to predict MDD and anxiety together as one case 
group.  Profile scoring was also performed to test if the CRP profile scores predicted BMI.  
Results 
Association between CRP and MDD and Anxiety Disorders 
 
The mean age at CRP measurement was 45.3 years (standard deviation (SD) 10.1 years).  
The mean BMI of 25.97 kg/m2 (SD 4.87 kg/m2) was slightly above the normal range of 20-
25 for adults.  Mean log CRP was 0.64 (SD 1.12).  The mean log CRP for those with both 
MDD and a co-morbid anxiety disorder was higher than controls with neither disorder, 
however this difference in means was not statistically significant (p=0.13).  The same 
pattern was seen in males and females although mean log CRP was higher in females (p 
=< 2.2x10-16).   
Consistent with another published study (386), mean log CRP was higher in those with a 
history of CSA in females (p=0.029, Table 6-2), however this difference was not significant 
after including BMI in the model (p=0.56). In males mean log CRP was higher in those 
without a history of CSA (p=0.11) (Table 6-2). When the total sample was divided into 
those with no history of CSA and those with a prior history of CSA, there was no significant 
difference in mean log CRP between MDD cases and controls (Table 6-2).  
Association between MDD and CRP levels 
 
The point estimates of log CRP levels were higher in MDD cases compared to controls 
(Table 6-2), although the difference was not significant (p=0.12). Upon inclusion of BMI in 
the model, the effect estimate and the statistical significance of the effect of MDD on log 
CRP levels were reduced, reflecting the highly significant effect of BMI on log CRP levels 
( = 0.09, S.E = 0.002, p = < 2 x 10-16). However, owing to missingness in the data, 
inclusion of BMI also reduced the number of MDD cases and controls to 2,433 cases and 
5,755 controls, hence reducing power (Table 6-2).  
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Association between Anxiety Disorders and CRP levels 
 
A nominally significant association between anxiety disorders and CRP was found (Table 
6-2, p =0.012). The estimated effect and significance increased when including only 
controls who were negative for both anxiety disorders and MDD (Table 6-2, p =0.0047). 
However, this result barely survives correction for performing 10 tests (although this is 
conservative since owing to the high rate of comorbidity between CSA, anxiety and MDD, 
the statistical tests are correlated).  Upon inclusion of BMI in the regression model, the 
estimate of the effect of having an anxiety disorder decreased, and statistical significance 
reduced, both when including those who did not have an anxiety disorder only, and when 
only including those who did not have either an anxiety disorder or MDD (Table 6-2).  
A significant association was also found between higher log CRP levels and social phobia 
(p=0.0045), however this was no longer significant when BMI was included in the model 
(p=0.090, Table 6-2).  This association was likely to be driving the association between 
CRP and anxiety disorders (in the combined anxiety disorders group), and when we 
excluded those individuals who met criteria for social phobia from the analysis, the 
association was no longer significant (p =0.099) – however excluding these individuals 
reduced the sample size to 515 cases (all 515 had BMI data). 
Association between childhood sexual abuse and CRP levels 
 
The association between log CRP levels and a history of CSA was not statistically 
significant (p=0.26 when controlling for age and sex, p=0.46 when also including BMI in 
the model – Table 6-2).  
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Table 6-2: Regression analyses for MDD, Anxiety disorders, or CSA explaining variation in log 
CRP 
Sample Number 
cases / 
controlsa 
βa (S.E.) P-
valuea 
Number 
cases / 
controls # 
β (S.E.) # P-
value# 
Regression of Log CRP on MDD vs No MDD 
Total sample 2445 / 5788 0.037(0.024) 0.12 2433 / 5755 0.015(0.022) 0.50 
Regression of Log CRP on Anxiety vs No Anxiety 
Total sample 1783 / 7061 0.074(0.029) 0.012 1770 / 7027 0.052(0.027) 0.058 
Regression of Log CRP on Anxiety vs No Anxiety or MDD 
Total sample 1783 / 4945 0.087(0.031) 0.0047 1770 / 4918 0.055(0.029) 0.055 
Regression of Log CRP on Social phobia vs No Social phobia 
Total sample 1374 / 6924 0.083(0.029) 0.0045 1368 / 6885 0.046(0.027) 0.090 
Regression of Log CRP on CSA vs No CSA 
Total sample 1275 / 6008 0.035(0.031) 0.26 1275 / 6001 0.021(0.029) 0.46 
Males only 341 / 2924 -0.094(0.060) 0.11 341 / 2922 -0.008(0.057) 0.89 
Females only 934 / 3084 0.094(0.043) 0.029 933 / 3077 0.023(0.039) 0.56 
Regression of Log CRP on MDD vs No MDD in those reporting no CSA 
Total sample 1600 / 4262 0.051 (0.032) 0.11 1596 / 4257 0.035 (0.029) 0.24 
Males only 667 / 2196 0.082 (0.046) 0.074 666 / 2195 0.060 (0.043) 0.16 
Females only 933 / 2066 0.027 (0.045) 0.55 930 / 2062 0.015 (0.040) 0.71 
Regression of Log CRP on MDD vs No MDD in those reporting CSA 
Total sample 580 / 666 0.042 (0.067) 0.54 579 / 666 0.004 (0.062) 0.95 
Males only 144 / 188 0.073 (0.124) 0.56 144 / 188 -0.006 (0.122) 0.96 
Females only 436 / 478 0.033 (0.080) 0.68 435 / 478 0.025 (0.071) 0.73 
 
Key: a = regression includes age and sex as covariates; # = regression includes age, sex and BMI as 
covariates; β = regression coefficient for binary factors as listed; CSA = history of childhood sexual abuse; 
MDD = major depressive disorder; S.E = standard error 
Genetic Profile Scoring 
 
Results of the genetic profile scoring analyses that used the CRP GWAS results to predict 
CRP and also MDD and anxiety disorders in the QIMRB sample are presented in Table 6-
3. CRP profile scores predicted CRP in the QIMRB sample (column 4), with up to 2.4% of 
the variance of CRP explained by this age, sex, and BMI adjusted model.  The CRP profile 
scores did not predict MDD or anxiety case/control status (columns 5 - 7, Table 6-3).  CRP 
profile scores did not predict BMI (results shown in Appendix, page 186). 
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Table 6-3: Log CRP genetic profile risk scores – prediction of CRP, MDD, Anxiety  
CRP sample size = 2,637 individuals (1,246 males; 1,391 females) 
P-value of 
SNPs in CRP 
discovery 
GWAS 
 N SNPs Variance 
of CRP 
explained 
(R2) 
P-value for 
prediction 
of CRP 
P-value for 
prediction 
of MDD  
P-value for 
prediction of 
Anxiety  
P-value for 
prediction of 
Any Disorder  
P < 0.001 1,972 2.42 5.2x10-14 0.44 0.98 0.88 
P < 0.01 11,154 2.12 1.8x10-12 0.77 0.73 0.85 
P < 0.1 70,982 1.18 1.3x10-7 0.92 0.10 0.36 
P < 0.5 241,214 0.84 6.9x10-6 0.78 0.18 0.41 
All SNPs 361,282 0.79 1.4x10-5 0.72 0.15 0.42 
 
Key: Any Disorder = MDD or Anxiety or both; BMI = body mass index; CRP = C-reactive protein; MDD = 
major depressive disorder 
MDD: number cases = 1,165 (487 males, 678 females); number controls = 1,182 (632 males, 550 females) 
Any Anxiety: number cases = 978 (435 males, 543 females); number controls = 1,368 (704 males, 664 
females)  
Any Disorder: number cases = 1,752 (761 males, 991 females); number controls = 885 (485 males, 400 
females) 
 
BMI profile scores predicted BMI in the QIMRB sample, with up to 6.8% of the variance 
explained (Table 6-4).  When BMI profile scores were used to predict MDD in the QIMRB 
sample, BMI did not predict MDD.  Similarly, BMI SNPs did not significantly predict anxiety 
case/control status. Furthermore, BMI and CRP profile scores did not predict MDD or 
anxiety case / control status when relatives were included in the analyses (results not 
shown).  
Table 6-4: BMI genetic profile risk scores – prediction of BMI, MDD, Anxiety;  
BMI sample size = 3,235 individuals (1,424 males; 1,811 females) 
P-value of 
SNPs in BMI 
discovery 
GWAS 
N SNPs Variance of 
BMI 
explained 
(R2) 
P-value for 
prediction 
of BMI 
P-value for 
prediction 
of MDD 
P-value for 
prediction 
of Anxiety 
P-value for 
prediction 
of Any 
Disorder 
P < 0.001 2966 6.54 1.3x10-7 0.23 0.47 0.39 
P < 0.01 10382 6.84 2.9x10-9 0.34 0.41 0.26 
P < 0.1 60778 6.47 2.9x10-7 0.18 0.26 0.063 
P < 0.5 233696 5.94 2.6x10-4 0.22 0.79 0.26 
All SNPs 370278 5.91 3.5x10-4 0.16 0.70 0.19 
 
Key: Any Disorder = MDD or Anxiety or both; BMI = body mass index; MDD = major depressive disorder 
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MDD: number cases = 1,596 (597 males, 999 females); number controls = 1,856 (831 males, 1,025 females) 
Any Anxiety: number cases = 1,172 (505 males, 667 females); number controls = 1,616 (799 males, 817 
females) 
Any Disorder: number cases = 2,283 (915 males, 1,368 females); number controls = 952 (509 males, 443 
females)  
Discussion 
 
CRP is an acute phase reactant, and higher levels of CRP have been associated with 
MDD (7, 271), anxiety disorders (33), and a history of early childhood adversity (28, 29).  
We set out to investigate the relationship between (i) CRP levels, MDD, and anxiety, and 
(ii) CRP levels and CSA, and to test whether those who carry more CRP increasing 
alleles, are at increased risk to develop depression and anxiety.  
Consistent with previous studies we found some evidence of increased levels of CRP in 
those with MDD compared to controls, but this did not reach statistical significance (p = 
0.12). Inclusion of BMI in the model reduced the significance of the association further, 
indicating that increased BMI in MDD cases may explain part of the increased levels of 
CRP.  
Our results do not support a role for inflammation in the aetiology of anxiety disorders. 
Although CRP levels were significantly higher in those with any anxiety disorder compared 
to those who did not have either MDD or an anxiety disorder (p=0.0047), the association 
was reduced to non-significance after accounting for BMI.  We specifically focused on the 
association between CRP and social phobia, as this was the anxiety disorder with the 
most cases. There was a significant association between CRP and social phobia 
(p=0.0045), but again after adjusting for BMI the association was no longer significant.   
This study found that BMI appears to be important in the phenotypic relationship between 
CRP and MDD and anxiety.  A prior study found the longitudinal association between 
Generalised Anxiety Disorder and later CRP levels was mediated by BMI (33).  With the 
prevalence of obesity increasing globally (387), this mediation by BMI is important.  
Increased rates of obesity are associated with increased rates of cardiovascular disease, 
diabetes (388), and MDD (355).  Furthermore, inflammation may contribute to increased 
risk of illnesses such as cardiovascular disease (359) and MDD (389). 
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This is one of the largest studies conducted of CRP with anxiety disorders to date and 
further supports the notion of shared aetiology between anxiety and MDD. In both men 
and women, the highest CRP levels were among those with comorbid anxiety and MDD. 
Although anxiety and MDD co-occur, BMI appears to mediate the relationship between 
these disorders and peripheral CRP levels.   
In females, we found the highest CRP levels were in those with anxiety disorders and a 
history of CSA, however the difference compared to controls was not significant.  Higher 
CRP levels in adults with a history of childhood adversity have been observed previously, 
however the difference was only statistically significant in those adults with current 
depression (28, 29).  It is thought that childhood adversity is important in explaining the co-
occurrence of depression and inflammation (28-30).  Furthermore, an interaction effect has 
been observed between polygenic risk scores and childhood trauma in MDD (390).  In 
males we found no evidence of a relationship between circulating CRP and report of 
childhood sexual abuse compared to males not reporting (p=0.11), however we note small 
numbers of males with this history and that men may be unlikely to admit to a history of 
sexual abuse in a phone interview.   
We did not find significant evidence that individuals who carry more alleles that increase 
CRP levels or BMI are at greater risk of suffering from MDD or anxiety disorders. We could 
not find other studies that had used CRP genetic profile scores with the objective of 
predicting anxiety disorders.  However, one previous study investigated whether BMI 
genetic risk scores predict obesity in patients with MDD (391).  The authors found that 
genetic risk scores had a larger effect on BMI in depressed patients, with the largest effect 
in patients with severe MDD (391). In an earlier study, the same group used BMI genetic 
risk scores as instrumental variables in a Mendelian randomisation study (392).  In this 
study, using weighted genetic risk scores or the FTO genotype as instrumental variables 
did not support the hypothesis that obesity increased the risk of MDD (392).  The effect of 
the FTO gene on BMI has also been investigated in an earlier study examining the genetic 
mechanism underlying the reported association between BMI and MDD (393).  The 
authors found the association between FTO and BMI to be specific to the group with MDD 
(and not the controls) (393). There appears to be a complex relationship between 
psychiatric disorders, CRP and BMI. Accounting for BMI in the present study reduced the 
significance of the association between CRP and MDD and anxiety.  
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Assessing measures of depression through a structured interview (even through a trained 
interviewer), is a limitation of this study. The use of telephone rather than face to face 
interviews may have resulted in participants providing different responses to some 
questions. In particular, it is unclear how telephone interviews would affect responses to 
questions of a sensitive nature such as exposure to childhood sexual abuse. It is possible 
that some participants may have felt less comfortable responding to these questions when 
asked over the telephone whereas others may have found it easier to disclose such 
experiences with the relative anonymity that the telephone interview provided.   
Clinical samples may provide stronger evidence for the association between CRP and 
psychopathology. Sample sizes were small for some of the anxiety disorders, so 
individuals meeting criteria for any of the anxiety disorders were grouped together in the 
analysis. It was therefore not possible to compare the association with CRP across anxiety 
disorders. Further investigation of the role of inflammation in anxiety disorders is warranted 
in those disorders where there were small case numbers.  A further limitation of the 
present study is that we correlate lifetime MDD and anxiety with current CRP, which does 
not give a picture of present levels of distress, and participants may be in remission and 
therefore have reduced levels of CRP.  
CRP values have been reported to remain stable despite multiple freeze/thaw cycles 
(394).  However another study found CRP values increased after long-term frozen storage, 
with values showing a high correlation between baseline (before storage) and after storage 
(395).  In our study there was also some variation in the time of day that blood was 
collected, with most blood samples collected in the morning, and some collected in the 
afternoon or evening (to suit study participants).  Furthermore, only one marker of 
inflammation was measured in the peripheral blood.  Measuring CRP in the CSF may 
provide more sensitive results, however the invasiveness of this procedure would preclude 
this.  Reliance on self-report BMI may also influence the results. 
Conclusion 
 
A point estimate of higher mean log CRP in the group that met criteria for MDD and a co-
morbid anxiety disorder, compared to those with neither disorder was not statistically 
significant (p=0.13).  The association between CRP and social phobia (p=0.0045), was not 
significant after adjusting for BMI (p=0.090).  Other results were not significant.  CRP 
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profile scores did not predict MDD or anxiety disorders in this large community sample.  
The complex relationship between CRP, BMI, MDD and anxiety disorders requires further 
study, but our results suggest that BMI is the key factor that mediates the reported 
relationship between circulating CRP and psychiatric disorders. Further phenotypic and 
genetic studies with greater power are needed; presentation of our results allows 
contribution to future meta-analyses. 
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CHAPTER 7: Thesis Discussion   
 
The hypothesis of this thesis was that pro-inflammatory cytokines, inflammatory markers, 
and biomarkers altered in inflammatory states would be phenotypically and genetically 
associated with measures of depression in adolescents.  This overarching hypothesis was 
developed from findings in the adult literature, where raised pro-inflammatory cytokines 
have been associated with Major Depressive Disorder (MDD) (6), anxiety disorders (16), 
and psychosis (15).  Whilst the literature has expanded in recent years, systematic 
literature reviews (20, 301) have concluded further research is warranted, to improve the 
understanding of the role of cytokines and inflammatory markers in adolescent mental 
illness in relation to neurodevelopment, stress and maltreatment.  Therefore, this chapter 
includes discussion of areas for further research, in the context of how this may lead to 
improved treatments for adolescent MDD.  To provide context there is some discussion of 
similarities and differences in regard to inflammation between adolescents and adults with 
MDD.  
MDD in children and adolescents appears to be associated with immune system 
dysregulation, including raised pro-inflammatory cytokines (161).  More recently, a 
developmental model of psychoneuroimmunology has been proposed, which connects 
stress exposure in childhood to immune function and physical and mental illness in 
adulthood.  This model links immune mechanisms from as early as the prenatal period to 
factors such as neurodevelopment and stress (396).  Key to this model  is the finding that 
a history of early childhood adversity has a significant role in the co-occurrence of MDD 
and inflammation throughout the life span, with this “biological embedding” seen as early 
as the adolescent years (28, 29).      
Table 7-1 details the overall findings of this thesis. In summary, the findings with potential 
clinical implications are as follows: i) the relationship between cytokines and MDD may not 
be the same in adolescents as in adults, ii) cytokines able to be measured in plasma 
(tumour necrosis factor-receptor type 1 (TNFR1) and transforming growth factor-β1 (TGF-
β1)) were found to be moderately heritable, and iii) the relationship between C-reactive 
protein (CRP) and MDD, and between CRP and anxiety disorders appears to be mediated 
by body mass index (BMI).   
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Table 7-1: Overall thesis findings 
Thesis Chapter Finding 
Literature review (chapter 2) Relationship between cytokines and MDD may not be the same in 
adolescents as that seen in adults and detailed investigation is 
warranted 
Cytokines, other 
inflammatory markers, and 
other biomarkers of immune 
function in healthy 
adolescents (chapter 3, part 
1) 
Cytokines able to be measured in plasma (TNFR1 and TGF-β1) 
were found to be moderately heritable. 
Important limitations in the measurement of cytokines were 
encountered. 
Iron (chapter 5) The phenotypic and genetic correlations between measures of iron 
and depression were not different from zero. Depression measures 
in adolescents were significantly higher in those in the middle 10th 
percentile of transferrin saturation measures compared to those in 
the highest 10th percentile, which may imply a highly non-linear 
relationship between measures of blood iron and depression 
C-reactive protein (chapter 6) The relationship between (i) CRP and MDD, and (ii) CRP and 
anxiety disorders appears to be mediated by BMI 
     
Cytokines in adolescent MDD 
 
The systematic literature review (Chapter 2) found that depression in adolescents may not 
show the same immune changes that occur in adults.  Specifically, results of plasma levels 
of tumour necrosis factor-α (TNF-α) in MDD have been inconsistent with different 
developmental stages. Plasma levels have been found to be significantly decreased in 
adolescents with suicidal ideation (191), yet in adults, regardless of suicidality, an 
association between elevated levels of circulating TNF-α and MDD has been observed in a 
meta-analysis (6).   
Another conclusion of Chapter 2 was that interleukin-1β (IL-1β) levels have also been 
reported to differ in children and adults with MDD.  In adults, elevated levels of IL-1β have 
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been reported (201), however in children with MDD normal levels of IL-1β were reported 
(183).  The important potential confounder of stress was addressed in the study by 
Brambilla et al., who examined IL-1β and TNF-α levels in children with first episode MDD 
that was unlikely to have been preceded by stressful life events (183).  This study also 
reported no difference in TNF-α levels between those with MDD and controls (183).       
Cytokines in healthy adolescents 
 
Studying the variation of cytokines in healthy adolescents provided useful information to 
guide future research of cytokines in clinical populations.  By estimating the heritability of 
cytokines in healthy adolescents, we were able to determine which cytokines and other 
inflammatory markers could be measured, and which cytokines may have a genetic 
contribution to variation of circulating levels.  We found a genetic contribution to variability 
of the cytokines TGF-β1 and TNFR1 in healthy adolescent twins.  This is potentially of 
relevance in the aetiology of MDD in adolescents.  In particular, the possibility of shared 
genetic factors between these cytokines and MDD could be investigated in future studies.   
The negative correlation between pro-inflammatory cytokines and Vitamin D in adolescent 
twins (Chapter 3) was not significant.  However, Grudet et al. found a negative correlation 
in a clinical sample of adults, and found that low levels of Vitamin D were associated with 
higher levels of the pro-inflammatory cytokines IL-6 and IL-1β in study participants with a 
psychiatric diagnosis (397).  Understanding the role of Vitamin D deficiency in 
inflammation may be an important area for further study in both healthy and clinical 
samples (12, 25).  It could be hypothesised that there will be a negative correlation found 
between Vitamin D and pro-inflammatory markers in MDD, anxiety disorders and 
psychosis.  Study numbers included 27 participants with MDD in the study by Grudet et al. 
(397), so this could be tested in studies with larger numbers that use a longitudinal design 
(to explore the direction of association).  
The pilot study conducted (Chapter 3) also highlighted the difficulties in measuring 
cytokines.  The plasma cytokines measured as part of a multiplex did not generate 
meaningful results.  The cytokines, other inflammatory markers, neurotrophins and 
antibodies measured in dried blood spots were sensitive to paper type and plate effects, 
often generating null reads for one or other paper.  The problems associated with 
generation of high quality measures of circulating cytokines need to be addressed before 
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attempts can be made to measure circulating levels of cytokines in the clinical group of 
adolescents. 
Cytokines in a clinical group of adolescents 
 
As yet the levels of circulating cytokines have not been measured in the study in the 
clinical sample (Chapter 4), since the final sample size was too small to generate useful 
results.  It is important that the cytokines can be measured accurately.  Furthermore, 
combining the blood samples of the adolescents who participated in our study with another 
study will provide sufficient statistical power.  Potential ways to progress the measurement 
of circulating cytokine levels in a clinical group of adolescents are discussed later in this 
chapter. 
Although the cytokines have not yet been measured, this work was influential in changing 
research protocols at the Royal Brisbane and Women’s Hospital (RBWH).  Significant 
challenges were encountered in the collection of data, which included obtaining consent 
for study participation (prior to discharge) in those adolescents who had a brief admission 
to the Inpatient Unit.  In view of these challenges in recruiting study participants, RBWH 
HRECs have now approved a process of consent where informed consent is obtained 
from parents over the telephone, and then later obtained from participants when they have 
capacity.    
Iron 
 
In addition to cytokines, other inflammatory markers, including measures of ferritin and 
transferrin, have been linked to MDD (9).  Specifically, lower levels of serum iron and 
transferrin, and higher levels of serum ferritin have been found in MDD (9).  These 
changes in iron measures may be seen in inflammatory states, however in the absence of 
inflammation, serum ferritin may be low if there is inadequate dietary intake of iron.  In 
adolescents, depression measures were significantly higher in those in the middle 10th 
percentile of transferrin saturation measures compared to those in the highest 10th 
percentile of transferrin saturation measures (Chapter 5).  As found in the existing 
literature examining the relationship between iron and depression (316), it may be that a 
phenotypic relationship is more likely to be observed at the lower range of iron measures.  
We did not measure circulating levels of haemoglobin, as we were hypothesising that 
 148 
 
markers of inflammation rather than haemoglobin per se would be associated with MDD.  
We also do not have information on dietary intake of iron (or information on potential 
causes of iron loss) in our study, however using longitudinal measures of iron and 
depression could provide useful information. 
To the best of our knowledge, there are no previous studies that had used genetic profile 
risk scores to investigate the relationship between iron measures and depression, so in 
keeping with our hypothesis that markers of inflammation would be associated with MDD, 
we used multiple approaches to explore evidence for a genetic relationship between these 
measures.  The variation between individuals in iron measures is partly under genetic 
control, with highly significant SNPs in the gene TF (transferrin) (329) and SNPs affecting 
ferritin (330).  After correction for multiple testing, genetic profile risk scores (GPRS) for the 
iron measures did not predict depression measures in the adolescent or adult cohort.  
GPRS for MDD showed no significant association with iron measures in adolescents or 
adults after correcting for multiple testing.  So no strong evidence was found for a genetic 
relationship between iron and depression measures in adolescents or adults, despite the 
study having sufficient power to address the hypothesis. 
C-Reactive Protein 
 
BMI appears to mediate the reported relationship between circulating CRP levels and 
MDD and anxiety disorders. This is important in view of the increasing prevalence of 
obesity (387), and the high prevalence of MDD and anxiety disorders in the population, 
with the onset of many of these disorders often in childhood or adolescence.   
Prior studies have found higher CRP levels in males with a history of MDD (compared to 
males with no history of MDD) (7, 32). However not all studies that have adjusted for BMI 
have found an association between elevated levels of CRP and MDD (145).  Whilst a 
genetic relationship between CRP and MDD was not observed (Chapter 6), very few 
studies have used CRP genetic profile risk scores with the objective of predicting MDD or 
anxiety.    
A previous study observed an association between higher CRP levels and Generalized 
Anxiety Disorder (GAD) (33).  However that study had much larger numbers of 
participants.  Whilst CRP did not predict anxiety status in our study, it is likely that the 
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sample size was too small (with the number of individuals who met criteria for any anxiety 
disorder besides social phobia being small). 
With the expansion of the stress depression literature, there is more support for the 
hypothesis that early childhood adversity is associated with inflammation in later life (28, 
29).  However, we did not find a significant association between CRP levels and a history 
of childhood sexual abuse (CSA).   
Figure 7-1 represents the relationships between inflammation and mental illness that were 
investigated during the thesis.  
Figure 7-1: Schematic representation of links between inflammation and mental illness 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis limitations and strengths  
 
A limitation of this thesis has been the challenges in measuring cytokines and other 
inflammatory markers, particularly in healthy adolescents (who will have low levels of 
circulating cytokines). To address the limitation of assay sensitivity, high sensitivity ELISA 
single assays can be used.  However, these assays generally cost more than a multiplex 
assay (295).   
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In Chapter 4, a limitation was the significant challenges that arose in attempting to collect 
data in a clinical sample.  However, this resulted in changes to the consent process at the 
RBWH Mental Health Service (approved by the Human Research and Ethics Committees), 
which has recognised these challenges.  
As a result of the challenges faced in collection of clinical data, the research reported in 
this thesis focused mostly on analysis of data from QIMRB studies of twins and their family 
members. A potential limitation of these data are that measures are cross-sectional 
measures (for example iron (Chapter 5) and CRP (Chapter 6) measures), so the direction 
of association is unable to be established.  This is also a limitation of the literature, with 
most of the studies investigating cytokines or inflammatory markers in adolescents with 
MDD (or anxiety disorders) also using a cross-sectional design.  Longitudinal designs 
generally require longer study durations.  Repeated study measurements may cost more, 
but the extra data obtained from a longitudinal study can answer questions such as the 
direction of an association.  Specifically, longitudinal studies can provide information on 
the temporal relationship between inflammation and mental illness, by addressing whether 
inflammation precedes or follows the development of MDD or anxiety disorders.  This in 
turn can provide implications for treatment.  Future study designs should aim to be 
longitudinal.       
A strength of the study design used in this thesis is the large numbers of study participants 
in Chapters 5 and 6.  A further strength is the quality of data collection employed in these 
large community studies of twins.  This allowed for controlling of potential mediators such 
as body mass index.  In Chapter 6, this also allowed analyses that stratified based on 
experience of childhood trauma.  In the literature some published studies have not 
controlled for these potential mediators that influence inflammation, or taken into account a 
history of early childhood adversity.     
Translation into clinical practice 
 
The direction of association between inflammation and mental illness is of importance, as 
this has implications for treatment.  In adults with MDD, there is evidence of a bidirectional 
association between inflammation and mood disorders, so inducing a pro-inflammatory 
state may induce mood symptoms (389).  In children and adolescents, the direction of the 
association between inflammation and MDD is not yet established (301).   
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In MDD, a link has been observed between treatment response and levels of cytokines 
and inflammatory markers. Specifically, depressed patients who do not respond to 
selective serotonin re-uptake inhibitors have been found to have high levels of the pro-
inflammatory cytokines TNF-α and IL-6 (216).  A proof of concept study reported that 
adults with treatment resistant MDD were more likely to respond to treatment with a 
cytokine antagonist where cytokines were elevated at baseline (226).       
With regard to anxiety disorders, the association between raised CRP and GAD observed 
in previous studies (33, 398) is important to note, in view of the link between early 
childhood adversity, persistent low grade inflammation and increased chance of 
developing mental and physical illness in adult life (29). However, the profile of 
inflammatory markers may not be the same in all anxiety disorders (399).  Furthermore, in 
adults it has also been hypothesised that different pathways may be involved in the 
association between inflammation and anxiety (compared to those hypothesised to link 
inflammation and MDD) (33, 399, 400).  Therefore, further understanding of the 
association between inflammation and anxiety disorders is needed prior to using 
interventions to target inflammation in these disorders.  
Treatment implications 
 
In adults with MDD, a small number of studies have investigated strategies to lower pro-
inflammatory cytokines and inflammatory markers.  These strategies have included 
exercise, omega-3 polyunsaturated fatty acids (omega-3 PUFAs), non-steroidal anti-
inflammatory drugs (NSAIDs), selective serotonin re-uptake inhibitors (SSRI’s) and 
cytokine antagonists.   
Regular exercise and physical activity has been shown to reduce levels of IL-1β, TNF-α, 
IL-6 and CRP (96).  A meta-analysis of adults with mood disorders indicated an 
antidepressant effect of omega-3 PUFAs (221).  Adding the cyclooxygenase-2 inhibitor 
celecoxib to treatment with reboxetine or sertraline in adults with MDD has been found to 
induce an antidepressant response (229, 230).  In adults with treatment resistant MDD and 
high baseline levels of CRP, infliximab (a cytokine antagonist) was found to reduce 
symptoms of depression (226).    
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Interventions that target inflammation successfully in adults may not have the same 
efficacy in adolescents, and only a small number of studies in this area have been 
conducted in children and adolescents.  In children with a first episode of MDD, omega-3 
PUFAs were found to improve depressive symptoms (222).  One study which measured 
cytokines in adolescent females with MDD or anxiety disorders found lower levels of the 
pro-inflammatory cytokine IL-6 in those treated with SSRIs (164).  The authors proposed 
this may be from anti-inflammatory properties of SSRIs (164).  A recent study measured 
cytokines in children and adolescents before and after 8 weeks of treatment with the SSRI 
fluoxetine for depression and / or anxiety, and found levels of TNF-α, IL-6, and IL-1β were 
significantly higher in those who did not respond to treatment (273).  
Raised pro-inflammatory cytokines and inflammatory markers are not specific to MDD.  It 
is becoming more apparent that this also occurs in anxiety disorders and psychosis (15, 
16).  This is consistent with the non-specific symptoms (for example irritability) that can be 
seen across mental illnesses (17).  Medications such as the newer atypical antipsychotics 
have been used to treat these non-specific symptoms in mental illnesses other than 
psychoses (401).  In this way, it is becoming increasingly apparent that existing diagnostic 
categories do not represent discrete syndromes (298).  Therefore, future studies that use 
the RDoC approach, examining domains such as these non-specific symptoms and 
inflammatory profiles, could potentially change diagnostic criteria and inform treatment 
interventions. 
It is important to note that measures that reduce inflammation in MDD may have different 
efficacy in anxiety disorders or psychosis.  Very few studies have investigated measures 
that target inflammation in anxiety disorders or psychosis, so this still needs to be 
established by conducting larger studies.  One study noted an improvement of negative 
symptoms of schizophrenia (in individuals who had been diagnosed with schizophrenia in 
the preceding 2 years) when antipsychotic treatment (amisulpride) was augmented with 
celecoxib (402).  However, to conduct these studies in adolescents, it would first need to 
be determined whether pro-inflammatory cytokines and other inflammatory markers are 
raised in those with treatment resistant illnesses. 
The stage of intervention is also important.  Specifically, the use of omega-3 PUFAs in 
adolescents and young adults assessed as at “ultra-high risk” of developing psychosis in 
the next 12 months has been found to reduce this risk (403). However, no evidence has 
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been found by meta-analysis of an improvement in psychotic symptoms when omega-3 
PUFAs are used as an augmentation to treatment for schizophrenia (404).   
Therefore, measures that reduce inflammation in a particular mental illness may not have 
the same efficacy in reducing inflammation in the presence of other mental illnesses.  
Similarly, interventions that target inflammation could potentially be associated with 
different clinical outcomes at different stages of illness.    
Future directions for research 
 
As a result of my thesis research I have the following recommendations for future 
research: 
1) An affordable assay that can successfully measure cytokines in low concentrations is 
important.  This was a major limitation of this thesis. Whilst high sensitivity ELISA single 
assays can be used, these assays generally cost more (295).  The multiplex assay allows 
measurement of the concentrations of several inflammatory markers simultaneously in 
small amounts of sample (243).  Therefore, improving the ability of the multiplex assay to 
accurately measure cytokines and inflammatory markers in low concentrations is a 
potential area for further research.  
Considering less invasive ways to measure cytokines and inflammatory markers is also 
important, particularly in children and adolescents.  Inflammatory markers have been 
measured in saliva in adolescents (405).  Serum levels of CRP have been found to 
correlate with saliva levels of CRP in adolescents expected to have high levels of 
inflammation, however the study sample size was small (405).  Therefore, future studies 
with larger sample sizes could explore this further.  
2) Further exploration of the relationship, in particular the direction of the association, 
between cytokines and other inflammatory markers in depression in adolescents.  These 
studies should be longitudinal, as longitudinal designs are essential to understanding 
childhood mental illness (406), and the direction of association between inflammation and 
mental illness in adolescents.  However, strategies would also need to be implemented (as 
discussed further in recommendation number 7) to improve recruitment of adolescents. 
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At present, elevated levels of circulating pro-inflammatory cytokines and inflammatory 
markers do not appear to be specific to MDD, anxiety disorders, or psychosis. So in adults, 
schizophrenia is also associated with immune system dysregulation, however whether this 
is a biomarker of illness (rather than causal) is not yet established (15, 407). However, 
there are very few studies of cytokines in adolescents with anxiety or psychotic disorders. 
So further investigation of the relationship between inflammatory markers and anxiety 
disorders, and between inflammatory markers and psychotic disorders in adolescents is 
required, as these disorders in this age group may not have the same immune changes 
reported in adults.  As there is considerable co-morbidity between anxiety disorders, 
depression and symptoms of psychosis in youth (297), combining samples from 
individuals with each of these disorders could increase study power.    
In adolescents, studying each of these disorders could include measurement of circulating 
cytokines and inflammatory markers in the acute stage and again in the recovery stage of 
illness.  A study hypothesis in this clinical group could be that lower levels of circulating 
cytokines and inflammatory markers would be found in the recovery stage of illness 
(compared to the acute stage).          
3) Further study to develop additional treatment options of adolescent MDD and other 
mental illnesses seen in adolescence, particularly in those individuals who have 
associated raised pro-inflammatory markers.  MDD is a heterogeneous disorder, and in 
adults different MDD subtypes have been associated with different inflammatory marker 
profiles (408).  Measurement of circulating cytokines and inflammatory markers in the 
acute stage and again after allowing an adequate trial of treatment may identify a 
subgroup of individuals in whom inflammatory markers remain elevated.  For this 
subgroup, this may lead to trials of interventions that target inflammation (such as exercise 
and / or omega-3 PUFAs) as an augmentation of treatment for adolescent MDD.  If these 
interventions were to be trialled, cytokines and inflammatory markers could be measured 
prior to augmenting treatment, with repeat measurement of cytokine levels, inflammatory 
markers, and clinical outcome after several months of intervention (e.g. regular exercise).     
4) Examining the genetic relationship between cytokines and mental illness (including 
whether there is a shared liability to immune system dysregulation and mental illness) in 
adolescents could increase our understanding and also have implications for treatment of 
mental illness in this age group.  For example, if some variants of the TNF-α gene are 
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more common in individuals with MDD (found by GWAS), an important question to ask 
would be whether these individuals also have higher levels of TNF-α that do not change 
with treatment of the depressive episode.   
5) The relationship between pro-inflammatory cytokines and Vitamin D in healthy 
adolescent twins (Chapter 3) requires further investigation, particularly as Vitamin D is 
easier (and cheaper) to measure than cytokines.  Vitamin D has been found to decrease 
pro-inflammatory cytokines (such as IL-1β, TNF-α and IL-6), and increase anti-
inflammatory cytokines (such as IL-4 and IL-10) (409, 410). To explore this further, the 
relationship between Vitamin D and cytokines associated with MDD (such as TNF-α and 
IL-6) could be investigated in a clinical group of adolescents.  It may be that a non-linear 
relationship is found, where those who have Vitamin D levels at the extreme ends of the 
range have increased rates of MDD.  This pattern has been reported previously for Vitamin 
D and schizophrenia, with neonates who had either low or high levels of Vitamin D 
observed to have an increased risk of schizophrenia later in life (249).  
If lower levels of Vitamin D are associated with MDD in adolescents, Vitamin D 
supplementation (and assessing clinical outcome of MDD) could be considered.  It could 
also be of benefit to see if increased levels of Vitamin D (with supplementation) decrease 
pro-inflammatory cytokines.   
6) Examining the relationship between externalizing or internalizing behaviours and 
inflammation in childhood and adolescence. Non-specific symptoms or behaviours of 
some mental illnesses have been associated with inflammation.  Specifically, externalizing 
behaviours in children have been associated with raised pro-inflammatory markers (411).  
However, very few studies have examined this.  It is possible that inflammation in 
childhood is a pathway through which behaviour problems early in life may increase risk 
for chronic diseases in adulthood (411).  Therefore examining this relationship further, with 
a longitudinal study design and in combination with the study suggested above (in 
recommendation number 2), could increase study power and provide useful information in 
a developmental psychoneuroimmunology context.   
7) Implementing strategies to increase success of data collection in child and adolescent 
mental health clinics.  This may be more likely to succeed if less invasive ways to measure 
cytokines and inflammatory markers can be further developed in this age group.  These 
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strategies will also be more likely to succeed if clinicians working in the clinics are also 
actively involved in the research projects. 
Conclusion 
 
An improved understanding of the role of cytokines and other inflammatory markers in 
depression in adolescents needs to be extended to understanding the role of these 
biomarkers in other mental illnesses seen in adolescents.  This could lead to improved 
treatment of mental illness in adolescents, particularly in the subgroup of individuals who 
have persistent raised levels of pro-inflammatory cytokines or inflammatory markers.  
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Appendices 
 
Figure 8-1: Distribution and correlations of cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8 (measured in 
DBS) 
 
Key: IL=interleukin  
Note: diagonal shows distribution of each cytokine; off-diagonals show correlations between a pair of 
cytokines (for example, the plot on the intersection of the 4th row and 5th column is a plot showing the 
correlation between the cytokines IL-5 and IL-6). 
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Figure 8-2: Distribution and correlation of cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8 after regression 
of within-paper rank normalised measures on sex and plate (measured in DBS) 
 
Key: IL=interleukin  
Note: diagonal shows distribution of each cytokine; off-diagonals show correlations between a pair of 
cytokines (for example, the plot on the intersection of the 4th row and 5th column is a plot showing the 
correlation between the cytokines IL-5 and IL-6). 
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Figure 8-3: Distribution and correlation of cytokines IL-10, IL-12, IL-17, IL-18, IL-6ra, and IFN-γ 
(measured in DBS) 
 
Key: IFN=interferon; IL=interleukin  
Note: diagonal shows distribution of each cytokine; off-diagonals show correlations between a pair of 
cytokines (for example, the plot on the intersection of the 4th row and 5th column is a plot showing the 
correlation between the cytokines IL-18 and IL-6ra). 
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Figure 8-4: Distribution and correlation of cytokines IL-10, IL-12, IL-17, IL-18, IL-6ra, and IFN-γ 
after regression of within-paper rank normalised measures on sex and plate (measured in DBS) 
 
Key: IFN=interferon; IL=interleukin  
Note: diagonal shows distribution of each cytokine; off-diagonals show correlations between a pair of 
cytokines (for example, the plot on the intersection of the 4th row and 5th column is a plot showing the 
correlation between the cytokines IL-18 and IL-6ra). 
 
 
 
 
 
 
 
 182 
 
 
 
Figure 8-5: Distribution and correlation of TREM-1, RANTES, BDNF, GM-CSF, NT-4 and CRP 
(measured in DBS) 
 
Key: BDNF=brain-derived neurotrophic factor; CRP=C-reactive protein; GM-CSF=Granulocyte Macrophage-
Colony Stimulating Factor; NT-4=neurotrophin-4; RANTES= Regulated and Normal T-cell Expressed and 
Secreted; TREM-1=Triggering Receptor Expressed on Myeloid cells-1  
Note: diagonal shows distribution of each cytokine, inflammatory marker, and neurotrophin; off-diagonals 
show correlations between a pair (for example, the plot on the intersection of the 4th row and 5th column is a 
plot showing the correlation between the cytokine GM-CSF and the neurotrophin NT-4). 
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Figure 8-6: Distribution and correlation of TREM-1, RANTES, BDNF, GM-CSF, NT-4 and CRP 
after regression of within-paper rank normalised measures on sex and plate (measured in DBS) 
 
Key: BDNF=brain-derived neurotrophic factor; CRP=C-reactive protein; GM-CSF=Granulocyte Macrophage-
Colony Stimulating Factor; NT-4=neurotrophin-4; RANTES= Regulated and Normal T-cell Expressed and 
Secreted; TREM-1=Triggering Receptor Expressed on Myeloid cells-1  
Note: diagonal shows distribution of each cytokine, inflammatory marker, and neurotrophin; off-diagonals 
show correlations between a pair (for example, the plot on the intersection of the 4th row and 5th column is a 
plot showing the correlation between the cytokine GM-CSF and the neurotrophin NT-4). 
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Figure 8-7: Distribution and correlation of antibodies hsv1igg, hhv6igg, cmvigg, toxoigg, gliadinigg, 
and hsv2igg (measured in DBS) 
 
 
Key: cmv=cytomegalovirus; hhv6igg=Human Herpes Virus 6; hsv=Herpes Simplex Virus; 
igg=immunoglobulin; toxo=toxoplasmosis  
Note: diagonal shows distribution of each antibody; off-diagonals show correlations between a pair of 
antibodies (for example, the plot on the intersection of the 4th row and 5th column is a plot showing the 
correlation between the toxoplasmosis and gliadin antibodies) 
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Figure 8-8: Distribution and correlation of hsv1igg, hhv6igg, cmvigg, toxoigg, gliadinigg, & hsv2igg 
after regression of within-paper rank normalised measures on sex and plate (measured in DBS) 
 
 
Key: cmv=cytomegalovirus; hhv6igg=Human Herpes Virus 6; hsv=Herpes Simplex Virus; 
igg=immunoglobulin; toxo=toxoplasmosis  
Note: diagonal shows distribution of each antibody; off-diagonals show correlations between a pair of 
antibodies (for example, the plot on the intersection of the 4th row and 5th column is a plot showing the 
correlation between the toxoplasmosis and gliadin antibodies) 
 
 
 
 
 186 
 
 
Table 8-1: Log CRP genetic profile risk scores – prediction of BMI 
P-value of 
SNPs in CRP 
discovery 
GWAS 
 N SNPs Variance of 
BMI 
explained 
(R2) 
P-value for 
prediction of 
BMI 
P < 0.001 1,972 0 0.52 
P < 0.01 11,154 0.04 0.18 
P < 0.1 70,982 0 0.62 
P < 0.5 241,214 0.03 0.21 
All SNPs 361,282 0.04 0.18 
Key: BMI = body mass index; CRP = C-reactive protein 
